

Vasopressin versus Norepinephrine Infusion in Patients

New England Journal of Medicine

358, 877-887

DOI: [10.1056/nejmoa067373](https://doi.org/10.1056/nejmoa067373)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Restructuring the Automotive Industry in the English West Midlands. <i>Local Economy</i> , 2005, 20, 249-265.	0.8	13
4	Current place of vasopressin analogues in the treatment of septic shock. <i>Current Infectious Disease Reports</i> , 2008, 10, 362-367.	1.3	5
5	New evidence in cardiovascular and geriatric medicine. <i>Internal and Emergency Medicine</i> , 2008, 3, 259-261.	1.0	1
6	Application of intensive care medicine principles in the management of the acute liver failure patient. <i>Liver Transplantation</i> , 2008, 14, S85-S89.	1.3	21
7	Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. <i>Resuscitation</i> , 2008, 79, 325-331.	1.3	42
8	Pharmacological treatment of sepsis. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 355-361.	1.0	20
9	“Terlipressin in the treatment of septic shock: the earlier the better?” <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2008, 22, 317-321.	1.7	11
10	Vasopressin analogues in the treatment of shock states: potential pitfalls. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2008, 22, 393-406.	1.7	28
11	Arginine vasopressin in the treatment of vasodilatory septic shock. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2008, 22, 275-286.	1.7	16
12	Arginine vasopressin vs. terlipressin in the treatment of shock states. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2008, 22, 359-368.	1.7	17
13	Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study. <i>Journal of Critical Care</i> , 2008, 23, 500-506.	1.0	28
14	Adjunctive therapies for severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, S34-S38.	1.1	11
15	Clinical Practice Guidelines for Improving Outcomes in Sepsis. <i>Heart Lung and Circulation</i> , 2008, 17, S26-S31.	0.2	6
17	China's barefoot doctor: past, present, and future. <i>Lancet, The</i> , 2008, 372, 1865-1867.	6.3	152
18	Acute kidney injury. <i>Lancet, The</i> , 2008, 372, 1863-1865.	6.3	111
19	Management of Sepsis: Early Resuscitation. <i>Clinics in Chest Medicine</i> , 2008, 29, 689-704.	0.8	35
21	Clinical Pharmacology 2008: Practical Information for Physicians, Nurses and Pharmacists. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 491-495.	1.3	0
22	Recently published papers: Sepsis “guidelines, treatment and novel approaches. <i>Critical Care</i> , 2008, 12, 120.	2.5	7

#	ARTICLE	IF	CITATIONS
23	Vasopressin in vasodilatory shock: is the heart in danger?. Critical Care, 2008, 12, 132.	2.5	4
24	Year in review 2007: Critical Care " shock. Critical Care, 2008, 12, 227.	2.5	6
25	Vasopressin and its role in critical care. Continuing Education in Anaesthesia, Critical Care & Pain, 2008, 8, 134-137.	0.6	58
26	Hypothalamic-pituitary-adrenal axis multiple and organ dysfunction syndrome in critical illness: A special focus on arginine-vasopressin and apelin. Journal of Organ Dysfunction, 2008, 4, 216-229.	0.3	5
27	Effects of Vasopressin in Septic Shock. AACN Advanced Critical Care, 2008, 19, 281-287.	0.6	2
28	Is Vasopressin Increasing or Decreasing Mortality in Patients with Septic Shock?. Surgical Infections, 2008, 9, 215-216.	0.7	0
29	Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Reviews in Molecular Medicine, 2008, 10, e32.	1.6	101
30	Drug use in acute meningococcal disease. Archives of Disease in Childhood: Education and Practice Edition, 2008, 93, 151-158.	0.3	7
31	Septic Shock " Vasopressin, Norepinephrine, and Urgency. New England Journal of Medicine, 2008, 358, 954-956.	13.9	87
33	Corticosteroids for Septic Shock. New England Journal of Medicine, 2008, 358, 2068-2071.	13.9	11
34	Vasopressin in Septic Shock. New England Journal of Medicine, 2008, 358, 2736-2738.	13.9	13
35	Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-1,3-Galactose. New England Journal of Medicine, 2008, 358, 2735-2736.	13.9	32
36	Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 618-623.	2.5	263
37	Effects of Vasopressin in Septic Shock. AACN Advanced Critical Care, 2008, 19, 281-287.	0.6	6
38	Sepsis and those who are "weak of heart". Critical Care Medicine, 2008, 36, 3108-3109.	0.4	3
39	Is the mortality rate for septic shock really decreasing?. Current Opinion in Critical Care, 2008, 14, 580-586.	1.6	29
40	Prone or supine positions: Differences in regional ventilation with positive end-expiratory pressure*. Critical Care Medicine, 2008, 36, 2469-2471.	0.4	0
41	Can we safely discharge patients from the intensive care unit after hours?*. Critical Care Medicine, 2008, 36, 2443-2444.	0.4	4

#	ARTICLE	IF	CITATIONS
42	Palliative care approach can provide safeguards for end-of-life care in the intensive care unit. <i>Critical Care Medicine</i> , 2008, 36, 2485-2486.	0.4	0
43	Point of care glucose testing—Need for a better mousetrap or time to rethink the hunt?*. <i>Critical Care Medicine</i> , 2008, 36, 3113-3114.	0.4	5
44	Implementing the best evidence; do not forget to be a good clinician*. <i>Critical Care Medicine</i> , 2008, 36, 3106-3107.	0.4	2
45	Is normalized mean blood glucose level good enough for the intensive care unit?—Glycemic variability as a new independent predictor of mortality*. <i>Critical Care Medicine</i> , 2008, 36, 3104-3106.	0.4	21
47	Moving the goalposts? Fluid volume assessment in severe acute pancreatitis*. <i>Critical Care Medicine</i> , 2008, 36, 2464-2466.	0.4	1
48	Hyperglycemia aggravates endotoxin-induced high mobility group box 1 protein release: Yet another reason not to be too sweet*. <i>Critical Care Medicine</i> , 2008, 36, 2475-2476.	0.4	6
49	Timely selection of adequate antifungal therapy for candidemia in the critically ill: Don't let the yeast rise!*. <i>Critical Care Medicine</i> , 2008, 36, 3097-3098.	0.4	2
51	The gray area between palliative care and active shortening of the dying process. <i>Critical Care Medicine</i> , 2008, 36, 2483-2484.	0.4	0
52	Relieving pain and suffering does not hasten death. <i>Critical Care Medicine</i> , 2008, 36, 2486-2487.	0.4	0
53	The crystal ball in end-of-life care. <i>Critical Care Medicine</i> , 2008, 36, 2482.	0.4	1
54	New recommendations for the use of corticosteroids in sepsis: Not so fast!. <i>Critical Care Medicine</i> , 2008, 36, 2489-2490.	0.4	4
55	Palliative care approach can provide safeguards for end-of-life care in the intensive care unit. <i>Critical Care Medicine</i> , 2008, 36, 2485.	0.4	0
56	Surviving Sepsis Campaign: Guideline Clarification. <i>Critical Care Medicine</i> , 2008, 36, 2490.	0.4	2
57	Surviving Sepsis Campaign Guidelines 2008: Revisiting vasopressor recommendations. <i>Critical Care Medicine</i> , 2008, 36, 2488.	0.4	5
58	Withdrawal assessment in the pediatric intensive care unit: Quantifying a morbidity of pain and sedation management in the critically ill child*. <i>Critical Care Medicine</i> , 2008, 36, 2479-2480.	0.4	6
59	Relieving suffering or hastening death: A misrepresentation. <i>Critical Care Medicine</i> , 2008, 36, 2484.	0.4	0
60	Troublesome terminology for a tough truth. <i>Critical Care Medicine</i> , 2008, 36, 2482-2483.	0.4	12
61	—Sunbreaks—for critical care in the modern era of genetic epidemiology*. <i>Critical Care Medicine</i> , 2008, 36, 2453-2455.	0.4	0

#	ARTICLE	IF	CITATIONS
62	Sepsis-induced vasoplegia—Is vasopressin V1A-receptor a new target?*. Critical Care Medicine, 2008, 36, 2468-2469.	0.4	1
63	Intracranial pressure—Looking behind a number is important*. Critical Care Medicine, 2008, 36, 2476-2477.	0.4	0
64	Normalization of glucose in the intensive care unit: Does one size really fit all?*. Critical Care Medicine, 2008, 36, 2448-2449.	0.4	8
65	Surviving sepsis in developing countries. Critical Care Medicine, 2008, 36, 2487-2488.	0.4	1
66	Laboratory testing guidelines in the intensive care unit: Less red and more green*. Critical Care Medicine, 2008, 36, 3102-3103.	0.4	4
67	Ventilation Strategy Using Low Tidal Volumes, Recruitment Maneuvers, and High Positive End-Expiratory Pressure for Acute Lung Injury and Acute Respiratory Distress Syndrome. Survey of Anesthesiology, 2008, 52, 271-272.	0.1	0
68	Are Blood Transfusions Associated With Greater Mortality Rates? Results of the Sepsis Occurrence in Acutely Ill Patients Study. Survey of Anesthesiology, 2008, 52, 277-278.	0.1	0
69	Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock. Survey of Anesthesiology, 2008, 52, 276-277.	0.1	0
70	Promises, promises: N-terminal proB-type natriuretic peptide as a biomarker in acute lung injury*. Critical Care Medicine, 2008, 36, 2461-2462.	0.4	0
71	Inappropriate therapy for staphylococcal infection is common and commonly fatal*. Critical Care Medicine, 2008, 36, 2462-2464.	0.4	2
72	How good is arterial pulse contour (LiDCOplus [®] , [†]) and the esophageal Doppler monitor (HemoSonic [®] , [‡]) in measuring left ventricular stroke volume during venous occlusion?*. Critical Care Medicine, 2008, 36, 3103-3104.	0.4	0
73	Heparin in the treatment of severe sepsis: A new look at an old therapy*. Critical Care Medicine, 2008, 36, 3098-3099.	0.4	3
74	Does mechanical ventilation “cohit” the lungs?*. Critical Care Medicine, 2008, 36, 2471-2473.	0.4	2
75	Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Critical Care Medicine, 2008, 36, 1937-1949.	0.4	1,405
76	Ventilator-associated pneumonia prevention: WHAP, positive end-expiratory pressure, or both?*. Critical Care Medicine, 2008, 36, 2441-2442.	0.4	2
77	Burning issues surrounding inflammation and coagulation in heatstroke*. Critical Care Medicine, 2008, 36, 2455-2456.	0.4	7
78	Surviving Sepsis Campaign: Guideline Clarification. Critical Care Medicine, 2008, 36, 2490-2491.	0.4	4
79	Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge*. Critical Care Medicine, 2008, 36, 3054-3061.	0.4	30

#	ARTICLE	IF	CITATIONS
80	Managing traumatic brain injury: What is the evidence?*. Critical Care Medicine, 2008, 36, 3116-3117.	0.4	1
81	Should we worry about chest wall influence on airway pressures during mechanical ventilation?*. Critical Care Medicine, 2008, 36, 3100-3101.	0.4	0
82	End-of-life care and organ procurement for transplantation: Palliation or euthanasia?*. Critical Care Medicine, 2008, 36, 2481-2482.	0.4	3
83	Positive End-Expiratory Pressure Setting in Adults With Acute Lung Injury and Acute Respiratory Distress Syndrome. Survey of Anesthesiology, 2008, 52, 272-273.	0.1	0
84	Hydrocortisone Therapy for Patients With Septic Shock. Survey of Anesthesiology, 2008, 52, 273-274.	0.1	0
85	Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis. Survey of Anesthesiology, 2008, 52, 274-276.	0.1	0
86	Risk Factors Associated With Bleeding During and After Percutaneous Dilational Tracheostomy. Survey of Anesthesiology, 2008, 52, 278-279.	0.1	0
87	Surviving sepsis in developing countries. Critical Care Medicine, 2008, 36, 2487.	0.4	17
88	Relieving suffering or intentionally hastening death: Drawing the line in function of the patient. Critical Care Medicine, 2008, 36, 2486.	0.4	1
89	Levosimendan in cardiogenic shock: Better than enoximone!*. Critical Care Medicine, 2008, 36, 2450-2451.	0.4	6
90	The use of S100B as a biomarker in subarachnoid hemorrhage: Clarity in its promise and limits*. Critical Care Medicine, 2008, 36, 2452-2453.	0.4	3
91	Parenteral ascorbic acid as a key for regulating microcirculation in critically ill*. Critical Care Medicine, 2008, 36, 2466-2468.	0.4	6
92	Just do it*. Critical Care Medicine, 2008, 36, 2456-2457.	0.4	3
93	Erythropoietin and the promise of ischemic multiorgan protection*. Critical Care Medicine, 2008, 36, 2446-2447.	0.4	3
94	Biomarkers in acute lung injury: Are we making progress?*. Critical Care Medicine, 2008, 36, 2457-2459.	0.4	13
95	The glycemia threat in sepsis: Too high, too low, or too variable!*. Critical Care Medicine, 2008, 36, 2459-2460.	0.4	2
96	Pharmacologic neuroprotection—Is xenon the light at the end of the tunnel?*. Critical Care Medicine, 2008, 36, 2477-2479.	0.4	23
97	Surviving Sepsis Campaign Guidelines 2008: Revisiting vasopressor recommendations. Critical Care Medicine, 2008, 36, 2488-2489.	0.4	2

#	ARTICLE	IF	CITATIONS
98	New recommendations for the use of corticosteroids in sepsis: Not so fast!. Critical Care Medicine, 2008, 36, 2490.	0.4	1
99	Therapeutic hypercapnia: Are we in "œstasis" or moving forward?*. Critical Care Medicine, 2008, 36, 2473-2474.	0.4	3
100	Vasopressin and the kidney: Two false friends?*. Critical Care Medicine, 2008, 36, 3111-3112.	0.4	0
101	Vasoactive drugs and acute kidney injury. Critical Care Medicine, 2008, 36, 2959.	0.4	2
102	Nitric oxide inhalation and glucocorticoids"Can there be a belt-and-braces approach in sepsis?*. Critical Care Medicine, 2008, 36, 3109-3110.	0.4	1
103	Critical care services: Is regionalization the answer?*. Critical Care Medicine, 2008, 36, 3114-3116.	0.4	5
104	Use it or lose it!*. Critical Care Medicine, 2008, 36, 2444-2445.	0.4	41
106	Severe Sepsis and Septic Shock. , 0, , 235-250.		0
107	Highlights from the 2008 Surviving Sepsis Campaign, Part 1. Hospital Pharmacy, 2008, 43, 454-458.	0.4	1
108	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	0.4	1
109	Vasopressin in Hemorrhagic Shock: Review Article. American Surgeon, 2009, 75, 1207-1212.	0.4	14
110	Guidelines on Management of Human Infection with the Novel Virus Influenza A (H1N1) " A Report from the Hospital das Cl�nicas of the University of S�o Paulo. Clinics, 2009, 64, 1015-1024.	0.6	11
111	The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury. CKJ: Clinical Kidney Journal, 2009, 2, 1-10.	1.4	16
112	Update in Critical Care 2008. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 743-758.	2.5	6
113	Post-resuscitation care: current therapeutic concepts. Acute Cardiac Care, 2009, 11, 131-137.	0.2	521
114	Vasopressin in the pediatric cardiac intensive care unit: Myth or reality. Annals of Pediatric Cardiology, 2009, 2, 65.	0.2	8
116	Vasopressin in Pediatric Vasodilatory Shock. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 632-639.	2.5	135
117	Clinical Year in Review II: Sepsis, Mechanical Ventilation, Occupational and Environmental Lung Disease, and Sleep. Proceedings of the American Thoracic Society, 2009, 6, 494-499.	3.5	3

#	ARTICLE	IF	CITATIONS
120	Sepsis in pregnancy and early goal-directed therapy. <i>Obstetric Medicine</i> , 2009, 2, 93-99.	0.5	9
121	Arginine-vasopressin attenuates beneficial norepinephrine effect on jejunal mucosal tissue oxygenation during endotoxaemia. <i>British Journal of Anaesthesia</i> , 2009, 103, 691-700.	1.5	16
122	β2 Adrenergic receptor on T lymphocytes and its clinical implications. <i>Progress in Natural Science: Materials International</i> , 2009, 19, 17-23.	1.8	30
123	Circulatory failure in severe sepsis. <i>Current Anaesthesia and Critical Care</i> , 2009, 20, 128-131.	0.3	1
124	Critical Care Nephrology: Core Curriculum 2009. <i>American Journal of Kidney Diseases</i> , 2009, 53, 898-910.	2.1	3
125	Severe sepsis in cirrhosis. <i>Hepatology</i> , 2009, 50, 2022-2033.	3.6	374
126	Hemodynamic resuscitation in septic shock: Cardiovascular support and adjunctive therapy. <i>Current Infectious Disease Reports</i> , 2009, 11, 357-364.	1.3	2
130	Pilot safety study of low-dose vasopressin in non-septic critically ill children. <i>Intensive Care Medicine</i> , 2009, 35, 355-359.	3.9	14
131	Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. <i>Intensive Care Medicine</i> , 2009, 35, 1286-1296.	3.9	44
132	Serum macrophage migration inhibitory factor reflects adrenal function in the hypothalamo-pituitary-adrenal axis of septic patients: an observational study. <i>BMC Infectious Diseases</i> , 2009, 9, 209.	1.3	12
133	Clinical applications of intravenous immunoglobulins (IVIg) “beyond immunodeficiencies and neurology. <i>Clinical and Experimental Immunology</i> , 2009, 158, 23-33.	1.1	118
134	Review article: Inotrope and vasopressor use in the emergency department. <i>EMA - Emergency Medicine Australasia</i> , 2009, 21, 342-351.	0.5	9
135	Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2009, 53, 1052-1059.	0.7	75
136	TAKOTSUBO CARDIOMYOPATHY WITH HYPERVASOPRESSINEMIA. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1119-1120.	1.3	3
137	THE EFFECT OF GLUCOSE TOLERANCE ON CENTRAL AND BRACHIAL PRESSURE IN ELDERLY PEOPLE. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1120-1122.	1.3	4
138	Vasopressin in pediatric vasodilatory shock: a multicentred randomized controlled trial. <i>Critical Care</i> , 2009, 13, P181.	2.5	1
139	Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. <i>Critical Care</i> , 2009, 13, R98.	2.5	51
140	Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?. <i>Critical Care</i> , 2009, 13, 169.	2.5	16

#	ARTICLE	IF	CITATIONS
141	Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial. <i>Critical Care</i> , 2009, 13, R113.	2.5	47
142	Arginine vasopressin in septic shock: supplement or substitute for norepinephrine?. <i>Critical Care</i> , 2009, 13, 178.	2.5	4
143	Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis. <i>Critical Care</i> , 2009, 13, R128.	2.5	31
144	Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. <i>Critical Care</i> , 2009, 13, R130.	2.5	186
145	Year in review 2008: <i>Critical Care</i> - metabolism. <i>Critical Care</i> , 2009, 13, 228.	2.5	6
146	Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. <i>Critical Care</i> , 2009, 13, R181.	2.5	188
147	Modern trends in fluid therapy for burns. <i>Burns</i> , 2009, 35, 757-767.	1.1	114
148	Local anesthesia using buffered 0.5% lidocaine with 1:200,000 epinephrine for tumors of the digits treated with Mohs micrographic surgery. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 639-643.	0.6	27
149	Sepsis and multiple organ failure. <i>Anaesthesia and Intensive Care Medicine</i> , 2009, 10, 165-168.	0.1	12
150	Adjunctive Measures for Treating Surgical Infections and Sepsis. <i>Surgical Clinics of North America</i> , 2009, 89, 349-363.	0.5	4
151	Inotrope and Vasopressor Therapy of Septic Shock. <i>Critical Care Clinics</i> , 2009, 25, 781-802.	1.0	40
152	Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2569-2575.	0.9	21
153	Acute-on-Chronic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction. , 2009, , 658-671.		0
154	Investigational vasopressin receptor modulators in the pipeline. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1119-1131.	1.9	12
155	Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress. <i>Journal of Intensive Care Medicine</i> , 2009, 24, 293-316.	1.3	388
156	Steroid Therapy of Septic Shock. <i>Critical Care Clinics</i> , 2009, 25, 825-834.	1.0	24
157	Pharmacological optimization of tissue perfusion. <i>British Journal of Anaesthesia</i> , 2009, 103, 82-88.	1.5	12
158	Terlipressin or Europressin?. <i>Critical Care</i> , 2009, 13, 192.	2.5	4

#	ARTICLE	IF	CITATIONS
159	Bench-to-bedside review: Vasopressin in the management of septic shock. <i>Critical Care</i> , 2009, 15, 226.	2.5	128
160	Pro: Fellowship Training in Intensive Care Is Required. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2009, 23, 110-111.	0.6	0
161	Quel agent vasopresseur utiliser au cours du choc septique? Praticien En Anesthesie Reanimation, 2009, 13, 51-57.	0.0	0
162	Vasopressine et choc septique. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2009, 18, 323-327.	0.1	0
163	Adrenal Insufficiency in Septic Shock. <i>Clinics in Chest Medicine</i> , 2009, 30, 17-27.	0.8	35
164	Approach to the Patient with Sepsis. <i>Clinics in Chest Medicine</i> , 2009, 30, 1-16.	0.8	12
165	Historical Perspectives in Critical Care Medicine: Blood Transfusion, Intravenous Fluids, Inotropes/Vasopressors, and Antibiotics. <i>Critical Care Clinics</i> , 2009, 25, 201-220.	1.0	13
166	The Management of Severe Sepsis and Septic Shock. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 485-501.	1.9	31
167	Hemodynamic support of shock state: Are we asking the right questions?*. <i>Critical Care Medicine</i> , 2009, 37, 736-740.	0.4	2
168	Vasopressin and its copilot copeptin in sepsis and septic shock*. <i>Critical Care Medicine</i> , 2009, 37, 749-750.	0.4	13
169	The vasopressin and copeptin response to infection, severe sepsis, and septic shock*. <i>Critical Care Medicine</i> , 2009, 37, 476-482.	0.4	97
170	Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock*. <i>Critical Care Medicine</i> , 2009, 37, 811-818.	0.4	234
171	Inhaled vasodilators for pulmonary hypertension in left heart disease: Should we start considering?*. <i>Critical Care Medicine</i> , 2009, 37, 1155-1156.	0.4	0
172	Solutions for care of patients with severe sepsis: Where and how?*. <i>Critical Care Medicine</i> , 2009, 37, 1128-1129.	0.4	1
173	The fate and role of mesenchymal stem cells engrafted in the heart after a myocardial infarction during a second ischemic event*. <i>Critical Care Medicine</i> , 2009, 37, 1130-1131.	0.4	0
174	Ultrasound is coming to a pediatric intensive care unit near you*. <i>Critical Care Medicine</i> , 2009, 37, 1170-1172.	0.4	2
175	Hemofiltration in the early phase of sepsis: Friend or foe?*. <i>Critical Care Medicine</i> , 2009, 37, 1125-1126.	0.4	17
176	The role of positive end-expiratory pressure in modulating the apoptosis response during atelectasis-induced lung injury*. <i>Critical Care Medicine</i> , 2009, 37, 1161-1162.	0.4	0

#	ARTICLE	IF	CITATIONS
177	Functional capillary density measurement: A useful new tool to assess the peripheral circulation in infants?*. Critical Care Medicine, 2009, 37, 1173-1174.	0.4	1
178	Terlipressinâ€™More than just a prodrug of lysine vasopressin?*. Critical Care Medicine, 2009, 37, 1135-1136.	0.4	10
179	The molecular sepsis signature*. Critical Care Medicine, 2009, 37, 1137-1138.	0.4	3
180	Two and a half weeks: Time enough for end-of-life care planning?*. Critical Care Medicine, 2009, 37, 1145.	0.4	1
181	How can we be helpful? Triggers for palliative care consultation in the surgical intensive care unit*. Critical Care Medicine, 2009, 37, 1147-1148.	0.4	601
182	Donâ€™t ask, donâ€™t tell: delirium in the intensive care unit*. Critical Care Medicine, 2009, 37, 1129-1130.	0.4	2
183	Prolonged mechanical ventilation: Pushing the limits of magic in medicine?*. Critical Care Medicine, 2009, 37, 2983-2985.	0.4	14
184	Pulmonary artery catheter determined right ventricular ejection fraction and right ventricular end-diastolic volume: Another case of â€™The Emperor Has No Clothesâ€™*. Critical Care Medicine, 2009, 37, 2992.	0.4	4
185	When is it time to go? The difficulty of intensive care unit discharge decisions at times of high census or admission demand*. Critical Care Medicine, 2009, 37, 2982-2983.	0.4	4
186	Optimizing intensive care management in paediatric sepsis. Current Opinion in Infectious Diseases, 2009, 22, 264-271.	1.3	8
187	CATECHOLAMINES, VASOPRESSIN AND MARKERS OF ACUTE LIVER INJURY IN SEPTIC SHOCK. Shock, 2009, 31, 222-223.	1.0	3
188	Cerebral vasospasm in patients suffering from aneurysmal subarachnoid hemorrhage: An unresolved diagnostic and therapeutic challenge*. Critical Care Medicine, 2009, 37, 1150-1151.	0.4	2
190	Management of Sepsis in the ICU. International Anesthesiology Clinics, 2009, 47, 55-66.	0.3	2
191	Breathing normobaric oxygen protects against splanchnic ischemic injury: How does it work?*. Critical Care Medicine, 2009, 37, 1162-1164.	0.4	1
192	Erythropoietin in sepsis: A new use for a familiar drug?*. Critical Care Medicine, 2009, 37, 1138-1139.	0.4	2
193	Would you like your colloid straight or with a twist of an anti-inflammatory antioxidant?*. Critical Care Medicine, 2009, 37, 1133-1134.	0.4	1
194	Clinical microvascular monitoring: A bright future without a future?*. Critical Care Medicine, 2009, 37, 2980-2981.	0.4	14
195	When is simple too simple? Immortal time bias in critical care*. Critical Care Medicine, 2009, 37, 2990-2991.	0.4	30

#	ARTICLE	IF	CITATIONS
196	Vasoplegic Syndrome During Liver Transplantation. <i>Anesthesia and Analgesia</i> , 2009, 108, 1941-1943.	1.1	31
197	Physiology of the circulation—An old—new vocabulary*. <i>Critical Care Medicine</i> , 2009, 37, 1143-1144.	0.4	2
198	Improving the assessment score in spontaneous intracerebral hemorrhage*. <i>Critical Care Medicine</i> , 2009, 37, 1152-1153.	0.4	1
199	Transfusion improves cerebral oxygenation . . . but not always*. <i>Critical Care Medicine</i> , 2009, 37, 1166-1167.	0.4	4
200	Poisoned patients are different—Sometimes fat is a good thing*. <i>Critical Care Medicine</i> , 2009, 37, 1157-1158.	0.4	52
201	To refer or not to refer: How do we answer the question?*. <i>Critical Care Medicine</i> , 2009, 37, 2989-2990.	0.4	0
202	Volume therapy, plasma osmolality, and vasopressin release in septic shock: —Scio ne nihil scire— (Socrates)*. <i>Critical Care Medicine</i> , 2009, 37, 2993-2994.	0.4	0
203	Internal space of interfaces for noninvasive ventilation: Dead, but not deadly*. <i>Critical Care Medicine</i> , 2009, 37, 1146-1147.	0.4	2
204	The digital patient: Predicting physiologic dynamics with mathematical models*. <i>Critical Care Medicine</i> , 2009, 37, 1167-1168.	0.4	19
205	Pay for performance in critical care: Like it or not, here it comes!*. <i>Critical Care Medicine</i> , 2009, 37, 1132-1133.	0.4	0
206	Under pressure — do not get lost in space*. <i>Critical Care Medicine</i> , 2009, 37, 2986-2987.	0.4	0
207	The —how to—of temperature management in the intensive care unit*. <i>Critical Care Medicine</i> , 2009, 37, 1172-1173.	0.4	3
208	Vasopressin plus corticosteroids: The shock duo!*. <i>Critical Care Medicine</i> , 2009, 37, 1126-1127.	0.4	13
209	Preventing fatal diagnostic errors: The position of D-dimer assays in the diagnostic procedures for acute chest pain*. <i>Critical Care Medicine</i> , 2009, 37, 1140-1141.	0.4	0
210	Does platelet hyperfunction explain grim survival rates after out-of-hospital cardiac arrest?*. <i>Critical Care Medicine</i> , 2009, 37, 1153-1155.	0.4	1
211	The red blood cell: An underestimated actor in alterations of the microcirculation*. <i>Critical Care Medicine</i> , 2009, 37, 1158-1160.	0.4	3
212	Whisper down the lane or a standardized handover?*. <i>Critical Care Medicine</i> , 2009, 37, 2987-2988.	0.4	2
213	Why do nice people get bad pneumonia? —Be quick or be dead— (Iron Maiden)*. <i>Critical Care Medicine</i> , 2009, 37, 2979-2980.	0.4	0

#	ARTICLE	IF	CITATIONS
215	Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study)*. <i>Critical Care Medicine</i> , 2009, 37, 410-416.	0.4	75
216	The effect of increasing doses of norepinephrine on tissue oxygenation and microvascular flow in patients with septic shock*. <i>Critical Care Medicine</i> , 2009, 37, 1961-1966.	0.4	216
217	Vasoactive drugs for vasodilatory shock in ICU. <i>Current Opinion in Critical Care</i> , 2009, 15, 398-402.	1.6	25
218	Prophylactic pulsatile cardiopulmonary bypass in the elderly—Stress response reduction at what cost?*. <i>Critical Care Medicine</i> , 2009, 37, 1142-1143.	0.4	1
219	Tomatoes, cadmium, and death in the critically ill—Time for a new approach in mortality prediction?*. <i>Critical Care Medicine</i> , 2009, 37, 1149-1150.	0.4	0
220	Understanding the shared responsibility in assessing the benefits and risks of research for the vulnerable critical care patient*. <i>Critical Care Medicine</i> , 2009, 37, 1169-1170.	0.4	2
221	<i>Pseudomonas aeruginosa</i> and <i>Candida albicans</i> : Do they really need to stick together?*. <i>Critical Care Medicine</i> , 2009, 37, 1164-1166.	0.4	4
222	Hyperglycemia: Breaking the barriers?*. <i>Critical Care Medicine</i> , 2009, 37, 1160-1161.	0.4	0
223	My flow, your flow, flow for all!*. <i>Critical Care Medicine</i> , 2009, 37, 1509-1510.	0.4	0
224	Pressor response to fluid resuscitation in endotoxic shock: Involvement of vasopressin*. <i>Critical Care Medicine</i> , 2009, 37, 2968-2972.	0.4	25
225	Arginine vasopressin plasma levels could indicate children undergoing cardiopulmonary bypass that might benefit from exogenous arginine vasopressin*. <i>Critical Care Medicine</i> , 2010, 38, 2079-2081.	0.4	1
226	Not Everything Labeled “Low-Dose” Vasopressin Is a Low Dose. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1012-1013.	2.5	0
227	Critical care trial design and interpretation: A primer. <i>Critical Care Medicine</i> , 2010, 38, 1882-1889.	0.4	9
228	Osmoregulation of vasopressin secretion is altered in the postacute phase of septic shock*. <i>Critical Care Medicine</i> , 2010, 38, 1962-1969.	0.4	34
229	pH1N1 influenza A: Timing is everything*. <i>Critical Care Medicine</i> , 2010, 38, 2081-2082.	0.4	2
230	Disorder of osmoregulation as a new pathogenetic mechanism of septic shock?*. <i>Critical Care Medicine</i> , 2010, 38, 2068-2069.	0.4	2
231	Prolongation of prothrombin time in the critically ill: Is it time for decisive action?*. <i>Critical Care Medicine</i> , 2010, 38, 2065-2066.	0.4	2
232	Should we target blood pressure in sepsis?. <i>Critical Care Medicine</i> , 2010, 38, S613-S619.	0.4	39

#	ARTICLE	IF	CITATIONS
233	Inotropes in cardiac patients: update 2011. <i>Current Opinion in Critical Care</i> , 2010, 16, 432-441.	1.6	43
234	Corticosteroids and the original vasopressin and septic shock trial subgroups. <i>Critical Care Medicine</i> , 2010, 38, 338-339.	0.4	1
235	Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock*. <i>Critical Care Medicine</i> , 2010, 38, 2016-2023.	0.4	65
236	Clinical repercussions of high-frequency percussive ventilation: A burning issue*. <i>Critical Care Medicine</i> , 2010, 38, 2069-2070.	0.4	2
237	Sex, drugs, false dawns, and magic bullets*. <i>Critical Care Medicine</i> , 2010, 38, 2078-2079.	0.4	0
238	Taking a closer look at mechanical ventilation in the United States*. <i>Critical Care Medicine</i> , 2010, 38, 2067.	0.4	1
239	Toll-like receptor-2 and disturbances of the cardiac rhythm: Life changes in a heartbeat*. <i>Critical Care Medicine</i> , 2010, 38, 2062-2063.	0.4	0
240	Critical care "normality" Individualized versus protocolized care. <i>Critical Care Medicine</i> , 2010, 38, S590-S599.	0.4	18
241	Caspase: The unfriendly "meat tenderizer" of sepsis*. <i>Critical Care Medicine</i> , 2010, 38, 2075-2076.	0.4	0
242	Vasopressin, levosimendan, and cardiovascular function in septic shock*. <i>Critical Care Medicine</i> , 2010, 38, 2071-2073.	0.4	0
243	The effects of vasopressin and its analogues on the liver and its disorders in the critically ill. <i>Current Opinion in Critical Care</i> , 2010, 16, 148-152.	1.6	11
244	We should abandon randomized controlled trials in the intensive care unit. <i>Critical Care Medicine</i> , 2010, 38, S534-S538.	0.4	175
245	Hands-only cardiopulmonary resuscitation: Bench-to-bedside or bedside-to-bench?*. <i>Critical Care Medicine</i> , 2010, 38, 2073-2075.	0.4	2
246	Does urinary L-type fatty acid-binding protein predict the severity of sepsis complicated by acute kidney injury?*. <i>Critical Care Medicine</i> , 2010, 38, 2076-2078.	0.4	0
247	Corticosteroids and the original vasopressin and septic shock trial subgroups. <i>Critical Care Medicine</i> , 2010, 38, 338.	0.4	1
248	Ubi poop, ibi evacua?*. <i>Critical Care Medicine</i> , 2010, 38, 2064-2065.	0.4	2
249	1. Pharmacologic Therapy for AKI.. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 1007-1012.	0.0	0
250	Drugs that affect autonomic functions or the extrapyramidal system. <i>Side Effects of Drugs Annual</i> , 2010, 32, 281-294.	0.6	0

#	ARTICLE	IF	CITATIONS
251	Terlipressin for Hepatorenal Syndrome: Novel Strategies and Future Perspectives. <i>Frontiers of Gastrointestinal Research</i> , 2010, , 189-197.	0.1	2
252	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c869-c869.	2.4	5,319
256	Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. <i>Intensive Care Medicine</i> , 2010, 36, 57-65.	3.9	147
257	Prevention of acute kidney injury and protection of renal function in the intensive care unit. <i>Intensive Care Medicine</i> , 2010, 36, 392-411.	3.9	182
258	The effects of vasopressin on acute kidney injury in septic shock. <i>Intensive Care Medicine</i> , 2010, 36, 83-91.	3.9	206
259	Best vasopressor for advanced vasodilatory shock: should vasopressin be part of the mix?. <i>Intensive Care Medicine</i> , 2010, 36, 1484-1487.	3.9	9
260	The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients. <i>Intensive Care Medicine</i> , 2010, 36, 2004-2018.	3.9	108
261	Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. <i>Intensive Care Medicine</i> , 2010, 36, 2019-2029.	3.9	191
265	The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction. <i>Journal of Anesthesia</i> , 2010, 24, 893-900.	0.7	5
266	The Resuscitation Package in Sepsis. <i>Current Infectious Disease Reports</i> , 2010, 12, 368-373.	1.3	1
267	Review of recent guidelines for the management of severe sepsis and septic shock. <i>Frontiers of Medicine in China</i> , 2010, 4, 54-58.	0.1	0
268	Vasopressin use is associated with death in acute trauma patients with shock. <i>Journal of Critical Care</i> , 2010, 25, 173.e9-173.e14.	1.0	29
269	Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: A retrospective cohort study. <i>Journal of Critical Care</i> , 2010, 25, 362.e7-362.e11.	1.0	29
270	Vasopressin for Refractory Hypotension in Extremely Low Birth Weight Infants. <i>Journal of Pediatrics</i> , 2010, 157, 502-504.	0.9	55
271	Arginine Vasopressin for the Treatment of Septic Shock in Adults. <i>Pharmacotherapy</i> , 2010, 30, 1057-1071.	1.2	23
272	PKC plays an important mediated effect in arginine vasopressin induced restoration of vascular responsiveness and calcium sensitization following hemorrhagic shock in rats. <i>European Journal of Pharmacology</i> , 2010, 628, 148-154.	1.7	27
274	Part 10: Paediatric basic and advanced life support. <i>Resuscitation</i> , 2010, 81, e213-e259.	1.3	106
275	The Etomidate Debate. <i>Annals of Emergency Medicine</i> , 2010, 56, 490-491.	0.3	11

#	ARTICLE	IF	CITATIONS
276	Attitudes to drug trials among relatives of unconscious intensive care patients. BMC Anesthesiology, 2010, 10, 6.	0.7	13
277	The challenge of evidence in clinical medicine. Journal of Evaluation in Clinical Practice, 2010, 16, 384-389.	0.9	45
278	Infusão intravenosa de vasopressina causa efeitos cardiovasculares adversos dose-dependentes em cães anestesiados. Arquivos Brasileiros De Cardiologia, 2010, 94, 229-234.	0.3	0
279	Pediatric Basic and Advanced Life Support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Pediatrics, 2010, 126, e1261-e1318.	1.0	64
281	Vasopressin and Its Immune Effects in Septic Shock. Journal of Innate Immunity, 2010, 2, 446-460.	1.8	60
282	How Does One Care for the Heart-Beating, Brain Dead, Adult Organ Donor Patient?. , 2010, , 637-642.		0
283	Acute Kidney Injury: Current Perspectives. Postgraduate Medicine, 2010, 122, 29-40.	0.9	19
284	Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults. JAMA - Journal of the American Medical Association, 2010, 303, 341.	3.8	247
285	Vasopressin and Methylene Blue: Alternate Therapies in Vasodilatory Shock. Seminars in Cardiothoracic and Vascular Anesthesia, 2010, 14, 186-189.	0.4	30
286	Which Organs Become Dysfunctional in Sepsis? How Does This Occur? How Is It Diagnosed and Managed?. , 2010, , 164-171.		0
287	What Vasopressor Agent Should Be Used in the Septic Patient?. , 2010, , 206-211.		1
288	Not Everything Labeled "Low-Dose" Vasopressin Is a Low Dose. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1012-1012.	2.5	0
289	EFFICACY AND SAFETY OF DOPAMINE VERSUS NOREPINEPHRINE IN THE MANAGEMENT OF SEPTIC SHOCK. Shock, 2010, 33, 375-380.	1.0	114
290	Counterpoint: Adherence to Early Goal-Directed Therapy. Chest, 2010, 138, 480-483.	0.4	30
291	Rebuttal From Dr Rivers. Chest, 2010, 138, 483-484.	0.4	5
292	Adrenergic Support in Septic Shock: A Critical Review. Hospital Practice (1995), 2010, 38, 62-73.	0.5	14
295	Treating Shock " Old Drugs, New Ideas. New England Journal of Medicine, 2010, 362, 841-843.	13.9	12
296	Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ: British Medical Journal, 2010, 340, c117-c117.	2.4	575

#	ARTICLE	IF	CITATIONS
297	Î² ₂ -Adrenergic Receptor Gene Polymorphism Is Associated with Mortality in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 143-149.	2.5	74
298	Continuous Terlipressin Infusion as Rescue Treatment in a Case Series of Children with Refractory Septic Shock. Annals of Pharmacotherapy, 2010, 44, 1545-1553.	0.9	25
299	Evidence-Based Acute Management of Sepsis—Rapid Intervention in the Critical Hours. Perioperative Nursing Clinics, 2010, 5, 189-202.	0.1	0
300	Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Critical Care, 2010, 14, R169.	2.5	293
301	Sepsis Syndromes. , 2010, , 419-444.		0
302	An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1128-1155.	2.5	267
303	Year in review 2009: Critical Care - shock. Critical Care, 2010, 14, 239.	2.5	10
304	Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study. Critical Care, 2010, 14, R200.	2.5	29
305	Is pituitary failure the real therapeutic target in septic shock?. Medical Hypotheses, 2010, 74, 574-577.	0.8	1
306	Role of V1a Receptor in AVP-Induced Restoration of Vascular Hyporeactivity and Its Relationship to MLCP-MLC20 Phosphorylation Pathway. Journal of Surgical Research, 2010, 161, 312-320.	0.8	25
307	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology, 2010, 63, e1-e37.	2.4	1,500
308	Reduction of the severe sepsis or septic shock associated mortality by reinforcement of the recommendations bundle: A multicenter study. Annales Francaises D'Anesthesie Et De Reanimation, 2010, 29, 621-628.	1.4	47
309	Use of pressor therapy in 34 hypotensive critically ill neonatal foals. Australian Veterinary Journal, 2010, 88, 472-477.	0.5	11
310	Delirium treatment: an unmet challenge. Lancet, The, 2010, 376, 1805-1807.	6.3	4
311	Vasopressin: A Review of Therapeutic Applications. Journal of Cardiothoracic and Vascular Anesthesia, 2010, 24, 330-347.	0.6	34
312	Have we found the prevention for intensive care unit-acquired paresis?. Critical Care, 2010, 14, 160.	2.5	7
313	Bench to bedside: A role for erythropoietin in sepsis. Critical Care, 2010, 14, 227.	2.5	26
314	Part 10: Pediatric Basic and Advanced Life Support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation, 2010, 122, S466-S515.	1.6	190

#	ARTICLE	IF	CITATIONS
315	Vasopressin for the treatment of vasodilatory shock: an ESICM systematic review and a meta-analysis. <i>Critical Care</i> , 2011, 15, .	2.5	0
316	Hormonal responses upon return of spontaneous circulation after cardiac arrest: a retrospective cohort study. <i>Critical Care</i> , 2011, 15, R53.	2.5	28
317	Glucocorticoids in sepsis: dissecting facts from fiction. <i>Critical Care</i> , 2011, 15, 446.	2.5	6
318	Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. <i>Critical Care</i> , 2011, 15, R217.	2.5	41
319	IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and mortality of severe sepsis. <i>Critical Care</i> , 2011, 15, R254.	2.5	38
320	New, Potent, Selective, and Short-Acting Peptidic V _{1a} Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4388-4398.	2.9	37
321	Steroid Therapy of Septic Shock. <i>Critical Care Nursing Clinics of North America</i> , 2011, 23, 171-180.	0.4	7
322	Hypothalamic-Pituitary Gland Axis Function and Dysfunction in Horses. <i>Veterinary Clinics of North America Equine Practice</i> , 2011, 27, 1-17.	0.3	13
323	Current management of sepsis in critically ill adult patients. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 847-856.	2.0	11
324	The implications and management of septic acute kidney injury. <i>Nature Reviews Nephrology</i> , 2011, 7, 218-225.	4.1	36
325	Inotrope and Vasopressor Therapy of Septic Shock. <i>Critical Care Nursing Clinics of North America</i> , 2011, 23, 127-148.	0.4	6
327	Vasopressors for hypotensive shock. , 2011, , CD003709.		52
329	Vasopressors and the search for the optimal trial design. <i>Contemporary Clinical Trials</i> , 2011, 32, 924-930.	0.8	3
330	Effects of Combination Dobutamine and Vasopressin Therapy on Microcirculatory Blood Flow in a Porcine Model of Severe Endotoxic Shock. <i>Journal of Surgical Research</i> , 2011, 171, 191-198.	0.8	13
331	A Small Dose of Arginine Vasopressin in Combination with Norepinephrine is a Good Early Treatment for Uncontrolled Hemorrhagic Shock After Hemostasis. <i>Journal of Surgical Research</i> , 2011, 169, 76-84.	0.8	21
332	Molecular Mechanisms of Sepsis. <i>Contributions To Microbiology</i> , 2011, 17, 48-85.	2.1	28
333	Stability of levothyroxine injection in glass, polyvinyl chloride, and polyolefin containers. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1723-1728.	0.5	4
334	Year in review 2010: Critical Care - multiple organ dysfunction and sepsis. <i>Critical Care</i> , 2011, 15, 236.	2.5	30

#	ARTICLE	IF	CITATIONS
335	Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 847-855.	2.5	151
336	Advances in resuscitation strategies. International Journal of Surgery, 2011, 9, 5-12.	1.1	19
339	Dantrolene to Dysproteinaemias. , 0, , 114-137.		0
340	Diretrizes para tratamento da sepse grave/choque séptico: ressuscitação hemodinâmica. Revista Brasileira De Terapia Intensiva, 2011, 23, 13-23.	0.1	4
341	Vasogenic shock physiology. Open Access Emergency Medicine, 2011, 3, 1.	0.6	4
342	Neuroendocrine-Immune Mediator Coordination and Disarray in Critical Illness. , 2011, , 1403-1412.		0
343	Vascular reactivity. , 0, , 277-292.		0
344	Corticosteroids and anti-inflammatory drugs. , 0, , 814-829.		0
345	Biomarkers of acute respiratory distress syndrome: Do good things lie nearby?*. Critical Care Medicine, 2011, 39, 207-209.	0.4	6
346	The meaning of do-not-resuscitation orders: A need for clarity*. Critical Care Medicine, 2011, 39, 193-194.	0.4	33
347	Role of selective V1a receptor agonism in ovine septic shock*. Critical Care Medicine, 2011, 39, 119-125.	0.4	64
348	The present is pregnant with the future*. Critical Care Medicine, 2011, 39, 215-216.	0.4	0
349	Mirror, mirror on the wall: Which is the best vasopressin receptor of them all?*. Critical Care Medicine, 2011, 39, 213-215.	0.4	0
350	Smoke signals in the intensive care unit*. Critical Care Medicine, 2011, 39, 197-198.	0.4	0
351	Small steps in the right direction for ventilator-induced lung injury: Prevention, prevention, prevention!*. Critical Care Medicine, 2011, 39, 196-197.	0.4	2
352	Identification of acute kidney injury*. Critical Care Medicine, 2011, 39, 200-201.	0.4	13
353	On pediatric delirium and the use of the Pediatric Confusion Assessment Method for the Intensive Care Unit*. Critical Care Medicine, 2011, 39, 220-221.	0.4	9
354	Introducing automated acute lung injury/acute respiratory distress syndrome electronic screening in intensive care unit practice: Is it the future?*. Critical Care Medicine, 2011, 39, 209-210.	0.4	3

#	ARTICLE	IF	CITATIONS
355	Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock*. Critical Care Medicine, 2011, 39, 1641-1648.	0.4	45
356	Hepatorenal syndromes in patients with end-stage liver failure admitted to the intensive care unit. Critical Care Medicine, 2011, 39, 2386-2387.	0.4	0
357	To keep our heads above the water. Critical Care Medicine, 2011, 39, 2387-2388.	0.4	0
358	Norepinephrine, venomotor tone, and preload dependency. Critical Care Medicine, 2011, 39, 2381-2382.	0.4	0
359	Albumin and brain injury: Time for a new approach?*. Critical Care Medicine, 2011, 39, 217-218.	0.4	6
360	Norepinephrine, venomotor tone, and preload dependency. Critical Care Medicine, 2011, 39, 2381.	0.4	3
361	The "take home message"™ from the "Take Heart America"™ program: Strengthen the chain!*. Critical Care Medicine, 2011, 39, 194-196.	0.4	1
362	Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality*. Critical Care Medicine, 2011, 39, 259-265.	0.4	1,257
363	Mild therapeutic hypothermia after cardiac arrest: Keep on chilling*. Critical Care Medicine, 2011, 39, 206-207.	0.4	5
364	Stop filling patients against central venous pressure, please!*. Critical Care Medicine, 2011, 39, 396-397.	0.4	6
365	Agreement in electrocardiogram interpretation in patients with septic shock*. Critical Care Medicine, 2011, 39, 2080-2086.	0.4	34
366	Is full enteral feeding nutritionally effective?. Critical Care Medicine, 2011, 39, 2382-2383.	0.4	0
367	Intensive care in poor-resource settings: Solutions are in the hands at home. Critical Care Medicine, 2011, 39, 2385-2386.	0.4	0
368	Cerebrospinal fluid lactic acid levels: Accurate, fast, and inexpensive. Critical Care Medicine, 2011, 39, 2383-2384.	0.4	5
369	Refining the use of therapeutic hypothermia after cardiac arrest*. Critical Care Medicine, 2011, 39, 201-202.	0.4	2
370	Drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction: What does the crystal ball tell you?*. Critical Care Medicine, 2011, 39, 204-205.	0.4	2
371	Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation: Useful, but for whom?*. Critical Care Medicine, 2011, 39, 190-191.	0.4	13
372	Measuring the effect of inappropriate initial antibiotic therapy on outcomes of patients with Gram-negative sepsis: An imprecise science*. Critical Care Medicine, 2011, 39, 199-200.	0.4	4

#	ARTICLE	IF	CITATIONS
373	Cerebrospinal fluid lactic acid levels: Accurate, fast, and inexpensive. <i>Critical Care Medicine</i> , 2011, 39, 2384-2385.	0.4	0
374	Monitoring the ill: Is this another measurement or will it change outcomes?*. <i>Critical Care Medicine</i> , 2011, 39, 202-203.	0.4	2
375	Time-dependent glycemic variability and mortality in critically ill patients with diabetes*. <i>Critical Care Medicine</i> , 2011, 39, 211-213.	0.4	6
376	No sadder sight*. <i>Critical Care Medicine</i> , 2011, 39, 221-222.	0.4	0
377	Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review. <i>Proceedings of Singapore Healthcare</i> , 2011, 20, 208-218.	0.2	0
378	Pediatric patients with out-of hospital cardiac arrest: Is therapeutic hypothermia for them?*. <i>Critical Care Medicine</i> , 2011, 39, 218-219.	0.4	3
379	Is full enteral feeding nutritionally effective?. <i>Critical Care Medicine</i> , 2011, 39, 2382.	0.4	1
380	Intensive care in poor-resource settings: Solutions are in the hands at home. <i>Critical Care Medicine</i> , 2011, 39, 2385.	0.4	3
381	Hepatorenal syndromes in patients with end-stage liver failure admitted to the intensive care unit. <i>Critical Care Medicine</i> , 2011, 39, 2387.	0.4	0
382	Sepsis-induced Cardiomyopathy. <i>Current Cardiology Reviews</i> , 2011, 7, 163-183.	0.6	215
383	Management of the postoperative pediatric cardiac surgical patient. <i>Critical Care Medicine</i> , 2011, 39, 1974-1984.	0.4	57
384	Through the magnifying glass*. <i>Critical Care Medicine</i> , 2011, 39, 191-192.	0.4	0
385	Current approach to the haemodynamic management of septic shock patients in European intensive care units: a cross-sectional, self-reported questionnaire-based survey. <i>European Journal of Anaesthesiology</i> , 2011, 28, 284-290.	0.7	23
386	Nitric oxide in enteric nervous system mediated the inhibitory effect of vasopressin on the contraction of circular muscle strips from colon in male rats. <i>Neurogastroenterology and Motility</i> , 2011, 23, e125-e135.	1.6	8
387	Norepinephrine and Hospital Mortality in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. <i>Artificial Organs</i> , 2011, 35, E11-7.	1.0	15
388	Persistent sepsis-induced hypotension without hyperlactatemia: Is it really septic shock?. <i>Journal of Critical Care</i> , 2011, 26, 435.e9-435.e14.	1.0	67
389	Vasopressor administration and sepsis: A survey of Canadian intensivists. <i>Journal of Critical Care</i> , 2011, 26, 532.e1-532.e7.	1.0	14
390	New Trends in Resuscitation. <i>Current Problems in Surgery</i> , 2011, 48, 531-564.	0.6	25

#	ARTICLE	IF	CITATIONS
391	Detectability of Vasopressin in Continuous Venovenous Hemodialysis Effluent of Patients with Vasodilatory Shock Treated with Exogenous Arginine Vasopressin. <i>Pharmacotherapy</i> , 2011, 31, 857-862.	1.2	2
394	The role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: Review of the literature. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 192-203.	0.5	17
395	Impact of Low-dose Vasopressin on Trauma Outcome: Prospective Randomized Study. <i>World Journal of Surgery</i> , 2011, 35, 430-439.	0.8	77
396	Vasopressin analogues and V1a receptor agonists in septic shock. <i>Inflammation Research</i> , 2011, 60, 425-427.	1.6	4
397	Interpretation of blood pressure signal: physiological bases, clinical relevance, and objectives during shock states. <i>Intensive Care Medicine</i> , 2011, 37, 411-419.	3.9	33
398	Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. <i>Intensive Care Medicine</i> , 2011, 37, 963-969.	3.9	28
399	Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality. <i>Intensive Care Medicine</i> , 2011, 37, 1432-1437.	3.9	34
400	Arginine-vasopressin and corticosteroids in septic shock: engaged but not yet married!. <i>Intensive Care Medicine</i> , 2011, 37, 1406-1408.	3.9	4
402	Kidney injury: the case of elderly patients. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2011, 7, 170-183.	0.2	0
404	Copeptin concentration in cord blood in infants with early-onset sepsis, chorioamnionitis and perinatal asphyxia. <i>BMC Pediatrics</i> , 2011, 11, 38.	0.7	53
405	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. <i>World Journal of Emergency Surgery</i> , 2011, 6, 2.	2.1	57
406	Translational research in sepsis - an ultimate challenge?. <i>Experimental & Translational Stroke Medicine</i> , 2011, 3, 14.	3.2	5
407	Surviving sepsis: going beyond the guidelines. <i>Annals of Intensive Care</i> , 2011, 1, 17.	2.2	58
408	Critical care of the end-stage liver disease patient awaiting liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 496-510.	1.3	44
409	Insights from the evidence evaluation process - Do we have the answers for therapeutic hypothermia?. <i>Resuscitation</i> , 2011, 82, 501-502.	1.3	12
410	Advances in the Management of Pediatric Pulmonary Hypertension. <i>Respiratory Care</i> , 2011, 56, 1314-1340.	0.8	39
412	Predicting Mortality in Patients with Acute Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 394-395.	2.5	2
413	Acute kidney injury. <i>Current Opinion in Critical Care</i> , 2011, 17, 562-568.	1.6	17

#	ARTICLE	IF	CITATIONS
414	Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol*. Critical Care Medicine, 2011, 39, 2066-2071.	0.4	317
415	Sepsis: The Inflammatory Foundation of Pathophysiology and Therapy. Hospital Practice (1995), 2011, 39, 99-112.	0.5	13
416	Vasopressin in Septic Shock. Journal of the Intensive Care Society, 2011, 12, 11-14.	1.1	6
417	Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Annals of Oncology, 2011, 22, 1019-1029.	0.6	54
418	Advances in the Management of Sepsis and the Understanding of Key Immunologic Defects. Anesthesiology, 2011, 115, 1349-1362.	1.3	95
419	A Single Nucleotide Polymorphism in NF- κ B Inducing Kinase Is Associated with Mortality in Septic Shock. Journal of Immunology, 2011, 186, 2321-2328.	0.4	42
420	Quel vasopresseur utiliser au cours du choc septique?. , 2011, , 229-235.		0
421	Traitement de la d'Ã©chec cardiaque. , 2011, , 237-249.		0
422	Vasopressine et analogues. , 2011, , 251-262.		0
423	Leucyl/Cystinyl Aminopeptidase Gene Variants in Septic Shock. Chest, 2011, 139, 1042-1049.	0.4	63
424	Novel Therapies for Septic Shock Over the Past 4 Decades. JAMA - Journal of the American Medical Association, 2011, 306, 194-9.	3.8	71
425	Roger C. Bone, MD and the Evolving Paradigms of Sepsis. Contributions To Microbiology, 2011, 17, 1-11.	2.1	12
426	Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V _{1a} Receptor Full Agonist for the Treatment of Vasodilatory Hypotension. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 786-796.	1.3	47
427	Impact of Early Postoperative Hydrocortisone Administration in Cardiac Surgical Patients after Cardiopulmonary Bypass. Annals of Pharmacotherapy, 2011, 45, 189-194.	0.9	16
428	Manejo del paciente en shock s'Ã©ptico. Revista M'Ã©dica Cl'Ã©nica Las Condes, 2011, 22, 293-301.	0.2	1
429	The Last Xigris'® Survivor. Surgical Infections, 2011, 12, 423-425.	0.7	6
430	Should Vasopressin Be Used in Septic Shock?. , 2011, , 212-217.		0
431	Critical Care Medicine. , 2011, , 1250-1272.		0

#	ARTICLE	IF	CITATIONS
432	Sepsis: an update for physicians. <i>Clinical Medicine</i> , 2011, 11, 619-622.	0.8	0
433	Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. , 2012, , 251-261.		2
434	Selective V _{1a} agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H1245-H1254.	1.5	41
435	Liste de contr�le de l'Association canadienne des m�decins d'urgence concernant le traitement de la sepsie: optimisation de la prise en charge de la sepsie au sein des services des urgences canadiens. <i>Canadian Journal of Emergency Medicine</i> , 2012, 14, 40-44.	0.5	0
436	Review of Vasopressor Therapy in the Setting of Vasodilatory Shock. <i>Advanced Emergency Nursing Journal</i> , 2012, 34, 16-23.	0.2	5
437	Emergency management of severe sepsis and septic shock. <i>Current Opinion in Critical Care</i> , 2012, 18, 295-300.	1.6	21
438	Protocolled resuscitation and the prevention of acute kidney injury. <i>Current Opinion in Critical Care</i> , 2012, 18, 613-622.	1.6	19
440	Inotropic and Vasoactive Drugs in Pediatric ICU. <i>Current Drug Targets</i> , 2012, 13, 900-905.	1.0	1
441	Experimental sepsis in pigs� effects of vasopressin on renal, hepatic, and intestinal dysfunction. <i>Upsala Journal of Medical Sciences</i> , 2012, 117, 257-263.	0.4	11
443	Section 3: Prevention and Treatment of AKI. <i>Kidney International Supplements</i> , 2012, 2, 37-68.	4.6	42
444	Surviving Sepsis. <i>Journal of the Intensive Care Society</i> , 2012, 13, 10-11.	1.1	1
445	The Clinical Handbook for Surgical Critical Care. , 0, , .		1
446	Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems. <i>Physiological Reviews</i> , 2012, 92, 1813-1864.	13.1	308
447	Normal-Range Blood Lactate Concentration in Septic Shock Is Prognostic and Predictive. <i>Shock</i> , 2012, 38, 4-10.	1.0	144
448	Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes. <i>Current Pharmaceutical Design</i> , 2012, 18, 6298-6307.	0.9	2
449	Colloid Update. <i>Current Pharmaceutical Design</i> , 2012, 18, 6291-6297.	0.9	7
450	Expanding our thinking regarding early goal-directed therapy*. <i>Critical Care Medicine</i> , 2012, 40, 2911-2912.	0.4	1
451	V1a receptor agonists. <i>Critical Care Medicine</i> , 2012, 40, 1999-2000.	0.4	0

#	ARTICLE	IF	CITATIONS
452	Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*. Critical Care Medicine, 2012, 40, 1957-1960.	0.4	15
453	Benefits of ethyl gallate versus norepinephrine in the treatment of cardiovascular collapse in Pseudomonas aeruginosa septic shock in dogs*. Critical Care Medicine, 2012, 40, 560-572.	0.4	7
455	The role of vasopressin in the management of sepsis. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.2	0
456	Management of bacterial infections in cirrhosis. Journal of Hepatology, 2012, 56, S1-S12.	1.8	296
457	Management of critically-ill cirrhotic patients. Journal of Hepatology, 2012, 56, S13-S24.	1.8	113
459	AA genotype of IL6 \sim 251A/T is associated with low PaO ₂ /FiO ₂ in critically ill patients and with increased IL6 expression. Respiriology, 2012, 17, 1253-1260.	1.3	30
460	A Human Vascular Model Based on Microdialysis for the Assessment of the Vasoconstrictive Dose-Response Effects of Norepinephrine and Vasopressin in Skin. Microcirculation, 2012, 19, 352-359.	1.0	5
461	Clinical review: The liver in sepsis. Critical Care, 2012, 16, 235.	2.5	211
462	Potential for overuse of corticosteroids and vasopressin in septic shock. Critical Care, 2012, 16, 447.	2.5	8
463	Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Critical Care, 2012, 16, R154.	2.5	133
464	CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. International Journal of Surgery, 2012, 10, 28-55.	1.1	1,546
465	Arginine vasopressin: The future of pressure-support resuscitation in hemorrhagic shock. Journal of Surgical Research, 2012, 178, 321-329.	0.8	29
466	Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis. New England Journal of Medicine, 2012, 367, 124-134.	13.9	1,594
468	Drotrecogin Alfa (Activated) in Adults with Septic Shock. New England Journal of Medicine, 2012, 366, 2055-2064.	13.9	1,112
469	Current Concepts in Resuscitation. Journal of Intensive Care Medicine, 2012, 27, 79-96.	1.3	17
470	Fever Control Using External Cooling in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1088-1095.	2.5	215
471	Use of inotropes and vasopressor agents in critically ill patients. British Journal of Pharmacology, 2012, 165, 2015-2033.	2.7	146
472	Vasopressors in shock: too early to move away from catecholamines?. British Journal of Pharmacology, 2012, 165, 2012-2014.	2.7	2

#	ARTICLE	IF	CITATIONS
473	Inotropes and vasopressors: more than haemodynamics!. British Journal of Pharmacology, 2012, 165, 2009-2011.	2.7	19
474	Early Goal-directed Therapy (EGDT) for Severe Sepsis/Septic Shock: Which Components of Treatment are More Difficult to Implement in a Community-based Emergency Department?. Journal of Emergency Medicine, 2012, 42, 503-510.	0.3	32
475	Treatment of severe sepsis. Anaesthesia and Intensive Care Medicine, 2012, 13, 199-203.	0.1	3
476	The evolution and current use of invasive hemodynamic monitoring for predicting volume responsiveness during resuscitation, perioperative, and critical care. Journal of Clinical Anesthesia, 2012, 24, 242-250.	0.7	13
477	Low-dose steroids in adult septic shock: results of the Surviving Sepsis Campaign. Intensive Care Medicine, 2012, 38, 1946-1954.	3.9	53
478	Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials, 2012, 13, 84.	0.7	66
479	Initial Emergency Department Diagnosis and Management of Adult Patients with Severe Sepsis and Septic Shock. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2012, 20, 41.	1.1	62
480	A Case Study in Intra-abdominal Sepsis. Surgical Clinics of North America, 2012, 92, 1661-1677.	0.5	15
481	Epidemiology of Sepsis in Surgical Patients. Surgical Clinics of North America, 2012, 92, 1425-1443.	0.5	32
482	Optimizing Drug Therapy in the Surgical Intensive Care Unit. Surgical Clinics of North America, 2012, 92, 1573-1620.	0.5	2
483	A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drug Investigation, 2012, 32, 179-187.	1.1	25
484	Possible interventional therapies in severe sepsis or septic shock. Acta Anaesthesiologica Taiwanica, 2012, 50, 74-77.	1.0	3
485	Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. American Journal of Surgery, 2012, 204, 856-861.	0.9	60
486	Surgical Prophylaxis and Other Complication Avoidance Care Bundles. Surgical Clinics of North America, 2012, 92, 285-305.	0.5	11
487	The Cardiopulmonary Effects of Vasopressin Compared With Norepinephrine in Septic Shock. Chest, 2012, 142, 593-605.	0.4	72
488	Pseudomonas aeruginosa -Catecholamine Inotrope Interactions. Chest, 2012, 142, 1200-1210.	0.4	84
489	Management of Acute Renal Dysfunction in Sepsis. Current Infectious Disease Reports, 2012, 14, 462-473.	1.3	4
491	Sepsis. Neurohospitalist, The, 2012, 2, 144-153.	0.3	14

#	ARTICLE	IF	CITATIONS
493	Ventricular End Diastolic Pressure (EDP). , 2012, , 2446-2446.		0
495	Biomarker (BNP)-guided Weaning from Mechanical Ventilation. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1202-1204.	2.5	2
496	Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). Annals of Intensive Care, 2012, 2, 15.	2.2	5
497	The Effects of Terlipressin on Regional Hemodynamics and Kidney Function in Experimental Hyperdynamic Sepsis. PLoS ONE, 2012, 7, e29693.	1.1	15
498	Management of Severe Sepsis and Septic Shock. , 2012, , .		0
499	Update in the Treatment of Severe Sepsis and Septic Shock. , 0, , .		0
500	Does Etomidate Increase Vasopressor Requirements in Patients Needing Mechanical Ventilation?. Canadian Journal of Hospital Pharmacy, 2012, 65, 272-6.	0.1	2
501	Critical Care Paper Review 2012. Tuberculosis and Respiratory Diseases, 2012, 73, 1.	0.7	2
502	Intravenous Arginine Vasopressin Infusion in Refractory Vasodilatory Shock: A Clinical Study. Indian Journal of Pediatrics, 2012, 79, 488-493.	0.3	13
503	Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Medicine, 2012, 38, 950-958.	3.9	191
504	Does body weight impact the efficacy of vasopressin therapy in the management of septic shock?. Journal of Critical Care, 2012, 27, 289-293.	1.0	21
505	Predictors of prolonged vasopressin infusion for the treatment of septic shock. Journal of Critical Care, 2012, 27, 318.e7-318.e12.	1.0	9
506	The impact of perioperative transfusion of blood products on survival after pediatric liver transplantation. Pediatric Transplantation, 2012, 16, 357-366.	0.5	45
507	Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Medicine, 2012, 38, 9-19.	3.9	88
508	Vasopressin improves systemic hemodynamics without compromising mesenteric perfusion in the resuscitation of asphyxiated newborn piglets: a doseâ€“response study. Intensive Care Medicine, 2012, 38, 491-498.	3.9	19
509	Transfusion requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus restrictive red blood cell transfusion in septic shock patients in the ICU: protocol for a randomised controlled trial. Trials, 2013, 14, 150.	0.7	42
510	Long-term mortality and quality of life after septic shock: a follow-up observational study. Intensive Care Medicine, 2013, 39, 881-888.	3.9	61
511	Vasopressin Compared with Norepinephrine Augments the Decline of Plasma Cytokine Levels in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 356-364.	2.5	65

#	ARTICLE	IF	CITATIONS
512	Pilot Study Comparing Sepsis Management with and without Electronic Clinical Practice Guidelines in an Academic Emergency Department. <i>Journal of Emergency Medicine</i> , 2013, 44, 698-708.	0.3	5
513	“Less Is More” in Critically Ill Patients. <i>JAMA Internal Medicine</i> , 2013, 173, 1369.	2.6	58
514	The Heart in Sepsis: From Basic Mechanisms to Clinical Management. <i>Current Vascular Pharmacology</i> , 2013, 11, 187-195.	0.8	4
515	Effects of IgM-Enriched Immunoglobulin Therapy in Septic-Shock-Induced Multiple Organ Failure: Pilot Study. <i>Journal of Anesthesia</i> , 2013, 27, 618-622.	0.7	20
516	The 2012 Surviving Sepsis Campaign: Management of Severe Sepsis and Septic Shock—An Update on the Guidelines for Initial Therapy. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 154-171.	0.6	1
517	Profilassi e gestione dell’insufficienza renale acuta in rianimazione. <i>EMC - Anestesia-Rianimazione</i> , 2013, 18, 1-15.	0.1	0
518	Circulatory shock. <i>Medicine</i> , 2013, 41, 64-69.	0.2	7
519	Fever and Signs of Shock. <i>Emergency Medicine Clinics of North America</i> , 2013, 31, 907-926.	0.5	3
520	Circulatory Shock. <i>New England Journal of Medicine</i> , 2013, 369, 1726-1734.	13.9	1,012
521	Infectiologie en reanimation. <i>Références En Réanimation</i> , 2013, , .	0.0	1
522	Residual rates of mortality in patients with severe sepsis: a fatality or a new challenge?. <i>Annals of Intensive Care</i> , 2013, 3, 27.	2.2	7
523	One size does not fit all in severe infection: obesity alters outcome, susceptibility, treatment, and inflammatory response. <i>Critical Care</i> , 2013, 17, R122.	2.5	102
524	Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study. <i>Critical Care</i> , 2013, 17, R72.	2.5	159
525	Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study. <i>Critical Care</i> , 2013, 17, R295.	2.5	124
527	Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). <i>Critical Care</i> , 2013, 17, 204.	2.5	1,724
528	Target blood pressure in sepsis: between a rock and a hard place. <i>Critical Care</i> , 2013, 17, 126.	2.5	8
529	On sepsis, troponin and vasopressin: the bitter truth. <i>Critical Care</i> , 2013, 17, 1002.	2.5	2
530	Outcomes of Patients on Multiple Vasoactive Drugs for Shock. <i>Journal of Intensive Care Medicine</i> , 2013, 28, 237-240.	1.3	18

#	ARTICLE	IF	CITATIONS
531	Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. <i>Intensive Care Medicine</i> , 2013, 39, 165-228.	3.9	3,906
532	The 2012 Guidelines for Severe Sepsis and Septic Shock: An Update for Emergency Nursing. <i>Journal of Emergency Nursing</i> , 2013, 39, 652-656.	0.5	2
533	Arginine vasopressin, via activation of post-junctional V1 receptors, induces contractile effects in mouse distal colon. <i>Regulatory Peptides</i> , 2013, 187, 29-34.	1.9	6
534	Is the Addition of Vasopressin to Norepinephrine Beneficial for the Treatment of Septic Shock?. <i>Annals of Emergency Medicine</i> , 2013, 62, 534-535.	0.3	2
535	Mean perfusion pressure deficit during the initial management of shock – an observational cohort study. <i>Journal of Critical Care</i> , 2013, 28, 816-824.	1.0	38
536	Prevençã³n y tratamiento de la insuficiencia renal aguda en la unidad de cuidados intensivos. <i>EMC - Anestesia-Reanimaci³n</i> , 2013, 39, 1-17.	0.1	0
537	Sepsis: Update in the Management. <i>Advances in Chronic Kidney Disease</i> , 2013, 20, 6-13.	0.6	17
538	Early Diagnosis and Evidence-Based Care of Surgical Sepsis. <i>Journal of Intensive Care Medicine</i> , 2013, 28, 107-117.	1.3	35
539	The principles and conduct of anaesthesia for emergency surgery. <i>Anaesthesia</i> , 2013, 68, 14-29.	1.8	14
540	Catecholamine Dosing and Survival in Adult Intensive Care Unit Patients. <i>World Journal of Surgery</i> , 2013, 37, 766-773.	0.8	22
542	Survival After Shock Requiring High-Dose Vasopressor Therapy. <i>Chest</i> , 2013, 143, 664-671.	0.4	158
543	The Physiology of Sepsis and Its Implications. , 2013, , 9-23.		0
544	Early Management of Sepsis, Severe Sepsis, and Septic Shock in the Surgical Patient. , 2013, , 73-91.		1
545	Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2013, 39, 811-822.	3.9	75
546	Management of Acute Kidney Injury. , 2013, , 237-247.		0
547	Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. <i>Critical Care</i> , 2013, 17, R174.	2.5	72
548	A Comparison of Initial Monotherapy with Norepinephrine Versus Vasopressin for Resuscitation in Septic Shock. <i>Annals of Pharmacotherapy</i> , 2013, 47, 301-310.	0.9	26
551	Mechanisms of Vascular Hyporesponsiveness in Septic Shock. <i>Current Vascular Pharmacology</i> , 2013, 11, 139-149.	0.8	2

#	ARTICLE	IF	CITATIONS
552	Tolerability and Safety of Enteral Nutrition in Critically Ill Patients Receiving Intravenous Vasopressor Therapy. <i>Journal of Parenteral and Enteral Nutrition</i> , 2013, 37, 641-651.	1.3	115
553	Vasopressin for cerebral perfusion pressure management in patients with severe traumatic brain injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2013, 75, 1024-1030.	1.1	19
554	Perioperative treatment of patients with sepsis. <i>Current Opinion in Anaesthesiology</i> , 2013, 26, 348-353.	0.9	1
555	Study Design and "Evidence" in Patient-oriented Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1167-1172.	2.5	36
556	Small Doses of Arginine Vasopressin in Combination With Norepinephrine "Buy" Time for Definitive Treatment for Uncontrolled Hemorrhagic Shock in Rats. <i>Shock</i> , 2013, 40, 398-406.	1.0	31
557	Characterizing vasopressin and other vasoactive mediators released during resuscitation of trauma patients. <i>Journal of Trauma and Acute Care Surgery</i> , 2013, 75, 620-628.	1.1	15
558	High-Dose Norepinephrine Treatment: Determinants of Mortality and Futility in Critically Ill Patients. <i>American Journal of Critical Care</i> , 2013, 22, 22-32.	0.8	27
559	Septic shock: new pharmacotherapy options or better trial design?. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 561-570.	0.9	6
560	Neurohormonal interactions on the renal oxygen delivery and consumption in haemorrhagic shock-induced acute kidney injury. <i>Acta Physiologica</i> , 2013, 209, 11-25.	1.8	30
561	Inotropic support in septic shock?. <i>Acta Anaesthesiologica Scandinavica</i> , 2013, 57, 405-407.	0.7	0
562	Metabolic and toxicological considerations for sepsis drug treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 79-89.	1.5	2
563	Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. <i>BMJ Open</i> , 2013, 3, e002186.	0.8	72
564	Vasopressors and Inotropes. , 2013, , 390-404.		5
565	Choc septique. <i>RÃ©fÃ©rences En RÃ©animation</i> , 2013, , 255-272.	0.0	0
566	Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. <i>Critical Care</i> , 2013, 17, R117.	2.5	43
567	Long-term mortality after critical care: what is the starting point?. <i>Critical Care</i> , 2013, 17, 191.	2.5	25
568	New insights in prevention and treatment of sepsis-induced acute kidney injury. <i>Journal of Translational Internal Medicine</i> , 2013, 1, 23-27.	1.0	0
569	Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock. <i>Current Vascular Pharmacology</i> , 2013, 11, 196-207.	0.8	4

#	ARTICLE	IF	CITATIONS
570	Surviving Sepsis Campaign. Critical Care Medicine, 2013, 41, 580-637.	0.4	6,362
571	Shock. JAAPA: Official Journal of the American Academy of Physician Assistants, 2013, 26, 21-24.	0.1	2
572	Vasopressor Dosing in Septic Shock. Critical Care Medicine, 2013, 41, e483-e484.	0.4	3
573	The authors reply. Critical Care Medicine, 2013, 41, e483.	0.4	2
574	Vasopressin Guidelines in Surviving Sepsis Campaign. Critical Care Medicine, 2013, 41, e482-e483.	0.4	5
575	Catecholamines and the Septic Heart. Shock, 2013, 39, 404-405.	1.0	4
577	Endocrine Pharmacology. , 2013, , 536-558.		0
578	Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock. Critical Care Research and Practice, 2013, 2013, 1-10.	0.4	59
579	Vascular Pharmacology. , 2013, , 75-93.		1
580	The Japanese Guidelines for the Management of Sepsis. Journal of the Japanese Society of Intensive Care Medicine, 2013, 20, 124-173.	0.0	15
582	The neuroendocrine response to critical illness. , 0, , 181-191.		0
584	Inotropes and vasopressors. , 2014, , 912-922.e1.		0
585	Mitochondrial Changes in Platelets Are Not Related to Those in Skeletal Muscle during Human Septic Shock. PLoS ONE, 2014, 9, e96205.	1.1	22
586	Perfusion Measurement of the Septic Patient in the Emergency Department. Emergency Medicine: Open Access, 2014, 04, .	0.1	1
587	4.8 Katecholamine und vasoaktive Substanzen. , 2014, , .		0
588	8.17 Sepsis und septischer Schock. , 2014, , .		0
589	Altered Agonist Sensitivity of a Mutant V2 Receptor Suggests a Novel Therapeutic Strategy for Nephrogenic Diabetes Insipidus. Molecular Endocrinology, 2014, 28, 634-643.	3.7	15
590	Severe sepsis and septic shock. Virulence, 2014, 5, 190-199.	1.8	50

#	ARTICLE	IF	CITATIONS
591	Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. <i>Critical Care</i> , 2014, 18, 534.	2.5	138
592	A Functional Synonymous Coding Variant in the <i>IL1RN</i> Gene Is Associated with Survival in Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 656-664.	2.5	42
593	Vasopressin, Sepsis, and Renal Perfusion—A VASST Deficit in Our Understanding*. <i>Critical Care Medicine</i> , 2014, 42, 1583-1584.	0.4	3
594	Sepsis and Pharmacogenomics. <i>Critical Care Medicine</i> , 2014, 42, 1944-1945.	0.4	0
595	Angiotensin-II. <i>Critical Care Medicine</i> , 2014, 42, 1961-1963.	0.4	4
596	Selepressin in Septic Shock. <i>Critical Care Medicine</i> , 2014, 42, 1747-1748.	0.4	8
598	Reading between the (guide)lines—the KDIGO practice guideline on acute kidney injury in the individual patient. <i>Kidney International</i> , 2014, 85, 39-48.	2.6	99
599	IL1RN Single-Nucleotide Polymorphisms in Septic Shock: Can Genetics Clear the Fog of the Cytokine Storm?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 599-600.	2.5	0
600	β ₂ -Agonists and Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 624-625.	2.5	6
601	Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. <i>BMJ</i> , The, 2014, 349, g4561-g4561.	3.0	228
602	Phaeochromocytoma crisis. <i>Clinical Endocrinology</i> , 2014, 80, 13-22.	1.2	84
603	How to Use a Subgroup Analysis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 405.	3.8	345
604	Protocol for a randomised controlled trial of Vasopressin versus Noradrenaline as Initial therapy in Septic shock (VANISH). <i>BMJ Open</i> , 2014, 4, e005866-e005866.	0.8	24
605	Angiotensin II: a new approach for refractory shock management?. <i>Critical Care</i> , 2014, 18, 694.	2.5	2
606	The Japanese guidelines for the management of sepsis. <i>Journal of Intensive Care</i> , 2014, 2, 55.	1.3	75
607	Interaction Between Fluids and Vasoactive Agents on Mortality in Septic Shock. <i>Critical Care Medicine</i> , 2014, 42, 2158-2168.	0.4	131
608	A Multibiomarker-Based Outcome Risk Stratification Model for Adult Septic Shock*. <i>Critical Care Medicine</i> , 2014, 42, 781-789.	0.4	107
609	What are the latest recommendations for managing severe sepsis and septic shock?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2014, 27, 15-19.	0.1	1

#	ARTICLE	IF	CITATIONS
610	The Attributable Mortality of Acute Kidney Injury. <i>Critical Care Medicine</i> , 2014, 42, 878-885.	0.4	60
611	Pharmacologic therapies for acute cardiogenic shock. <i>Current Opinion in Cardiology</i> , 2014, 29, 250-257.	0.8	44
612	Efficacy of Transthoracic Echocardiography for Diagnosing Heart Failure in Septic Shock. <i>American Journal of the Medical Sciences</i> , 2014, 347, 295-298.	0.4	18
613	Current controversies in the support of sepsis. <i>Current Opinion in Critical Care</i> , 2014, 20, 681-684.	1.6	9
614	Fluid choices impact outcome in septic shock. <i>Current Opinion in Critical Care</i> , 2014, 20, 378-384.	1.6	5
615	The Interaction of Vasopressin and Corticosteroids in Septic Shock. <i>Critical Care Medicine</i> , 2014, 42, 1325-1333.	0.4	106
616	Randomized ICU Trials Do Not Demonstrate an Association Between Interventions That Reduce Delirium Duration and Short-Term Mortality. <i>Critical Care Medicine</i> , 2014, 42, 1442-1454.	0.4	81
617	Serious Adverse Events Associated With Vasopressin and Norepinephrine Infusion in Septic Shock*. <i>Critical Care Medicine</i> , 2014, 42, 1812-1820.	0.4	57
618	PCSK9 is a critical regulator of the innate immune response and septic shock outcome. <i>Science Translational Medicine</i> , 2014, 6, 258ra143.	5.8	287
619	Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1308.	3.8	1,311
620	Adrenergic Agents. , 2014, , 1-26.		0
622	Vasopressin in Hemorrhagic Shock: A Systematic Review and Meta-Analysis of Randomized Animal Trials. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	31
623	The Surviving Sepsis Campaign Guidelines 2012: Update for Emergency Physicians. <i>Annals of Emergency Medicine</i> , 2014, 63, 35-47.	0.3	54
625	The Meta-Genome of Sepsis: Host Genetics, Pathogens and the Acute Immune Response. <i>Journal of Innate Immunity</i> , 2014, 6, 272-283.	1.8	38
626	Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies. <i>Annals of the New York Academy of Sciences</i> , 2014, 1323, 101-114.	1.8	51
627	Sensitivity of systemic inflammatory response syndrome for critical illness among ED patients. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1319-1325.	0.7	21
628	Targeting HMGB1 in the treatment of sepsis. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 257-268.	1.5	125
629	Early versus delayed administration of norepinephrine in patients with septic shock. <i>Critical Care</i> , 2014, 18, 532.	2.5	219

#	ARTICLE	IF	CITATIONS
630	Early Identification and Management of Patients with Severe Sepsis and Septic Shock in the Emergency Department. <i>Emergency Medicine Clinics of North America</i> , 2014, 32, 759-776.	0.5	9
632	Anesthetic Care of Septic Patients. <i>Advances in Anesthesia</i> , 2014, 32, 191-203.	0.5	1
634	Red blood cell transfusion in septic shock - clinical characteristics and outcome of unselected patients in a prospective, multicentre cohort. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2014, 22, 14.	1.1	27
635	Clinical trials comparing norepinephrine with vasopressin in patients with septic shock: a meta-analysis. <i>Military Medical Research</i> , 2014, 1, 6.	1.9	8
636	Administration of intrapulmonary sodium polyacrylate to induce lung injury for the development of a porcine model of early acute respiratory distress syndrome. <i>Intensive Care Medicine Experimental</i> , 2014, 2, 5.	0.9	3
637	Timing of vasopressor initiation and mortality in septic shock: a cohort study. <i>Critical Care</i> , 2014, 18, R97.	2.5	124
638	Man With Air Below the Right Diaphragm. <i>Annals of Emergency Medicine</i> , 2014, 63, 13-47.	0.3	3
639	Is There a Good MAP for Septic Shock?. <i>New England Journal of Medicine</i> , 2014, 370, 1649-1651.	13.9	34
640	High versus Low Blood-Pressure Target in Patients with Septic Shock. <i>New England Journal of Medicine</i> , 2014, 370, 1583-1593.	13.9	911
642	Update in Sepsis and Pulmonary Infections 2013. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 25-31.	2.5	4
645	Vasoplegia in septic shock: Do we really fight the right enemy?. <i>Journal of Critical Care</i> , 2014, 29, 83-87.	1.0	48
646	Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials. <i>Journal of Critical Care</i> , 2014, 29, 706-710.	1.0	32
648	Early vasopressin reduces incidence of new onset arrhythmias. <i>Journal of Critical Care</i> , 2014, 29, 482-485.	1.0	33
649	Effects of terlipressin on microcirculation of small bowel mesentery in rats with endotoxic shock. <i>Journal of Surgical Research</i> , 2014, 188, 503-509.	0.8	11
650	How Outcomes Are Defined in Clinical Trials of Mechanically Ventilated Adults and Children. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 886-893.	2.5	58
651	Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1204-1213.	2.5	177
654	Vasoactive Agents. <i>Introductory Series in Medicine</i> , 2014, , 113-135.	0.0	0
656	Vasoconstrictor Responses to Vasopressor Agents in Human Pulmonary and Radial Arteries. <i>Anesthesiology</i> , 2014, 121, 930-936.	1.3	98

#	ARTICLE	IF	CITATIONS
658	Vasoactive drugs. , 0, , 161-172.		0
659	The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis*. Critical Care Medicine, 2014, 42, e525-e533.	0.4	75
660	Increased Activation of the Rho-A/Rho-Kinase Pathway in the Renal Vascular System Is Responsible for the Enhanced Reactivity to Exogenous Vasopressin in Endotoxemic Rats*. Critical Care Medicine, 2014, 42, e461-e471.	0.4	11
661	Angiotensin II in Septic Shock. Critical Care Medicine, 2014, 42, e550-e559.	0.4	61
662	Early Management of Severe Sepsis. Chest, 2014, 145, 1407-1418.	0.4	77
663	Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Critical Care, 2015, 19, 193.	2.5	18
665	Arterial system. , 0, , 144-149.		0
666	Vasopressin Decreases Pulmonaryâ€™toâ€™Systemic Vascular Resistance Ratio in a Porcine Model of Severe Hemorrhagic Shock. Shock, 2015, 43, 475-482.	1.0	28
667	Emerging therapies for the treatment of sepsis. Current Opinion in Anaesthesiology, 2015, 28, 411-416.	0.9	16
668	CT-proAVP IS NOT A GOOD PREDICTOR OF VASOPRESSOR NEED IN SEPTIC SHOCK. Shock, 2015, 44, 330-335.	1.0	5
669	C-TERMINAL PORTION OF PRO-ARGININE-VASOPRESSIN (CT-PRO-AVP) AS A PREDICTIVE BIOMARKER IN SEPSIS. Shock, 2015, 44, 381-382.	1.0	0
670	Endocrine dysfunction in sepsis: a beneficial or deleterious host response?. Germs, 2015, 5, 17-25.	0.5	38
671	What happens to the fluid balance during and after recovering from septic shock?. Revista Brasileira De Terapia Intensiva, 2015, 27, 10-7.	0.1	7
672	Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery. Current Vascular Pharmacology, 2015, 14, 63-72.	0.8	0
673	TRENDS OF VASOPRESSOR USING IN MEDICAL INTENSIVE CARE UNIT: A 7-YEAR COHORT STUDY. Intensive Care Medicine Experimental, 2015, 3, A960.	0.9	2
674	Vasopressors in septic shock: a systematic review and network meta-analysis. Therapeutics and Clinical Risk Management, 2015, 11, 1047.	0.9	44
675	Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0129305.	1.1	212
676	Non-Adrenergic Vasopressors in Patients with or at Risk for Vasodilatory Shock. A Systematic Review and Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0142605.	1.1	49

#	ARTICLE	IF	CITATIONS
677	Sepsis and ARDS: The Dark Side of Histones. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	62
678	Is It Time to Beta Block the Septic Patient?. BioMed Research International, 2015, 2015, 1-6.	0.9	14
679	Shock Management For Cardio-Surgical ICU Patients â€” The Golden Hours. Cardiac Failure Review, 2015, 1, 75.	1.2	14
680	Does the Mean Arterial Pressure Influence Mortality Rate in Patients with Acute Hypoxemic Respiratory Failure under Mechanical Ventilation?. Tuberculosis and Respiratory Diseases, 2015, 78, 85.	0.7	2
681	Raised cardiac troponin in intensive care patients with sepsis, in the absence of angiographically documented coronary artery disease: A systematic review. Journal of the Intensive Care Society, 2015, 16, 52-57.	1.1	29
682	Personalizing blood pressure management in septic shock. Annals of Intensive Care, 2015, 5, 41.	2.2	94
683	Prevention and treatment of sepsis-induced acute kidney injury: an update. Annals of Intensive Care, 2015, 5, 51.	2.2	46
684	<i>VPS13D</i> Gene Variant Is Associated with Altered IL-6 Production and Mortality in Septic Shock. Journal of Innate Immunity, 2015, 7, 545-553.	1.8	9
685	Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?. Critical Care, 2015, 19, 418.	2.5	191
686	A review of sepsis-induced cardiomyopathy. Journal of Intensive Care, 2015, 3, 48.	1.3	206
687	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine, the, 2015, 3, 53-60.	5.2	166
689	Farmacologia dei simpaticomimetici: indicazioni terapeutiche in rianimazione. EMC - Anestesia-Rianimazione, 2015, 20, 1-15.	0.1	0
691	Vasopressin Does Not Raise Cardiac Enzymes Following Cardiac Surgery: A Randomized Double-Blind Clinical Trial. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 46-51.	0.6	13
692	A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. Journal of Critical Care, 2015, 30, 653.e9-653.e17.	1.0	155
693	Exogenous Vasopressin-Induced Hyponatremia in Patients With Vasodilatory Shock. Journal of Intensive Care Medicine, 2015, 30, 253-258.	1.3	41
694	Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 249-260.	1.0	123
695	Early Peripheral Perfusionâ€”guided Fluid Therapy in Patients with Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 477-480.	2.5	60
696	Controversies regarding choice of vasopressor therapy for management of septic shock in animals. Journal of Veterinary Emergency and Critical Care, 2015, 25, 48-54.	0.4	21

#	ARTICLE	IF	CITATIONS
697	Sepsis-Induced Acute Kidney Injury. <i>Critical Care Clinics</i> , 2015, 31, 649-660.	1.0	71
698	Protocol-Based Management of Severe Sepsis and Septic Shock. <i>Current Anesthesiology Reports</i> , 2015, 5, 407-418.	0.9	0
699	AKI Associated with Cardiac Surgery. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 500-514.	2.2	232
701	Advances in Sepsis Research. <i>Clinics in Chest Medicine</i> , 2015, 36, 521-530.	0.8	14
702	Hormonal therapies in septic shock. <i>Journal of Pediatric Infectious Diseases</i> , 2015, 04, 119-126.	0.1	0
703	Current concepts on hemodynamic support and therapy in septic shock. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2015, 65, 395-402.	0.2	6
704	What's new in vasopressin?. <i>Intensive Care Medicine</i> , 2015, 41, 2177-2179.	3.9	11
706	Continuation of Statin Therapy and Vasopressor Use in Septic Shock. <i>Annals of Pharmacotherapy</i> , 2015, 49, 790-795.	0.9	2
707	Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. <i>Journal of Critical Care</i> , 2015, 30, 975-981.	1.0	68
708	Sepsis-Associated Acute Kidney Injury: Macrohemodynamic and Microhemodynamic Alterations in the Renal Circulation. <i>Seminars in Nephrology</i> , 2015, 35, 64-74.	0.6	105
709	Clinical Approach to the Patient With AKI and Sepsis. <i>Seminars in Nephrology</i> , 2015, 35, 12-22.	0.6	72
710	Beneficial and side effects of arginine vasopressin and terlipressin for septic shock. <i>Journal of Surgical Research</i> , 2015, 195, 568-579.	0.8	19
711	Multicenter, Randomized, Placebo-Controlled Phase III Study of Pyridoxalated Hemoglobin Polyoxyethylene in Distributive Shock (PHOENIX)*. <i>Critical Care Medicine</i> , 2015, 43, 57-64.	0.4	47
712	Cardiac Vasoplegia Syndrome: Pathophysiology, Risk Factors and Treatment. <i>American Journal of the Medical Sciences</i> , 2015, 349, 80-88.	0.4	122
713	Pharmacotherapy of Sepsis. <i>Critical Care Nursing Quarterly</i> , 2015, 38, 121-136.	0.4	2
714	Angiotensin II in septic shock. <i>Critical Care</i> , 2015, 19, 98.	2.5	78
715	Hypotensive resuscitation in combination with arginine vasopressin may prolong the hypotensive resuscitation time in uncontrolled hemorrhagic shock rats. <i>Journal of Trauma and Acute Care Surgery</i> , 2015, 78, 760-766.	1.1	5
716	Identification of a Nonsynonymous Polymorphism in the SVEP1 Gene Associated With Altered Clinical Outcomes in Septic Shock*. <i>Critical Care Medicine</i> , 2015, 43, 101-108.	0.4	29

#	ARTICLE	IF	CITATIONS
717	The impact of endocrine supplementation on adverse events in septic shock. <i>Journal of Critical Care</i> , 2015, 30, 1169-1173.	1.0	7
718	Insuffisance rénale aiguë péricritique : quoi de neuf ? <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2015, 24, 654-660.	0.1	0
719	Impact of endotracheal intubation on septic shock outcome: A post hoc analysis of the SEPSISPAM trial. <i>Journal of Critical Care</i> , 2015, 30, 1174-1178.	1.0	33
720	Early goal-directed therapy: from discovery through enthusiasm to equipoise?. <i>Intensive Care Medicine</i> , 2015, 41, 1676-1678.	3.9	2
721	Microcirculatory dysfunction and resuscitation: why, when, and how. <i>British Journal of Anaesthesia</i> , 2015, 115, 366-375.	1.5	61
722	The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. <i>British Journal of Anaesthesia</i> , 2015, 115, 656-675.	1.5	121
724	Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines. <i>Canadian Journal of Emergency Medicine</i> , 2015, 17, 1-16.	0.5	24
725	Risk factors for mortality in septic patients who received etomidate. <i>American Journal of Emergency Medicine</i> , 2015, 33, 1340-1343.	0.7	7
726	Early goal-directed resuscitation of patients with septic shock: current evidence and future directions. <i>Critical Care</i> , 2015, 19, 286.	2.5	51
727	Intraoperative administration of vasopressin during coronary artery bypass surgery is associated with acute postoperative kidney injury. <i>Journal of Critical Care</i> , 2015, 30, 963-968.	1.0	14
728	An ongoing search for potential targets and therapies for lethal sepsis. <i>Military Medical Research</i> , 2015, 2, 20.	1.9	10
730	Hyperlactatemia is an independent predictor of mortality and denotes distinct subtypes of severe sepsis and septic shock. <i>Journal of Critical Care</i> , 2015, 30, 439.e1-439.e6.	1.0	64
731	Essentials of Sepsis Management. <i>Surgical Clinics of North America</i> , 2015, 95, 355-365.	0.5	4
732	Management of Complications of End-Stage Liver Disease in the Intensive Care Unit. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 94-103.	1.3	8
733	Lactic acidosis, hyperlactatemia and sepsis. <i>Italian Journal of Medicine</i> , 2016, 10, 282.	0.2	3
734	The quest for the optimal blood pressure in septic shock. <i>Journal of Thoracic Disease</i> , 2016, 8, E1019-E1022.	0.6	3
735	Nephroprotective strategies in septic shock: the VANISH trial. <i>Journal of Thoracic Disease</i> , 2016, 8, E1508-E1510.	0.6	2
736	Effects of Safflower Yellow on the Treatment of Severe Sepsis and Septic Shock: A Randomized Controlled Clinical Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	5

#	ARTICLE	IF	CITATIONS
737	Vasoactive agents for the treatment of sepsis. <i>Annals of Translational Medicine</i> , 2016, 4, 333-333.	0.7	21
738	The Treatment of Sepsis: From Failed Therapies to New Possibilities. , 2016, , 221-231.		1
739	Noradrenaline. , 2016, , 273.		0
740	Involvement of Central Endothelin ETA and Cannabinoid CB1 Receptors and Arginine Vasopressin Release in Sepsis Induced by Cecal Ligation and Puncture in Rats. <i>Shock</i> , 2016, 46, 290-296.	1.0	12
741	Interleukin-6 Levels Act as a Diagnostic Marker for Infection and a Prognostic Marker in Patients with Organ Dysfunction in Intensive Care Units. <i>Shock</i> , 2016, 46, 254-260.	1.0	56
742	Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 550-558.	2.5	105
743	Midodrine for the weaning of vasopressor infusions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 260-265.	0.7	31
744	Genetic and epigenetic factors in the regulation of the immune response. <i>Current Opinion in Pediatrics</i> , 2016, 28, 281-286.	1.0	6
745	Selepressin in Septic Shock. <i>Critical Care Medicine</i> , 2016, 44, 234-236.	0.4	19
746	Vasopressors for hypotensive shock. <i>The Cochrane Library</i> , 2016, 2, CD003709.	1.5	127
747	Increased Ratio of Visceral to Subcutaneous Adipose Tissue in Septic Patients Is Associated With Adverse Outcome*. <i>Critical Care Medicine</i> , 2016, 44, 1966-1973.	0.4	31
748	Elevated Plasma Angiopoietin-2 Levels Are Associated With Fluid Overload, Organ Dysfunction, and Mortality in Human Septic Shock. <i>Critical Care Medicine</i> , 2016, 44, 2018-2027.	0.4	52
749	Assessment of adequacy of volume resuscitation. <i>Current Opinion in Critical Care</i> , 2016, 22, 424-427.	1.6	13
750	Renal protection in the 21st century. <i>Current Opinion in Critical Care</i> , 2016, 22, 554-559.	1.6	5
751	Genomics and pharmacogenomics of sepsis: so close and yet so far. <i>Critical Care</i> , 2016, 20, 185.	2.5	14
752	Management of acute kidney injury in sepsis. <i>Clinical Queries Nephrology</i> , 2016, 5, 16-20.	0.2	0
753	Methylene blue compared to norepinephrine in the management of vasoplegic syndrome in pediatric patients after cardiopulmonary bypass: a randomized controlled study. <i>Egyptian Journal of Anaesthesia</i> , 2016, 32, 269-275.	0.2	10
754	Preventive strategies and potential therapeutic interventions for delirium in sepsis. <i>Hospital Practice (1995)</i> , 2016, 44, 190-202.	0.5	4

#	ARTICLE	IF	CITATIONS
755	Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial. <i>Critical Care</i> , 2016, 20, 82.	2.5	46
756	Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure. <i>Journal of Intensive Care</i> , 2016, 4, 24.	1.3	38
757	Vasopressors in shock: are we meeting our target and do we really understand what we are aiming at?. <i>Intensive Care Medicine</i> , 2016, 42, 1176-1178.	3.9	10
758	Septic shock: A global response. <i>Presse Medicale</i> , 2016, 45, e91-e92.	0.8	1
759	Plasma cytokine levels predict response to corticosteroids in septic shock. <i>Intensive Care Medicine</i> , 2016, 42, 1970-1979.	3.9	35
760	Vasopressin in Pediatric Critical Care. <i>Journal of Pediatric Intensive Care</i> , 2016, 05, 182-188.	0.4	3
761	Echocardiography as a guide for fluid management. <i>Critical Care</i> , 2016, 20, 274.	2.5	63
762	Vasopressin to Reduce Mortality in Patients with Septic Shock and Acute Kidney Injury. , 2016, , 113-120.		0
763	TNFAIP2 Inhibits Early TNF α -Induced NF- κ B Signaling and Decreases Survival in Septic Shock Patients. <i>Journal of Innate Immunity</i> , 2016, 8, 57-66.	1.8	28
764	Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. <i>New England Journal of Medicine</i> , 2016, 375, 1638-1648.	13.9	271
765	Heparin-binding protein is important for vascular leak in sepsis. <i>Intensive Care Medicine Experimental</i> , 2016, 4, 33.	0.9	64
766	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 509.	3.8	456
767	Scandinavian <sc>SSAI</sc> clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure. <i>Acta Anaesthesiologica Scandinavica</i> , 2016, 60, 1347-1366.	0.7	45
768	Control groups in recent septic shock trials: a systematic review. <i>Intensive Care Medicine</i> , 2016, 42, 1912-1921.	3.9	13
769	Epidemiology of Vasopressin Use for Adults with Septic Shock. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1760-1767.	1.5	31
771	Reducing Mortality in Acute Kidney Injury. , 2016, , .		0
772	Sepsis and septic shock. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16045.	18.1	978
773	Vasopressin: a first-line agent for septic shock?. <i>Nature Reviews Nephrology</i> , 2016, 12, 718-719.	4.1	9

#	ARTICLE	IF	CITATIONS
774	Effect of non-adrenergic vasopressors on macro- and microvascular coupling in distributive shock. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2016, 30, 465-477.	1.7	19
775	Precision Fluid Management in Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2016, 42, 266-278.	0.9	68
776	Evaluation and treatment of the critically ill cirrhotic patient. <i>GastroenterologËa Y HepatologËa (English Edition)</i> , 2016, 39, 607-626.	0.0	1
777	Vasopressors During Sepsis. <i>Clinics in Chest Medicine</i> , 2016, 37, 251-262.	0.8	12
779	Effect of Body Weight on Hemodynamic Response in Patients Receiving Fixed-Dose Vasopressin for Septic Shock. <i>Annals of Pharmacotherapy</i> , 2016, 50, 816-823.	0.9	12
780	Sepsi acuta. <i>EMC - Urgenze</i> , 2016, 20, 1-11.	0.0	0
781	Goal-directed therapy to maintain haemostasis. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2016, 30, 217-228.	1.7	4
782	Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 147-155.	2.5	260
783	Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-analysis. <i>Journal of the Intensive Care Society</i> , 2016, 17, 136-145.	1.1	13
784	Postoperative blood pressure deficit and acute kidney injury progression in vasopressor-dependent cardiovascular surgery patients. <i>Critical Care</i> , 2016, 20, 74.	2.5	61
785	The use of angiotensin II in distributive shock. <i>Critical Care</i> , 2016, 20, 137.	2.5	26
786	Temporal trends in the utilization of vasopressors in intensive care units: an epidemiologic study. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 19.	1.0	21
787	Mean arterial pressure and vasopressor load after out-of-hospital cardiac arrest: Associations with one-year neurologic outcome. <i>Resuscitation</i> , 2016, 105, 116-122.	1.3	66
788	A Selective V1A Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock*. <i>Critical Care Medicine</i> , 2016, 44, 23-31.	0.4	83
789	Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis. <i>Journal of Innate Immunity</i> , 2016, 8, 211-220.	1.8	107
790	Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. <i>Intensive Care Medicine</i> , 2016, 42, 1387-1397.	3.9	135
791	Pharmacological modulation of cardiac function and blood vessel calibre. <i>Anaesthesia and Intensive Care Medicine</i> , 2016, 17, 48-54.	0.1	0
794	Beyond the Golden Hours. <i>Clinics in Chest Medicine</i> , 2016, 37, 347-365.	0.8	1

#	ARTICLE	IF	CITATIONS
795	Management of Acute Kidney Injury and Acid-Base Balance in the Septic Patient. <i>Clinics in Chest Medicine</i> , 2016, 37, 277-288.	0.8	7
796	Cardiac Function and Dysfunction in Sepsis. <i>Clinics in Chest Medicine</i> , 2016, 37, 289-298.	0.8	41
797	Lactic Acidosis in Sepsis: It's Not All Anaerobic. <i>Chest</i> , 2016, 149, 252-261.	0.4	244
798	Emerging drugs for the treatment of sepsis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 27-37.	1.0	24
799	Norepinephrine Dosing in Obese and Nonobese Patients With Septic Shock. <i>American Journal of Critical Care</i> , 2016, 25, 27-32.	0.8	20
800	Challenges with Diagnosing and Managing Sepsis in Older Adults. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 231-241.	2.0	50
801	Quantifying the improvement in sepsis diagnosis, documentation, and coding: the marginal causal effect of year of hospitalization on sepsis diagnosis. <i>Annals of Epidemiology</i> , 2016, 26, 66-70.	0.9	28
802	Effects of terlipressin on patients with sepsis via improving tissue blood flow. <i>Journal of Surgical Research</i> , 2016, 200, 274-282.	0.8	48
803	Comparative Effectiveness of Second Vasoactive Agents in Septic Shock Refractory to Norepinephrine. <i>Journal of Intensive Care Medicine</i> , 2017, 32, 451-459.	1.3	12
804	Tolerability of Enteral Nutrition in Mechanically Ventilated Patients With Septic Shock Who Require Vasopressors. <i>Journal of Intensive Care Medicine</i> , 2017, 32, 540-546.	1.3	45
805	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Medicine</i> , 2017, 43, 304-377.	3.9	4,590
806	Intensity of Vasopressor Therapy for Septic Shock and the Risk of In-Hospital Death. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 938-943.	0.6	28
807	Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis. <i>Critical Care</i> , 2017, 21, 1.	2.5	146
808	PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. <i>Journal of Cellular Physiology</i> , 2017, 232, 2330-2338.	2.0	61
809	Rebranding of generic parenteral vasopressin: Effect on clinician practices and perceptions. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 105-106.	0.5	11
810	Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit. <i>Annals of Pharmacotherapy</i> , 2017, 51, 203-208.	0.9	19
811	Vasopressors induce passive pulmonary hypertension by blood redistribution from systemic to pulmonary circulation. <i>Basic Research in Cardiology</i> , 2017, 112, 21.	2.5	7
812	New Consensus Definitions for Sepsis and Septic Shock: Implications for Treatment Strategies and Drug Development?. <i>Drugs</i> , 2017, 77, 353-361.	4.9	8

#	ARTICLE	IF	CITATIONS
813	Neuroendocrine Derangements in Early Septic Shock. <i>Shock</i> , 2017, 48, 284-293.	1.0	8
814	Utilizing a drug information center for submitting reconsiderations for local coverage determinations. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 106-107.	0.5	3
815	Non-Hemodynamic Effects of Catecholamines. <i>Shock</i> , 2017, 48, 390-400.	1.0	58
816	EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. <i>Journal of Hepatology</i> , 2017, 66, 1047-1081.	1.8	601
817	Cardiovascular Responsiveness to Vasopressin and β 1-Adrenergic Receptor Agonists After Burn Injury. <i>Journal of Burn Care and Research</i> , 2017, 38, 90-98.	0.2	5
818	Sepsis and septic shock: Pathogenesis and treatment perspectives. <i>Journal of Critical Care</i> , 2017, 40, 229-242.	1.0	105
819	A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension. <i>Canadian Journal of Anaesthesia</i> , 2017, 64, 703-715.	0.7	39
820	The intensive care medicine research agenda on septic shock. <i>Intensive Care Medicine</i> , 2017, 43, 1294-1305.	3.9	61
821	Norepinephrine in septic shock: when and how much?. <i>Current Opinion in Critical Care</i> , 2017, 23, 342-347.	1.6	36
822	Prevention and Therapy of Acute Kidney Injury in the Developing World. <i>Kidney International Reports</i> , 2017, 2, 544-558.	0.4	21
823	Vasopressin Dosing for Septic Shock. <i>Annals of Pharmacotherapy</i> , 2017, 51, 711-712.	0.9	1
824	Vasoplegic syndrome: An update on perioperative considerations. <i>Journal of Clinical Anesthesia</i> , 2017, 40, 63-71.	0.7	57
825	Concomitant vasopressin and hydrocortisone therapy on short-term hemodynamic effects and vasopressor requirements in refractory septic shock. <i>Journal of Critical Care</i> , 2017, 42, 6-11.	1.0	3
826	American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. <i>Critical Care Medicine</i> , 2017, 45, 1061-1093.	0.4	475
827	37th International Symposium on Intensive Care and Emergency Medicine (part 1 of 3). <i>Critical Care</i> , 2017, 21, .	2.5	1
828	Vasopressin, Norepinephrine, and Vasodilatory Shock after Cardiac Surgery. <i>Anesthesiology</i> , 2017, 126, 9-11.	1.3	8
829	Greater Treatment Effect With Lower Disease Severity. <i>Critical Care Medicine</i> , 2017, 45, 1094-1095.	0.4	2
831	The Use of Stroke Volume Variation to Guide Donor Management Is Associated With Increased Organs Transplanted per Donor. <i>Progress in Transplantation</i> , 2017, 27, 200-206.	0.4	3

#	ARTICLE	IF	CITATIONS
832	Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017. <i>Intensive Care Medicine</i> , 2017, 43, 730-749.	3.9	243
833	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Critical Care Medicine</i> , 2017, 45, 486-552.	0.4	2,336
834	Heparin-Binding Protein (HBP). <i>Shock</i> , 2017, 48, 313-320.	1.0	43
835	Organ donor management: Eight common recommendations and actions that deserve reflection. <i>Medicina Intensiva</i> , 2017, 41, 559-568.	0.4	17
836	The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience*. <i>Critical Care Medicine</i> , 2017, 45, 940-948.	0.4	54
837	Evaluating the impact of obesity on safety and efficacy of weight-based norepinephrine dosing in septic shock: A single-center, retrospective study. <i>Intensive and Critical Care Nursing</i> , 2017, 41, 104-108.	1.4	6
838	Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery. <i>Anesthesiology</i> , 2017, 126, 85-93.	1.3	237
839	The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock. <i>Journal of Critical Care</i> , 2017, 40, 41-45.	1.0	25
840	Sepsis: Current Definition, Pathophysiology, Diagnosis, and Management. <i>Nutrition in Clinical Practice</i> , 2017, 32, 296-308.	1.1	77
841	Sepsis-related mortality in 497 cases with blood culture-positive sepsis in an emergency department. <i>International Journal of Infectious Diseases</i> , 2017, 58, 52-57.	1.5	34
842	Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock. <i>Chest</i> , 2017, 151, 1229-1238.	0.4	729
843	Early Management of Sepsis, Severe Sepsis, and Septic Shock in the Surgical Patient. , 2017, , 71-93.		3
844	R1 autonomic nervous system in acute kidney injury. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 162-171.	0.9	20
845	Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors. <i>Critical Care Medicine</i> , 2017, 45, e1226-e1232.	0.4	8
846	Terlipressin versus other vasoactive drugs for hepatorenal syndrome. <i>The Cochrane Library</i> , 2017, 2017, CD011532.	1.5	34
847	Septic shock resuscitation in the first hour. <i>Current Opinion in Critical Care</i> , 2017, 23, 561-566.	1.6	14
848	What Definition Should We Use for Sepsis and Septic Shock?*. <i>Critical Care Medicine</i> , 2017, 45, 1564-1567.	0.4	8
849	New Guidelines on Noninvasive Ventilation. A Few Answers, and Several More Questions. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 811-813.	2.5	3

#	ARTICLE	IF	CITATIONS
850	The critical care literature 2016. <i>American Journal of Emergency Medicine</i> , 2017, 35, 1547-1554.	0.7	0
851	Postoperative complications in cirrhotic pediatric deceased donor liver transplantation: Focus on transfusion therapy. <i>Pediatric Transplantation</i> , 2017, 21, e13020.	0.5	9
852	Serum levels of interleukin-6 may predict organ dysfunction earlier than <sc>SOFA</sc> score. <i>Acute Medicine & Surgery</i> , 2017, 4, 255-261.	0.5	17
854	Prevention preferable to treatment. <i>Medicine (United States)</i> , 2017, 96, e5627.	0.4	0
855	Sepsis and Septic Shock Strategies. <i>Surgical Clinics of North America</i> , 2017, 97, 1339-1379.	0.5	61
857	Update of Sepsis in the Intensive Care Unit. <i>Journal of Innate Immunity</i> , 2017, 9, 441-455.	1.8	106
859	Veno-Venous Extracorporeal Life Support in Hemodynamically Unstable Patients With ARDS. <i>Anesthesia and Analgesia</i> , 2017, 124, 846-848.	1.1	24
860	Perioperative Myocardial Infarction in Non-Cardiac Surgery Patients: A Prospective Observational Study. <i>Scandinavian Journal of Surgery</i> , 2017, 106, 180-186.	1.3	15
861	Acute Kidney Injury After Cardiac Surgery by Complete KDIGO Criteria Predicts Increased Mortality. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 827-836.	0.6	44
862	Optimum treatment of vasopressor-dependent distributive shock. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 5-10.	2.0	7
863	Practical Considerations in Sepsis Resuscitation. <i>Journal of Emergency Medicine</i> , 2017, 52, 472-483.	0.3	8
864	Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. <i>Journal of Critical Care</i> , 2017, 37, 219-223.	1.0	18
865	The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. <i>Journal of Critical Care</i> , 2017, 37, 91-98.	1.0	60
866	Postoperative Cardiac Ischemia Detection by Continuous 12-Lead Electrocardiographic Monitoring in Vascular Surgery Patients: A Prospective, Observational Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 950-956.	0.6	7
867	Risk of Hyponatremia in Patients with Aneurysmal Subarachnoid Hemorrhage Treated with Exogenous Vasopressin Infusion. <i>Neurocritical Care</i> , 2017, 26, 182-190.	1.2	5
868	Vasopressors and Inotropes in Sepsis. <i>Emergency Medicine Clinics of North America</i> , 2017, 35, 75-91.	0.5	40
869	Impact of Norepinephrine Weight-Based Dosing Compared With Non-Weight-Based Dosing in Achieving Time to Goal Mean Arterial Pressure in Obese Patients With Septic Shock. <i>Annals of Pharmacotherapy</i> , 2017, 51, 194-202.	0.9	12
870	A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. <i>Liver International</i> , 2017, 37, 552-561.	1.9	82

#	ARTICLE	IF	CITATIONS
871	Understanding patient-centredness: contrasting expert versus patient perspectives on vasopressor therapy for shock. <i>Intensive Care Medicine</i> , 2017, 43, 1052-1054.	3.9	8
872	Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock. <i>Annals of Pharmacotherapy</i> , 2017, 51, 13-20.	0.9	28
873	Organ donor management: Eight common recommendations and actions that deserve reflection. <i>Medicina Intensiva (English Edition)</i> , 2017, 41, 559-568.	0.1	1
874	Migraine and risk of perioperative ischemic stroke and hospital readmission: hospital based registry study. <i>BMJ: British Medical Journal</i> , 2017, 356, i6635.	2.4	48
875	The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. <i>Critical Care</i> , 2017, 21, 324.	2.5	44
876	Predicting and managing sepsis in burn patients: current perspectives. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1107-1117.	0.9	72
877	Detecting impaired myocardial relaxation in sepsis with a novel tissue Doppler parameter (septal e^{\prime}). <i>Critical Care</i> , 2017, 21, 175.	2.5	9
878	Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. <i>Critical Care</i> , 2017, 21, 213.	2.5	93
879	Combined use of high doses of vasopressin and corticosteroids in a patient with Crohn's disease with refractory septic shock after intestinal perforation: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 320.	0.4	4
880	Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury. <i>Annals of Intensive Care</i> , 2017, 7, 105.	2.2	34
881	Application of updated guidelines on diastolic dysfunction in patients with severe sepsis and septic shock. <i>Annals of Intensive Care</i> , 2017, 7, 121.	2.2	25
882	Validating a point of care lactate meter in adult patients with sepsis presenting to the emergency department of a tertiary care hospital of a low- to middle-income country. <i>World Journal of Emergency Medicine</i> , 2017, 8, 184.	0.5	15
883	25 Systemic Complications and Disease-Specific Phenomena Leading to Ischemic Injury. , 2017, , .		0
884	Role of vasopressin in current anesthetic practice. <i>Korean Journal of Anesthesiology</i> , 2017, 70, 245.	0.9	26
885	Vasopressor hormones in shock—noradrenaline, vasopressin or angiotensin II: which one will make the race?. <i>Journal of Thoracic Disease</i> , 2017, 9, 1843-1847.	0.6	1
887	Vasopressors in Sepsis. , 2018, , 127-138.		1
888	Association between intraoperative opioid administration and 30-day readmission: a pre-specified analysis of registry data from a healthcare network in New England. <i>British Journal of Anaesthesia</i> , 2018, 120, 1090-1102.	1.5	79
889	The Endocrine System in Sepsis. , 2018, , 61-79.		1

#	ARTICLE	IF	CITATIONS
890	Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. <i>Critical Care Medicine</i> , 2018, 46, e628-e633.	0.4	32
891	Prospective Open-label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock. <i>Pharmacotherapy</i> , 2018, 38, 531-538.	1.2	59
892	Review article: Sepsis in the emergency department – Part 3: Treatment. <i>EMA - Emergency Medicine Australasia</i> , 2018, 30, 144-151.	0.5	10
893	Handbook of Sepsis. , 2018, , .		10
894	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (JSCG 2016). <i>Acute Medicine & Surgery</i> , 2018, 5, 3-89.	0.5	61
895	The IL20 Genetic Polymorphism Is Associated with Altered Clinical Outcome in Septic Shock. <i>Journal of Innate Immunity</i> , 2018, 10, 181-188.	1.8	8
896	Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms. <i>Journal of International Medical Research</i> , 2018, 46, 1303-1310.	0.4	47
897	Vasopressors in Sepsis. <i>Surgical Infections</i> , 2018, 19, 202-207.	0.7	22
898	Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock. <i>Pharmacotherapy</i> , 2018, 38, 319-326.	1.2	24
899	Evaluation of Vasopressin for Vasoplegic Shock in Patients With Preoperative Left Ventricular Dysfunction After Cardiac Surgery: A Propensity-Score Analysis. <i>Shock</i> , 2018, 50, 519-524.	1.0	17
900	Is Heparin-Binding Protein Inhibition a Mechanism of Albumin's Efficacy in Human Septic Shock?. <i>Critical Care Medicine</i> , 2018, 46, e364-e374.	0.4	14
901	The adrenergic system as an alternative to catecholamines in low-output septic shock. <i>Critical Care</i> , 2018, 22, 10.	2.5	17
902	Angiotensin II increases blood pressure in patients with refractory vasodilatory shock. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 42-43.	1.7	0
903	Management of Refractory Vasodilatory Shock. <i>Chest</i> , 2018, 154, 416-426.	0.4	157
904	Procalcitonin and Presepsin as Prognostic Markers After Out-of-Hospital Cardiac Arrest. <i>Shock</i> , 2018, 50, 395-400.	1.0	20
905	Pharmacological Considerations in Acute and Chronic Liver Disease. , 2018, , 211-232.		0
906	In Reply. <i>Anesthesiology</i> , 2018, 128, 231-233.	1.3	0
907	Inclusion and definition of acute renal dysfunction in critically ill patients in randomized controlled trials: a systematic review. <i>Critical Care</i> , 2018, 22, 106.	2.5	5

#	ARTICLE	IF	CITATIONS
908	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). <i>Journal of Intensive Care</i> , 2018, 6, 7.	1.3	74
911	Early-phase Innate Immune Suppression in Murine Severe Sepsis Is Restored with Systemic Interferon- $\hat{1}^2$. <i>Anesthesiology</i> , 2018, 129, 131-142.	1.3	6
912	Angiotensin in Critical Care. Annual Update in Intensive Care and Emergency Medicine, 2018, , 113-122.	0.1	0
913	Vasodilatory Shock in the ICU: Perils, Pitfalls and Therapeutic Options. Annual Update in Intensive Care and Emergency Medicine, 2018, , 99-111.	0.1	2
914	A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock. <i>Annals of Pharmacotherapy</i> , 2018, 52, 920-927.	0.9	8
915	Hemodynamic Support. Hot Topics in Acute Care Surgery and Trauma, 2018, , 343-357.	0.1	0
916	Evaluating Vasopressor Discontinuation Strategies in Patients With Septic Shock on Concomitant Norepinephrine and Vasopressin Infusions. <i>Annals of Pharmacotherapy</i> , 2018, 52, 733-739.	0.9	27
917	Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. <i>Intensive Care Medicine</i> , 2018, 44, 311-322.	3.9	57
918	Cerebral Blood Flow Autoregulation in Sepsis for the Intensivist: Why Its Monitoring May Be the Future of Individualized Care. <i>Journal of Intensive Care Medicine</i> , 2018, 33, 63-73.	1.3	37
919	Misdirected Sympathy: The Role of Sympatholysis in Sepsis and Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2018, 33, 74-86.	1.3	24
920	Effects of Intraoperative Fluid Management on Postoperative Outcomes. <i>Annals of Surgery</i> , 2018, 267, 1084-1092.	2.1	165
921	Untreated Relative Hypotension Measured as Perfusion Pressure Deficit During Management of Shock and New-Onset Acute Kidney Injury”A Literature Review. <i>Shock</i> , 2018, 49, 497-507.	1.0	9
922	Novel Interventions. <i>Critical Care Clinics</i> , 2018, 34, 161-173.	1.0	21
923	Patterns of vasopressor utilization during the resuscitation of massively transfused trauma patients. <i>Injury</i> , 2018, 49, 8-14.	0.7	11
924	Predictors of Vasopressin Responsiveness in Critically Ill Adults. <i>Annals of Pharmacotherapy</i> , 2018, 52, 126-132.	0.9	6
925	Intensive care medicine in 2050: vasopressors in sepsis. <i>Intensive Care Medicine</i> , 2018, 44, 1130-1132.	3.9	8
926	Chimeric antigen receptor T-cell therapy “assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
927	Diabetes insipidus after discontinuation of vasopressin infusion for septic shock. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 287-290.	0.7	13

#	ARTICLE	IF	CITATIONS
928	Pathophysiology of Septic Shock. <i>Critical Care Clinics</i> , 2018, 34, 43-61.	1.0	78
929	Vasoplegia After Cardiovascular Procedures—Pathophysiology and Targeted Therapy. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1013-1022.	0.6	119
930	Vasopressin versus Norepinephrine after Cardiopulmonary Bypass. <i>Anesthesiology</i> , 2018, 128, 229-230.	1.3	0
931	Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. <i>Shock</i> , 2018, 50, 388-394.	1.0	7
932	Vitamin C in sepsis. <i>Current Opinion in Anaesthesiology</i> , 2018, 31, 55-60.	0.9	64
933	Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series. <i>Canadian Journal of Anaesthesia</i> , 2018, 65, 560-568.	0.7	65
934	Pulmonary Hypertension in Patients for Transcatheter and Surgical Aortic Valve Replacement: A Focus on Outcomes and Perioperative Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 2005-2018.	0.6	4
935	Clinical applications of lactate testing in patients with sepsis and septic shock. <i>Journal of Emergency and Critical Care Medicine</i> , 0, 2, 14-14.	0.7	10
936	Terlipressin for septic shock patients: protocol for a systematic review and meta-analysis. <i>Journal of Emergency and Critical Care Medicine</i> , 0, 2, 108-108.	0.7	1
937	When All Else Fails: Novel Use of Angiotensin II for Vasodilatory Shock: A Case Report. <i>A&A Practice</i> , 2018, 11, 175-180.	0.2	24
938	Vasopressin-induced hyponatremia in a patient with pulmonary hypertension and right heart failure treated for septic shock. <i>Case Reports in Internal Medicine</i> , 2018, 5, 36.	0.0	0
939	Hyperoxia toxicity in septic shock patients according to the Sepsis-3 criteria: a post hoc analysis of the HYPER2S trial. <i>Annals of Intensive Care</i> , 2018, 8, 90.	2.2	34
941	Development and performance of a novel vasopressor-driven mortality prediction model in septic shock. <i>Annals of Intensive Care</i> , 2018, 8, 112.	2.2	43
942	CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. <i>Scientific Reports</i> , 2018, 8, 16764.	1.6	26
943	Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. <i>EBioMedicine</i> , 2018, 38, 257-264.	2.7	34
944	Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. <i>Journal of Intensive Care</i> , 2018, 6, 73.	1.3	12
945	Pharmacological modulation of cardiac function and blood vessel calibre. <i>Anaesthesia and Intensive Care Medicine</i> , 2018, 19, 648-655.	0.1	0
946	When and how to use predictive biomarkers for corticosteroid treatment of septic shock. <i>Critical Care</i> , 2018, 22, 318.	2.5	3

#	ARTICLE	IF	CITATIONS
948	Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions. <i>Annals of Intensive Care</i> , 2018, 8, 102.	2.2	31
949	Essentials of Shock Management. , 2018, , .		0
950	Mean arterial pressure and mortality in patients with distributive shock: a retrospective analysis of the MIMIC-III database. <i>Annals of Intensive Care</i> , 2018, 8, 107.	2.2	89
951	Intraoperative management of liver transplant recipients having severe renal dysfunction: results of 42 cases. <i>Annals of Surgical Treatment and Research</i> , 2018, 95, 45.	0.4	8
952	Renal autoregulation in experimental septic shock and its response to vasopressin and norepinephrine administration. <i>Journal of Applied Physiology</i> , 2018, 125, 1661-1669.	1.2	4
953	Septic shock-3 vs 2: an analysis of the ALBIOS study. <i>Critical Care</i> , 2018, 22, 237.	2.5	17
954	Net ultrafiltration intensity and mortality in critically ill patients with fluid overload. <i>Critical Care</i> , 2018, 22, 223.	2.5	72
955	Vitamin C supplementation in the critically ill: A systematic review and meta-analysis. <i>SAGE Open Medicine</i> , 2018, 6, 205031211880761.	0.7	48
956	Perioperative renal protection. <i>Current Opinion in Critical Care</i> , 2018, 24, 568-574.	1.6	10
957	Are large randomised controlled trials in severe sepsis and septic shock statistically disadvantaged by repeated inadvertent underestimates of required sample size?. <i>BMJ Open</i> , 2018, 8, e020068.	0.8	12
958	Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. <i>Critical Care</i> , 2018, 22, 285.	2.5	113
959	Norepinephrine Administration Is Associated with Higher Mortality in Dialysis Requiring Acute Kidney Injury Patients with Septic Shock. <i>Journal of Clinical Medicine</i> , 2018, 7, 274.	1.0	13
960	Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. <i>Journal of Critical Care</i> , 2018, 47, 333-337.	1.0	34
961	Searching for better outcomes in septic shock trials. <i>Journal of Critical Care</i> , 2018, 47, 331-332.	1.0	0
962	Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. <i>Journal of Critical Care</i> , 2018, 47, 211-218.	1.0	102
963	Vasopressin atrial coronary constriction in humans: The unknown clinical significance of a laboratory finding. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 2108-2109.	0.4	0
964	Surviving sepsis campaign: research priorities for sepsis and septic shock. <i>Intensive Care Medicine</i> , 2018, 44, 1400-1426.	3.9	159
965	Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. <i>Intensive Care Medicine</i> , 2018, 44, 1816-1825.	3.9	106

#	ARTICLE	IF	CITATIONS
967	Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock. <i>Critical Care Medicine</i> , 2018, 46, 1334-1356.	0.4	102
968	Terlipressin or norepinephrine, or both in septic shock?. <i>Intensive Care Medicine</i> , 2018, 44, 1964-1966.	3.9	10
969	Hyperinflation of Vasopressors (Vasopressin, Norepinephrine, Ephedrine, etc). <i>Journal of Pharmacy Practice</i> , 2018, 31, 399-402.	0.5	4
972	Vasoplegia treatments: the past, the present, and the future. <i>Critical Care</i> , 2018, 22, 52.	2.5	134
973	Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis. <i>Annals of Intensive Care</i> , 2018, 8, 16.	2.2	2
974	Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1889.	3.8	145
975	Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. <i>Journal of Hematology and Oncology</i> , 2018, 11, 35.	6.9	302
976	Angiotensin in Critical Care. <i>Critical Care</i> , 2018, 22, 69.	2.5	46
977	Predictors of response to fixed-dose vasopressin in adult patients with septic shock. <i>Annals of Intensive Care</i> , 2018, 8, 35.	2.2	71
978	Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock. <i>Scientific Reports</i> , 2018, 8, 7105.	1.6	12
979	In Reply. <i>Anesthesiology</i> , 2018, 128, 230-231.	1.3	0
980	Angiotensin II: a new therapeutic option for vasodilatory shock. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1287-1298.	0.9	21
981	Comparison of qSOFA and SOFA score for predicting mortality in severe sepsis and septic shock patients in the emergency department of a low middle income country. <i>Turkish Journal of Emergency Medicine</i> , 2018, 18, 148-151.	0.3	18
982	Management of acute-on-chronic liver failure: an algorithmic approach. <i>Hepatology International</i> , 2018, 12, 402-416.	1.9	31
983	Esmolol infusion in patients with septic shock and tachycardia: a prospective, single-arm, feasibility study. <i>Pilot and Feasibility Studies</i> , 2018, 4, 132.	0.5	12
984	A global perspective on vasoactive agents in shock. <i>Intensive Care Medicine</i> , 2018, 44, 833-846.	3.9	69
985	Safe Use of Vasopressin and Angiotensin <sc>II</sc> for Patients with Circulatory Shock. <i>Pharmacotherapy</i> , 2018, 38, 851-861.	1.2	18
986	Vasodilatory shock in the ICU and the role of angiotensin II. <i>Current Opinion in Critical Care</i> , 2018, 24, 277-285.	1.6	13

#	ARTICLE	IF	CITATIONS
987	Sepsis and septic shock. Lancet, The, 2018, 392, 75-87.	6.3	1,205
988	Sepsis: An Update on Current Practices in Diagnosis and Management. American Journal of the Medical Sciences, 2018, 356, 277-286.	0.4	46
989	Sepsis-induced acute kidney injury: A disease of the microcirculation. Microcirculation, 2019, 26, e12483.	1.0	118
990	Does the Implementation of a Quality Improvement Care Bundle Reduce the Incidence of Acute Kidney Injury in Patients Undergoing Emergency Laparotomy?. Journal of Clinical Medicine, 2019, 8, 1265.	1.0	6
994	Cell Components and Function. , 2019, , 6-8.		0
996	The Cell Membrane. , 2019, , 13-17.		0
998	The Lower Airways. , 2019, , 24-29.		0
999	Oxygen Transport. , 2019, , 30-36.		1
1000	Carbon Dioxide Transport. , 2019, , 37-39.		0
1001	Alveolar Diffusion. , 2019, , 40-44.		0
1002	Ventilation and Dead Space. , 2019, , 45-49.		0
1003	Static Lung Volumes. , 2019, , 50-55.		0
1004	Spirometry. , 2019, , 56-62.		0
1005	Hypoxia and Shunts. , 2019, , 63-67.		0
1006	Ventilation-Perfusion Relationships. , 2019, , 68-70.		7
1007	Ventilation-Perfusion Zones in the Lung. , 2019, , 71-73.		0
1008	Oxygen Delivery and Demand. , 2019, , 74-76.		0
1009	Alveolar Gas Equation. , 2019, , 77-79.		0

#	ARTICLE	IF	CITATIONS
1010	Oxygen Cascade. , 2019, , 80-81.		1
1011	Lung Compliance. , 2019, , 82-87.		0
1012	Work of Breathing. , 2019, , 88-92.		0
1013	Control of Ventilation. , 2019, , 93-96.		0
1014	Pulmonary Circulation. , 2019, , 97-101.		0
1015	Oxygen Toxicity. , 2019, , 102-103.		0
1016	Ventilatory Failure. , 2019, , 104-106.		0
1017	Anaesthesia and the Lung. , 2019, , 107-110.		0
1018	Cardiac Anatomy and Function. , 2019, , 111-116.		0
1019	Cardiac Cycle. , 2019, , 117-120.		0
1020	Cardiac Output and Its Measurement. , 2019, , 121-130.		0
1021	Starling's Law and Cardiac Dysfunction. , 2019, , 131-135.		0
1022	Cardiac Pressure-Volume Loops. , 2019, , 136-140.		0
1023	Cardiac Ischaemia. , 2019, , 141-144.		0
1024	Systemic Circulation. , 2019, , 145-147.		0
1025	Arterial System. , 2019, , 148-154.		0
1026	Arterial Pressure Waveforms. , 2019, , 155-157.		3
1027	Capillaries and Endothelium. , 2019, , 158-162.		0

#	ARTICLE	IF	CITATIONS
1028	Venous System. , 2019, , 163-165.		0
1029	Venous Pressure Waveforms. , 2019, , 166-167.		0
1030	Lymphatics. , 2019, , 168-169.		0
1031	Cardiovascular Reflexes. , 2019, , 170-174.		0
1032	Valsalva Manoeuvre. , 2019, , 175-177.		0
1033	Exercise Physiology. , 2019, , 178-184.		0
1034	Exercise Testing. , 2019, , 185-188.		0
1035	Neuronal Structure and Function. , 2019, , 189-191.		0
1036	The Brain. , 2019, , 192-197.		0
1037	Cerebrospinal Fluid. , 2019, , 198-199.		0
1038	Bloodâ€“Brain Barrier. , 2019, , 200-201.		0
1039	Cerebral Blood Flow. , 2019, , 202-205.		0
1040	Intracranial Pressure and Head Injury. , 2019, , 206-210.		0
1041	The Spinal Cord. , 2019, , 211-220.		0
1042	Resting Membrane Potential. , 2019, , 221-224.		0
1043	Nerve Action Potential and Propagation. , 2019, , 225-230.		0
1044	Synapses and the Neuromuscular Junction. , 2019, , 231-238.		0
1045	Skeletal Muscle. , 2019, , 239-245.		0

#	ARTICLE	IF	CITATIONS
1046	Muscle Spindles and Golgi Tendon Organs. , 2019, , 246-248.		0
1047	Smooth Muscle. , 2019, , 249-251.		0
1048	Cardiac Muscle. , 2019, , 252-261.		0
1049	The Electrocardiogram. , 2019, , 262-266.		0
1051	Pain Physiology. , 2019, , 272-275.		0
1052	The Eye and Intraocular Pressure. , 2019, , 276-278.		0
1053	Saliva, Oesophagus and Swallowing. , 2019, , 279-282.		0
1054	Stomach and Vomiting. , 2019, , 283-288.		0
1055	Gastrointestinal Digestion and Absorption. , 2019, , 289-294.		0
1056	Liver: Anatomy and Blood Supply. , 2019, , 295-298.		0
1057	Liver Function. , 2019, , 299-306.		0
1058	Renal Function, Anatomy and Blood Flow. , 2019, , 307-312.		0
1059	Renal Filtration and Reabsorption. , 2019, , 313-317.		0
1060	Renal Regulation of Water and Electrolyte Balance. , 2019, , 318-328.		1
1061	Acidâ€‘Base Physiology. , 2019, , 329-337.		0
1062	Micturition. , 2019, , 338-340.		0
1063	Haemostasis. , 2019, , 341-349.		0
1064	Transfusion. , 2019, , 350-355.		0

#	ARTICLE	IF	CITATIONS
1065	Anaemia and Polycythaemia. , 2019, , 356-359.		0
1066	Immune System. , 2019, , 360-370.		0
1067	Plasma Constituents. , 2019, , 371-372.		0
1069	Starvation. , 2019, , 384-386.		0
1070	Stress Response. , 2019, , 387-390.		0
1071	Hypothalamus and Pituitary. , 2019, , 391-395.		1
1072	Thyroid, Parathyroid and Adrenal. , 2019, , 396-404.		5
1073	Maternal Physiology during Pregnancy. , 2019, , 405-410.		0
1074	Foetal Physiology. , 2019, , 411-417.		0
1075	Paediatric Physiology. , 2019, , 418-421.		0
1076	Physiology of Ageing. , 2019, , 422-426.		0
1077	Physiology of Obesity. , 2019, , 427-430.		0
1078	Altitude. , 2019, , 431-433.		0
1079	Diving. , 2019, , 434-435.		0
1080	Temperature Regulation. , 2019, , 436-438.		0
1082	Effect of Detailed Titration Instructions on Time to Hemodynamic Stability in ICU Patients Requiring Norepinephrine. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 606-612.	0.4	6
1083	A current appraisal of evidence for the approach to sepsis and septic shock. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611985651.	1.1	5
1084	Hypotension within one-hour from starting CRRT is associated with in-hospital mortality. Journal of Critical Care, 2019, 54, 7-13.	1.0	32

#	ARTICLE	IF	CITATIONS
1085	Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients. <i>Scientific Reports</i> , 2019, 9, 10588.	1.6	28
1086	Terlipressin or norepinephrine in septic shock: do we have the answer?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1270-S1273.	0.6	1
1087	The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. <i>Annals of the New York Academy of Sciences</i> , 2019, 1455, 12-33.	1.8	46
1088	Vasopressor therapy in critically ill patients with shock. <i>Intensive Care Medicine</i> , 2019, 45, 1503-1517.	3.9	91
1089	Choc septique r� fractaire � la noradr� naline. <i>Anesth� sie & R� animation</i> , 2019, 5, 315-321.	0.1	0
1090	Angiotensin II: A New Vasopressor for the Treatment of Distributive Shock. <i>Clinical Therapeutics</i> , 2019, 41, 2594-2610.	1.1	3
1091	Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury. <i>Seminars in Nephrology</i> , 2019, 39, 462-472.	0.6	22
1092	Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1487-1495.	2.5	116
1093	Microvascular Thrombosis and Ischaemic Limb Losses in Critically Ill Patients. <i>Hamostaseologie</i> , 2019, 39, 006-019.	0.9	19
1094	Less is more: catecholamine-sparing strategies in septic shock. <i>Intensive Care Medicine</i> , 2019, 45, 1810-1812.	3.9	12
1095	Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1476.	3.8	107
1096	Hydrocortisone in Vasodilatory Shock. <i>Critical Care Clinics</i> , 2019, 35, 263-275.	1.0	9
1097	The journey to CART cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. <i>Blood Cancer Journal</i> , 2019, 9, 10.	2.8	57
1098	Angiotensin II in Vasodilatory Shock. <i>Critical Care Clinics</i> , 2019, 35, 229-245.	1.0	12
1099	Vasopressin in Vasodilatory Shock. <i>Critical Care Clinics</i> , 2019, 35, 247-261.	1.0	30
1100	Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 257-267.	0.5	10
1101	Early May Be Better: Early Low-Dose Norepinephrine in Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1049-1051.	2.5	12
1102	Beyond Mean Arterial Pressure and Lactate: Perfusion End Points for Managing the Shocked Patient. <i>Emergency Medicine Clinics of North America</i> , 2019, 37, 395-408.	0.5	16

#	ARTICLE	IF	CITATIONS
1103	Perioperative Renal Pharmacological Protection During Cardiovascular Surgery. , 2019, , 177-194.		2
1104	Terlipressin as a first choice in septic shockâ€”not yet. Journal of Thoracic Disease, 2019, 11, S1384-S1386.	0.6	1
1105	Reply. Biology of Blood and Marrow Transplantation, 2019, 25, e211-e212.	2.0	1
1106	Optimal norepinephrine-equivalent dose to initiate epinephrine in patients with septic shock. Journal of Critical Care, 2019, 53, 69-74.	1.0	4
1107	Vitamin C alone does not improve treatment outcomes in mechanically ventilated patients with severe sepsis or septic shock: a retrospective cohort study. Journal of Thoracic Disease, 2019, 11, 1562-1570.	0.6	22
1109	Shock, Resuscitation, and Fluid Therapy Strategies in Acute Care Surgery: From Pathophysiology to Practice. Hot Topics in Acute Care Surgery and Trauma, 2019, , 145-179.	0.1	0
1110	Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. Critical Care, 2019, 23, 156.	2.5	27
1111	Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials. Critical Care, 2019, 23, 168.	2.5	29
1112	Systemic Inflammatory Response-Syndrome (SIRS), Sepsis und Multiorganversagen. Springer Reference Medizin, 2019, , 2143-2161.	0.0	0
1113	Prescribing of Pressor Agents in Septic Shock: A Survey of Critical Care Pharmacists. Journal of Pharmacy Technology, 2019, 35, 187-193.	0.5	8
1114	Vasoplegic syndrome in cardiac surgery: Definitions, pathophysiology, diagnostic approach and management. Revista EspaÃ±ola De AnestesiologÃa Y ReanimaciÃ³n (English Edition), 2019, 66, 277-287.	0.1	2
1115	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Medicine, 2019, 45, 844-855.	3.9	97
1116	Reappraisal of Ventilator-Free Days in Critical Care Research. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 828-836.	2.5	210
1117	Terlipressin for septic shock patients: a meta-analysis of randomized controlled study. Journal of Intensive Care, 2019, 7, 16.	1.3	27
1118	Blood Pressure Targets in theÂInitial Stabilization. Lessons From the ICU, 2019, , 359-366.	0.1	1
1119	Arginine vasopressin attenuates the effects of TNF-Î± in aortic endothelial cells by inducing ectodomain shedding of TNF receptor 1. Biochemical and Biophysical Research Communications, 2019, 511, 780-786.	1.0	2
1120	Lessons from theÂICU: Choosing the Right Vasopressor. Lessons From the ICU, 2019, , 367-377.	0.1	0
1121	Comments Regarding â€œASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cellsâ€• Biology of Blood and Marrow Transplantation, 2019, 25, e209-e210.	2.0	4

#	ARTICLE	IF	CITATIONS
1122	The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis. <i>Critical Care</i> , 2019, 23, 91.	2.5	32
1123	Utilization of vasopressin before and after protocol implementation in a surgical intensive care unit. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 243-250.	0.5	0
1124	Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock. <i>Annals of Pharmacotherapy</i> , 2019, 53, 877-885.	0.9	10
1125	Inotropes and Vasoactive Agents: Differences Between Europe and the United States. <i>Current Anesthesiology Reports</i> , 2019, 9, 202-213.	0.9	1
1127	Sepsis: mechanisms of bacterial injury to the patient. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2019, 27, 19.	1.1	130
1128	Vasoactive Drugs, Renal Function, and Acute Kidney Injury. , 2019, , 1344-1348.e2.		0
1129	Challenges in the management of septic shock: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 420-433.	3.9	52
1130	<i>Endocrine Pharmacology</i> . , 2019, , 708-731.		4
1131	Adult Congenital Heart Disease. , 2019, , 905-910.e2.		0
1132	Sepsis and septic shock: current approaches to management. <i>Internal Medicine Journal</i> , 2019, 49, 160-170.	0.5	105
1133	24th International Symposium on Infections in the Critically Ill Patient. <i>Medical Sciences (Basel)</i> , Tj ETQq0 0 0 rgBT /Qverlock_10 Tf 50 3.	1.3	1
1134	Toxicities of CD19 CAR ^T cell immunotherapy. <i>American Journal of Hematology</i> , 2019, 94, S42-S49.	2.0	102
1135	Síndrome vasopléjico en cirugía cardíaca: definición, fisiopatología, enfoque diagnóstico y manejo. <i>Revista Española De Anestesiología Y Reanimación</i> , 2019, 66, 277-287.	0.1	5
1136	Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor. <i>Critical Care</i> , 2019, 23, 353.	2.5	4
1137	Efficacy of IgM-enriched Immunoglobulin for Vasopressor-resistant Vasoplegic Shock After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 381-386.	0.5	7
1138	Reporting of Organ Support Outcomes in Septic Shock Randomized Controlled Trials: A Methodologic Review—The Sepsis Organ Support Study. <i>Critical Care Medicine</i> , 2019, 47, 984-992.	0.4	9
1139	Selepressin in septic shock: A wake-up call for new drugs. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2019, 38, 579-581.	0.6	0
1140	Fifty Years of Management of Vasodilatory Shock. <i>International Anesthesiology Clinics</i> , 2019, 57, 31-47.	0.3	3

#	ARTICLE	IF	CITATIONS
1141	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Survival in Sepsis. <i>Critical Care Medicine</i> , 2019, 47, 489-491.	0.4	2
1142	Renal Medullary Hypoxia: A New Therapeutic Target for Septic Acute Kidney Injury?. <i>Seminars in Nephrology</i> , 2019, 39, 543-553.	0.6	29
1143	Just a Little Off the Top, Please*. <i>Critical Care Medicine</i> , 2019, 47, 1810-1813.	0.4	0
1144	Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review. <i>Critical Care Medicine</i> , 2019, 47, 1680-1691.	0.4	105
1145	Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial*. <i>Critical Care Medicine</i> , 2019, 47, 1743-1750.	0.4	26
1146	Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis*. <i>Critical Care Medicine</i> , 2019, 47, 463-466.	0.4	34
1147	Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study. <i>Critical Care</i> , 2019, 23, 400.	2.5	22
1148	Pharmacological Interventions in Acute Kidney Injury. , 2019, , 725-738.e13.		0
1149	Vasopressors and Inotropes. , 2019, , 520-534.		6
1150	Vasopressin therapy in cardiac surgery. <i>Journal of Cardiac Surgery</i> , 2019, 34, 20-27.	0.3	5
1152	Precision Medicine in Acute Kidney Injury: A Promising Future?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 814-816.	2.5	11
1153	Adult Critical Care Medicine. , 2019, , .		0
1154	Distributive Shock. , 2019, , 208-215.e4.		2
1155	Recent Updates in the Pharmacological Management of Sepsis and Septic Shock: A Systematic Review Focused on Fluid Resuscitation, Vasopressors, and Corticosteroids. <i>Annals of Pharmacotherapy</i> , 2019, 53, 385-395.	0.9	16
1157	Real-Time Temperature Measurements of HMEC-1 Cells During Inflammation Production and Repair Detected by Wireless Thermometry. <i>IEEE Transactions on Biomedical Engineering</i> , 2019, 66, 1898-1904.	2.5	9
1158	Dobutamine Versus Vasopressin After Mesenteric Ischemia. <i>Journal of Surgical Research</i> , 2019, 235, 410-423.	0.8	11
1159	Sepsis associated acute kidney injury. <i>BMJ: British Medical Journal</i> , 2019, 364, k4891.	2.4	380
1160	The association of early postoperative desaturation in the operating theatre with hospital discharge to a skilled nursing or long-term care facility. <i>Anaesthesia</i> , 2019, 74, 457-467.	1.8	35

#	ARTICLE	IF	CITATIONS
1161	Noradrenaline-Specific, Efficient Visualization in Brain Tissue Triggered by Unique Cascade Nucleophilic Substitution. <i>Analytical Chemistry</i> , 2019, 91, 2255-2259.	3.2	18
1162	Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations. <i>Pharmacotherapy</i> , 2019, 39, 369-381.	1.2	19
1163	Effect of vasopressin on a porcine model of persistent pulmonary hypertension of the newborn. <i>Pediatric Pulmonology</i> , 2019, 54, 319-332.	1.0	8
1164	Renal Outcomes of Vasopressin and Its Analogs in Distributive Shock: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Critical Care Medicine</i> , 2019, 47, e44-e51.	0.4	15
1165	Identification of Acute Kidney Injury Subphenotypes with Differing Molecular Signatures and Responses to Vasopressin Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 863-872.	2.5	105
1166	Vasopressin vs noradrenaline: Have we found the perfect recipe to improve outcome in septic shock?. <i>Journal of Critical Care</i> , 2019, 49, 99-104.	1.0	3
1167	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 854-862.	2.5	62
1168	Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. <i>Journal of Critical Care</i> , 2019, 50, 188-194.	1.0	10
1169	Incidence of Clinically Significant Hypotension Stratified by Vasopressin Duration. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 77-78.	1.3	3
1170	Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock. <i>Pharmacotherapy</i> , 2019, 39, 382-398.	1.2	21
1171	The Septic Heart. <i>Chest</i> , 2019, 155, 427-437.	0.4	195
1172	Hemodynamic Instability Secondary to Vasopressin Withdrawal in Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 761-765.	1.3	19
1173	Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 910-916.	1.3	28
1174	Associated Mortality of Liberal Fluid Administration in Sepsis. <i>Journal of Pharmacy Practice</i> , 2019, 32, 579-583.	0.5	1
1175	Mobilisation is feasible in intensive care patients receiving vasoactive therapy: An observational study. <i>Australian Critical Care</i> , 2019, 32, 139-146.	0.6	20
1176	Discontinuation of Vasopressin Before Norepinephrine in the Recovery Phase of Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 805-810.	1.3	28
1177	Safety of the Peripheral Administration of Vasopressor Agents. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 26-33.	1.3	75
1178	Vasoactive Agents for Adult Septic Shock: An Update and Review. <i>Journal of Pharmacy Practice</i> , 2020, 33, 523-532.	0.5	5

#	ARTICLE	IF	CITATIONS
1179	Impact of the Sequence of Norepinephrine and Vasopressin Discontinuation in Patients Recovering From Septic Shock. <i>Hospital Pharmacy</i> , 2020, 55, 26-31.	0.4	1
1180	Vasopressin Administration Is Associated With Rising Serum Lactate Levels in Patients With Sepsis. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 881-888.	1.3	4
1181	Angiotensin II in Decompensated Cirrhosis Complicated by Septic Shock. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2020, 24, 266-272.	0.4	9
1182	The Specific Organism: Not Bacterial Gram Type: Drives the Inflammatory Response in Septic Shock. <i>Journal of Innate Immunity</i> , 2020, 12, 182-190.	1.8	4
1183	Management of Sepsis in the Pediatric Patient. <i>Journal of Radiology Nursing</i> , 2020, 39, 24-31.	0.2	0
1184	Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States. <i>Annals of Pharmacotherapy</i> , 2020, 54, 213-218.	0.9	1
1185	Cost-effectiveness of second-line vasopressors for the treatment of septic shock. <i>Journal of Critical Care</i> , 2020, 55, 48-55.	1.0	12
1186	A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1490-1496.	1.3	11
1187	Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock. <i>Pharmacotherapy</i> , 2020, 40, 33-39.	1.2	15
1188	Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 314-321.	0.9	9
1189	Characterization and validation of a novel measure of septic shock severity. <i>Intensive Care Medicine</i> , 2020, 46, 135-137.	3.9	12
1190	From a pressure-guided to a perfusion-centered resuscitation strategy in septic shock: Critical literature review and illustrative case. <i>Journal of Critical Care</i> , 2020, 56, 294-304.	1.0	12
1191	Reversal of Vasodilatory Shock. <i>Anesthesia and Analgesia</i> , 2020, 130, 15-30.	1.1	29
1192	Exciting developments in the field of acute kidney injury. <i>Nature Reviews Nephrology</i> , 2020, 16, 69-70.	4.1	11
1193	How do I diagnose and manage acute endocrine emergencies in the ICU?. , 2020, , 519-528.e1.		0
1194	Very Low Density Lipoprotein Receptor Sequesters Lipopolysaccharide Into Adipose Tissue During Sepsis. <i>Critical Care Medicine</i> , 2020, 48, 41-48.	0.4	13
1195	Adrenergic Downregulation in Critical Care: Molecular Mechanisms and Therapeutic Evidence. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1023-1041.	0.6	13
1196	Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis. <i>Shock</i> , 2020, 53, 50-57.	1.0	16

#	ARTICLE	IF	CITATIONS
1197	Paradoxical hypotension is an unrecognized risk of push-dose epinephrine overdose. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1280-1281.	0.7	0
1198	Canadian Critical Care Society clinical practice guideline: The use of vasopressin and vasopressin analogues in critically ill adults with distributive shock. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 369-376.	0.7	14
1199	Is Mortality a Useful Primary End Point for Critical Care Trials?. <i>Chest</i> , 2020, 158, 206-211.	0.4	26
1200	Effect of Vasopressors on the Macro- and Microcirculation During Systemic Inflammation in Humans In Vivo. <i>Shock</i> , 2020, 53, 171-174.	1.0	15
1201	Perioperative Management of Patients with Sepsis and Septic Shock, Part I. <i>Anesthesiology Clinics</i> , 2020, 38, 107-122.	0.6	5
1202	Clinical Controversy Over Vasopressin in Septic Shock: A Survey of Critical Care Pharmacists. <i>Hospital Pharmacy</i> , 2021, 56, 626-628.	0.4	2
1203	Vasopressors in septic shock: which, when, and how much?. <i>Annals of Translational Medicine</i> , 2020, 8, 794-794.	0.7	32
1204	Optimal VAsopressor TitratiON in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial. <i>BMJ Open</i> , 2020, 10, e037947.	0.8	4
1205	Effects of thiamine on vasopressor requirements in patients with septic shock: a prospective randomized controlled trial. <i>BMC Anesthesiology</i> , 2020, 20, 280.	0.7	16
1206	Non-catecholamine vasopressors in the treatment of adult patients with septic shock—evidence from meta-analysis and trial sequential analysis of randomized clinical trials. <i>Journal of Intensive Care</i> , 2020, 8, 83.	1.3	12
1207	Perioperative Renoprotection: General Mechanisms and Treatment Approaches. <i>Anesthesia and Analgesia</i> , 2020, 131, 1679-1692.	1.1	13
1208	Hemodynamic Response to Vasopressin Dosage of 0.03 Units/Min vs. 0.04 Units/Min in Patients With Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 92-99.	1.3	5
1209	Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. <i>Frontiers in Medicine</i> , 2020, 7, 588863.	1.2	14
1210	Vasopressin in Conjunction With Norepinephrine in Septic Shock: A Retrospective Cohort Study From a Low Middle-Income Country. , 2020, 2, e0274.		2
1211	ATS Core Curriculum 2020. <i>Adult Critical Care Medicine</i> . <i>ATS Scholar</i> , 2020, 1, 436-455.	0.5	1
1212	Timing of norepinephrine initiation in patients with septic shock: a systematic review and meta-analysis. <i>Critical Care</i> , 2020, 24, 488.	2.5	62
1213	Genetic variation implicates plasma angiotensinogen-converting enzyme 2 in the development of acute kidney injury sub-phenotypes. <i>BMC Nephrology</i> , 2020, 21, 284.	0.8	18
1214	Subphenotypes in critical care: translation into clinical practice. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 631-643.	5.2	117

#	ARTICLE	IF	CITATIONS
1215	Using intravenous pump infusion data to optimize continuous infusion concentrations and reduce drug and fluid waste. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1497-1503.	0.5	3
1216	Distribution and relative expression of vasoactive receptors on arteries. <i>Scientific Reports</i> , 2020, 10, 15383.	1.6	9
1217	Updates in Sepsis Resuscitation. <i>Emergency Medicine Clinics of North America</i> , 2020, 38, 807-818.	0.5	6
1218	Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock*. <i>Critical Care Medicine</i> , 2020, 48, 1445-1453.	0.4	41
1219	Variation in Fluid and Vasopressor Use in Shock With and Without Physiologic Assessment: A Multicenter Observational Study. <i>Critical Care Medicine</i> , 2020, 48, 1436-1444.	0.4	7
1220	Beneficial Effects of Vasopressin Compared With Norepinephrine on Renal Perfusion, Oxygenation, and Function in Experimental Septic Acute Kidney Injury. <i>Critical Care Medicine</i> , 2020, 48, e951-e958.	0.4	21
1221	Effects of intraoperative hemodynamic management on postoperative acute kidney injury in liver transplantation: An observational cohort study. <i>PLoS ONE</i> , 2020, 15, e0237503.	1.1	10
1222	Comparison of Vasopressor Duration in Septic Shock Patients With and Without Cirrhosis. <i>Annals of Pharmacotherapy</i> , 2021, 55, 970-979.	0.9	6
1223	New strategies to optimize renal haemodynamics. <i>Current Opinion in Critical Care</i> , 2020, 26, 536-542.	1.6	14
1225	Tissue Inhibitor of Metalloproteinases-2 Mediates Kidney Injury during Sepsis. <i>Nephron</i> , 2020, 144, 644-649.	0.9	2
1226	Assessing the Course of Organ Dysfunction Using Joint Longitudinal and Time-to-Event Modeling in the Vasopressin and Septic Shock Trial. , 2020, 2, e0104.		5
1227	Methylene Blue for Refractory Shock in Children: A Systematic Review and Survey Practice Analysis. <i>Pediatric Critical Care Medicine</i> , 2020, 21, e378-e386.	0.2	7
1228	Push-Dose Vasopressin for Hypotension in Septic Shock. <i>Journal of Emergency Medicine</i> , 2020, 58, 313-316.	0.3	2
1229	A Furosemide Excretion Stress Test Predicts Mortality in Mice After Sepsis and Outperforms the Furosemide Stress Test During Vasopressin Administration. , 2020, 2, e0112.		0
1230	Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 830-842.	2.5	82
1231	Sepsis With Preexisting Heart Failure: Management of Confounding Clinical Features. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 989-1012.	1.3	21
1232	Acute Kidney Injury: From Diagnosis to Prevention and Treatment Strategies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1704.	1.0	48
1233	Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis. <i>Chest</i> , 2020, 158, 164-173.	0.4	131

#	ARTICLE	IF	CITATIONS
1234	Septic shock patients with adequate tissue perfusion parameters still need the recommended minimal Mean Arterial Pressure: Not really. <i>Journal of Critical Care</i> , 2020, 56, 308-310.	1.0	0
1235	A 16-Year-Old Girl with Systemic Lupus Erythematosus (SLE) with Septicaemia as Initial Presentation. <i>Journal of Enam Medical College</i> , 2020, 10, 49-54.	0.1	0
1236	Vasopressor Dosing in Septic Shock Clinical Trials: A Systematic Review and Ecologic Study. <i>Annals of the American Thoracic Society</i> , 2020, 17, 773-776.	1.5	1
1237	Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 145-151.	0.2	10
1238	Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop. <i>Intensive Care Medicine</i> , 2020, 46, 930-942.	3.9	49
1239	Angiotensin II for the emergency physician. <i>Emergency Medicine Journal</i> , 2020, 37, 717-721.	0.4	2
1240	The initial resuscitation of septic shock. <i>Journal of Critical Care</i> , 2020, 57, 108-117.	1.0	27
1242	Narrative Review of Controversies Involving Vasopressin Use in Septic Shock and Practical Considerations. <i>Annals of Pharmacotherapy</i> , 2020, 54, 706-714.	0.9	7
1243	What is the role of vasopressors and inotropes in septic shock?. , 2020, , 250-255.e1.		0
1244	How do I manage hemodynamic decompensation in a critically ill patient?. , 2020, , 345-350.e1.		0
1245	Establishing the Therapeutic Index of Fluid Resuscitation in the Septic Patient: A Narrative Review and Meta-Analysis. <i>Pharmacotherapy</i> , 2020, 40, 256-269.	1.2	5
1246	Combination of vitamin C, thiamine and hydrocortisone added to standard treatment in the management of sepsis: results from an open label randomised controlled clinical trial and a review of the literature. <i>Infectious Diseases</i> , 2020, 52, 271-278.	1.4	63
1247	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. <i>BioFactors</i> , 2020, 46, 367-380.	2.6	46
1249	Vasopressor and Inotrope Therapy in Cardiac Critical Care. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 843-856.	1.3	29
1250	Clinical Efficiency of Vasopressin or Its Analogs in Comparison With Catecholamines Alone on Patients With Septic Shock: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 563.	1.6	10
1251	Two subphenotypes of septic acute kidney injury are associated with different 90-day mortality and renal recovery. <i>Critical Care</i> , 2020, 24, 150.	2.5	54
1252	Comment on "Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options": <i>Critical Care</i> , 2020, 24, 138.	2.5	0
1253	Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 635-645.	1.3	8

#	ARTICLE	IF	CITATIONS
1254	Sepsis in the critically ill patient: current and emerging management strategies. Expert Review of Anti-Infective Therapy, 2021, 19, 635-647.	2.0	12
1255	Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis. Pharmacological Research, 2021, 163, 105272.	3.1	6
1256	Heart Dysfunction in Sepsis. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 298-309.	0.6	15
1257	Machine Learning Models with Preoperative Risk Factors and Intraoperative Hypotension Parameters Predict Mortality After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 857-865.	0.6	31
1258	Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock. Seminars in Cardiothoracic and Vascular Anesthesia, 2021, 25, 67-73.	0.4	7
1259	Vasopressor dose equivalence: A scoping review and suggested formula. Journal of Critical Care, 2021, 61, 233-240.	1.0	64
1260	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Circulation, 2021, 143, 921-934.	1.6	55
1261	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. ESC Heart Failure, 2021, 8, 26-36.	1.4	6
1262	Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?. Lancet Respiratory Medicine, 2021, 9, 207-216.	5.2	54
1263	Predictors of dysrhythmias with norepinephrine use in septic shock. Journal of Critical Care, 2021, 61, 133-137.	1.0	17
1264	Vasopressor Therapy in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 059-077.	0.8	30
1265	Analysis of Vasopressor Discontinuation and the Incidence of Rebound Hypotension in Patients With Septic Shock. Hospital Pharmacy, 2021, 56, 47-53.	0.4	0
1266	Does Switching Norepinephrine to Phenylephrine in Septic Shock Complicated by Atrial Fibrillation With Rapid Ventricular Response Improve Time to Rate Control?. Journal of Intensive Care Medicine, 2021, 36, 191-196.	1.3	5
1267	Cardiovascular Agents. , 2021, , 559-605.		0
1268	Combined hydrocortisone, ascorbic acid, and thiamine therapy for septic shock with complicated intraabdominal infection: before and after cohort study. Annals of Surgical Treatment and Research, 2021, 100, 356.	0.4	1
1269	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (JSCG 2020). Acute Medicine & Surgery, 2021, 8, e659.	0.5	37
1270	Cardiogenic Shock Part 1: Epidemiology, Classification, Clinical Presentation, Physiological Process, and Nonmechanical Treatments. , 2021, , 759-791.		0
1271	Catecholaminergic Vasopressors Reduce Toll-Like Receptor Agonist-Induced Microvascular Endothelial Cell Permeability But Not Cytokine Production. Critical Care Medicine, 2021, 49, e315-e326.	0.4	12

#	ARTICLE	IF	CITATIONS
1272	Hämodynamik und Kreislaufunterstützung. , 2021, , 105-123.		0
1273	Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. Shock, 2021, 56, 869-870.	1.0	0
1274	Application of perioperative hemodynamics today and potentials for tomorrow. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2021, 35, 551-564.	1.7	3
1275	The Surviving Sepsis Campaign: Fluid Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients. Critical Care Medicine, 2021, 49, 623-635.	0.4	25
1276	Evaluation of Evidence, Pharmacology, and Interplay of Fluid Resuscitation and Vasoactive Therapy in Sepsis and Septic Shock. Shock, 2021, 56, 484-492.	1.0	3
1277	Significance of lactate clearance in septic shock patients with high bilirubin levels. Scientific Reports, 2021, 11, 6313.	1.6	9
1278	Outcomes Associated With Norepinephrine Use Among Cardiac Intensive Care Unit Patients with Severe Shock. Shock, 2021, 56, 522-528.	1.0	9
1279	Vasopressor Responsiveness Beyond Arterial Pressure. Shock, 2021, Publish Ahead of Print, 352-359.	1.0	8
1280	Norepinephrine in Septic Shock: A Systematic Review and Meta-analysis. Western Journal of Emergency Medicine, 2021, 22, 196-203.	0.6	10
1281	The surviving sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. Intensive Care Medicine Experimental, 2021, 9, 10.	0.9	21
1282	Analysis of Mortality in Patients Treated With Phenylephrine in Septic Shock. Journal of Pharmacy Practice, 2021, , 089719002110002.	0.5	3
1283	Effect of Vasopressin Dose on Hemodynamic Response in Obese Patients With Septic Shock: A Retrospective Observational Study. Annals of Pharmacotherapy, 2021, 55, 1447-1454.	0.9	4
1284	Major publications in the critical care pharmacotherapy literature: 2019. Journal of Critical Care, 2021, 62, 197-205.	1.0	4
1285	Outcome of acute kidney injury: how to make a difference?. Annals of Intensive Care, 2021, 11, 60.	2.2	11
1286	Vasopressin Loading for Refractory Septic Shock: A Preliminary Analysis of a Case Series. Frontiers in Medicine, 2021, 8, 644195.	1.2	5
1287	Practice Patterns in the Initiation of Secondary Vasopressors and Adjunctive Corticosteroids during Septic Shock in the United States. Annals of the American Thoracic Society, 2021, 18, 2049-2057.	1.5	7
1288	Treatment of Severe Acute on Chronic Liver Failure. Journal of Clinical Gastroenterology, 2021, 55, 667-676.	1.1	12
1289	Efficacy and safety of vasopressin and terlipressin in preterm neonates: a protocol for a systematic review. BMJ Paediatrics Open, 2021, 5, e001067.	0.6	3

#	ARTICLE	IF	CITATIONS
1290	Comparison of Early Versus Late Initiation of Hydrocortisone in Patients With Septic Shock in the ICU Setting. <i>Annals of Pharmacotherapy</i> , 2022, 56, 264-270.	0.9	9
1291	Good clinical practice for the use of vasopressor and inotropic drugs in critically ill patients: state-of-the-art and expert consensus. <i>Minerva Anestesiologica</i> , 2021, 87, 714-732.	0.6	5
1292	Vasoactive agents in acute mesenteric ischaemia in critical care. A systematic review. <i>F1000Research</i> , 2021, 10, 453.	0.8	3
1293	Pheochromocytoma with abdominal aortic aneurysm presenting as recurrent dyspnea, hemoptysis, and hypotension: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 4754-4759.	0.3	1
1294	Early Vitamin C, Hydrocortisone, and Thiamine Treatment for Septic Cardiomyopathy: A Propensity Score Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 610.	1.1	7
1295	Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection. <i>Journal of Pharmacy Practice</i> , 2023, 36, 60-66.	0.5	21
1296	Trends of vasopressor use in intensive care units in Colombia. <i>Colombian Journal of Anesthesiology</i> , 0, , .	0.5	0
1297	Renin Kinetics Are Superior to Lactate Kinetics for Predicting In-Hospital Mortality in Hypotensive Critically Ill Patients*. <i>Critical Care Medicine</i> , 2022, 50, 50-60.	0.4	22
1298	Vasopressor-Sparing Strategies in Patients with Shock: A Scoping-Review and an Evidence-Based Strategy Proposition. <i>Journal of Clinical Medicine</i> , 2021, 10, 3164.	1.0	20
1299	Safety of treating acute liver injury and failure. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 191-203.	1.0	6
1300	Dose equivalence between metaraminol and norepinephrine in critical care. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 303-310.	1.1	4
1301	Increased risk of catheter-related infection in critically ill patients given catecholamine inotropes during continuous renal replacement therapy. <i>Hemodialysis International</i> , 2021, , .	0.4	2
1302	Vasoactive pharmacologic therapy in cardiogenic shock: a critical review. <i>Journal of Drug Assessment</i> , 2021, 10, 68-85.	1.1	7
1303	Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-104.	0.9	11
1304	Hemodynamic Monitoring and Support. <i>Critical Care Medicine</i> , 2021, 49, 1638-1650.	0.4	16
1305	Association between intraoperative fluid balance, vasopressors and graft complications in liver transplantation: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0254455.	1.1	6
1306	Assessment and Management of Hypoperfusion in Sepsis and Septic Shock. , 0, , .		0
1307	The Role of PCSK9 in Infectious Diseases. <i>Current Medicinal Chemistry</i> , 2022, 29, 1000-1015.	1.2	2

#	ARTICLE	IF	CITATIONS
1308	Early Care of Adults With Suspected Sepsis in the Emergency Department and Out-of-Hospital Environment: A Consensus-Based Task Force Report. <i>Annals of Emergency Medicine</i> , 2021, 78, 1-19.	0.3	51
1309	The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG) Tj ETQq1 1 0.784314 rgBT /Over	1.3	92
1310	Incidence and predictors of delirium on the intensive care unit in patients with acute kidney injury, insight from a retrospective registry. <i>Scientific Reports</i> , 2021, 11, 17260.	1.6	5
1311	Pitfalls in Study Interpretation. <i>Surgical Infections</i> , 2021, 22, 646-650.	0.7	4
1312	The order of vasopressor discontinuation and incidence of hypotension: a retrospective cohort analysis. <i>Scientific Reports</i> , 2021, 11, 16680.	1.6	2
1313	Association between polyvascular disease and clinical outcomes in patients with cardiogenic shock: Results from the RESCUE registry. <i>International Journal of Cardiology</i> , 2021, 339, 70-74.	0.8	1
1314	Sub-therapeutic vasopressin but not therapeutic vasopressin improves gastrointestinal microcirculation in septic rats: A randomized, placebo-controlled, blinded trial. <i>PLoS ONE</i> , 2021, 16, e0257034.	1.1	3
1315	Principles of Resuscitation. <i>Critical Care Nursing Clinics of North America</i> , 2021, 33, 225-244.	0.4	1
1316	Definitions of acute renal dysfunction. <i>Current Opinion in Critical Care</i> , 2021, Publish Ahead of Print, 553-559.	1.6	11
1317	Vasoactive agents in acute mesenteric ischaemia in critical care. A systematic review. <i>F1000Research</i> , 0, 10, 453.	0.8	8
1318	Should Vasopressors Be Started Early in Septic Shock?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 683-688.	0.8	3
1319	Risk assessment of sepsis through measurement of proAVP (copeptin): a secondary analysis of the TRIAGE study. <i>Endocrine Connections</i> , 2021, 10, 995-1005.	0.8	3
1320	Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock*. <i>Critical Care Medicine</i> , 2022, 50, 614-623.	0.4	56
1321	Vasopressor and inotrope treatment for septic shock: An umbrella review of reviews. <i>Journal of Critical Care</i> , 2021, 65, 65-71.	1.0	6
1322	Vasopressin infusion in COVID-19 critical illness is not associated with impaired viral clearance: a pilot study. <i>British Journal of Anaesthesia</i> , 2021, 127, e146-e148.	1.5	7
1323	The effect of early vasopressin use on patients with septic shock: A systematic review and meta-analysis. <i>American Journal of Emergency Medicine</i> , 2021, 48, 203-208.	0.7	17
1324	Sepsis and Septic Shock. , 2022, , 564-575.		0
1325	Preservation of Renal Function. , 2022, , 222-250.		0

#	ARTICLE	IF	CITATIONS
1327	Pathophysiology of Sepsis and Heart-Lung Interactions: Part 1, Presentation and Mechanisms. , 2021, , 821-848.		0
1328	Pathophysiology of Sepsis and Heart-Lung Interactions: Part 2, Treatment. , 2021, , 849-869.		0
1329	Vasopressor Support for Patients with Cardiopulmonary Failure. , 2021, , 751-758.		0
1330	Hemodynamic Instability During Liver Transplantation in Patients With End-stage Liver Disease: A Consensus Document from ILTS, LICAGE, and SATA. Transplantation, 2021, 105, 2184-2200.	0.5	15
1331	Angiotensin II in Septic Shock. Annual Update in Intensive Care and Emergency Medicine, 2015, , 129-137.	0.1	2
1332	Systemic Inflammatory Response Syndrome (SIRS), Sepsis und Multiorganversagen. , 2012, , 1578-1592.		1
1333	Sepsis, Severe Sepsis, and Septic Shock. , 2010, , 987-1010.		30
1334	Renal Physiology. , 2010, , 441-476.		2
1335	Shock " an overview. , 2009, , 97-104.		7
1337	Sepsis and Septic Shock " Basics of diagnosis, pathophysiology and clinical decision making. Medical Clinics of North America, 2020, 104, 573-585.	1.1	153
1340	SIRS, sepsis and multiorgan failure. , 2011, , 315-330.		6
1341	Moderate-dose Vasopressin Therapy May Impair Gastric Mucosal Perfusion in Severe Sepsis. Anesthesiology, 2011, 114, 1396-1402.	1.3	18
1342	A clinical approach to acute mesenteric ischemia. Current Opinion in Critical Care, 2021, 27, 183-192.	1.6	17
1343	Blood Interleukin-6 Levels Predict Multiple Organ Dysfunction in Critically Ill Patients. Shock, 2021, 55, 790-795.	1.0	6
1344	Vasoplegic syndrome following cardiothoracic surgery" review of pathophysiology and update of treatment options. Critical Care, 2020, 24, 36.	2.5	97
1345	Subcostal TAPSE: a retrospective analysis of a novel right ventricle function assessment method from the subcostal position in patients with sepsis. Ultrasound Journal, 2019, 11, 19.	1.3	7
1346	Vasopressin and its analogues in shock states: a review. Annals of Intensive Care, 2020, 10, 9.	2.2	60
1347	Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model. Intensive Care Medicine Experimental, 2019, 7, 54.	0.9	11

#	ARTICLE	IF	CITATIONS
1348	Cytokines and Signaling Molecules Predict Clinical Outcomes in Sepsis. PLoS ONE, 2013, 8, e79207.	1.1	39
1349	Selepressin and Arginine Vasopressin Do Not Display Cardiovascular Risk in Atherosclerotic Rabbit. PLoS ONE, 2016, 11, e0165422.	1.1	4
1350	Sepsis in a Panorama: What the Cardiovascular Physician Should Know. Methodist DeBakey Cardiovascular Journal, 2021, 14, 89.	0.5	6
1351	Did the beneficial renal outcomes with vasopressin VANISH?. Annals of Translational Medicine, 2016, 4, S67-S67.	0.7	4
1352	Combination era, using combined vasopressors showed benefits in treating septic shock patients: a network meta-analysis of randomized controlled trials. Annals of Translational Medicine, 2019, 7, 535-535.	0.7	8
1353	Pharmacologic Agents for the Treatment of Vasodilatory Shock. Current Pharmaceutical Design, 2019, 25, 2133-2139.	0.9	3
1354	Mechanisms of Vascular Hyporesponsiveness in Septic Shock. Current Vascular Pharmacology, 2013, 11, 139-149.	0.8	18
1355	The Heart in Sepsis: From Basic Mechanisms to Clinical Management. Current Vascular Pharmacology, 2013, 11, 187-195.	0.8	55
1356	Vasopressors to treat refractory septic shock. Minerva Anestesiologica, 2020, 86, 537-545.	0.6	18
1357	The gut in critically ill patients: how unrecognized "7th organ dysfunction" feeds sepsis. Minerva Anestesiologica, 2020, 86, 595-597.	0.6	4
1358	Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Intensive Care Medicine, 2017, 52, 101-107.	2.7	81
1359	Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Efficacy and Mechanism Evaluation, 2018, 5, 1-94.	0.9	3
1360	Incidence of Hypotension after Discontinuation of Norepinephrine or Arginine Vasopressin in Patients with Septic Shock: a Systematic Review and Meta-Analysis. Journal of Korean Medical Science, 2020, 35, e8.	1.1	3
1361	Vasopressor Therapy and the Brain: Dark Side of the Moon. Frontiers in Medicine, 2019, 6, 317.	1.2	4
1362	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version). Zhong Xi Yi Jie He Xue Bao, 2010, , 701-741.	0.7	31
1363	Septic shock: The initial moments and beyond. Cleveland Clinic Journal of Medicine, 2013, 80, 175-184.	0.6	6
1364	Sepsis and septic shock: Guideline-based management. Cleveland Clinic Journal of Medicine, 2020, 87, 53-64.	0.6	112
1365	Pharmacologic agents for acute hemodynamic instability: Recent advances in the management of perioperative shock: A systematic review. Annals of Cardiac Anaesthesia, 2015, 18, 543.	0.3	14

#	ARTICLE	IF	CITATIONS
1366	Does vasopressin improve the mortality of septic shock patients treated with high-dose NA. Indian Journal of Critical Care Medicine, 2016, 20, 137-140.	0.3	3
1367	Sepsis-induced acute kidney injury. Indian Journal of Critical Care Medicine, 2010, 14, 14-21.	0.3	35
1368	Vasopressin: Its current role in anesthetic practice. Indian Journal of Critical Care Medicine, 2011, 15, 71-77.	0.3	18
1369	Vasopressin in septic shock; assessment of sepsis biomarkers: A randomized, controlled trial. Indian Journal of Critical Care Medicine, 2017, 21, 578-584.	0.3	6
1370	Angiotensin in Clinical Practice. Journal of Translational Critical Care Medicine, 2019, 1, 7.	0.0	1
1371	Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort. World Journal of Hepatology, 2017, 9, 106.	0.8	8
1372	Controversies in Sepsis Managementâ€”What is the Way Forward?. Annals of the Academy of Medicine, Singapore, 2020, 49, 661-668.	0.2	7
1373	Advances in Vasodilatory Shock: A Concise Review. Indian Journal of Critical Care Medicine, 2019, 23, 475-480.	0.3	4
1374	Management of sepsis. Journal of the Korean Medical Association, 2013, 56, 819.	0.1	3
1375	Vasopressin in vasoplegic shock: A systematic review. World Journal of Critical Care Medicine, 2020, 9, 88-98.	0.8	6
1376	Microcirculation improvement after short-term infusion of vasopressin in septic shock is dependent on noradrenaline. Clinics, 2017, 72, 750-757.	0.6	10
1377	Antihypertensive Medications Prior to Shock Onset Do Not Impact Initial Vasopressor Requirements in Patients With Shock. Journal of Pharmacy Practice, 2021, , 089719002110486.	0.5	1
1378	Perioperative Multimodal General Anesthesia Focusing on Specific CNS Targets in Patients Undergoing Cardiac Surgeries: The Pathfinder Feasibility Trial. Frontiers in Medicine, 2021, 8, 719512.	1.2	4
1379	The Epidemiology of Extremity Threat and Amputation after Vasopressor-Dependent Sepsis. Annals of the American Thoracic Society, 2022, 19, 625-632.	1.5	6
1380	Vasopressin-Induced Hyponatremia in Patients With Aneurysmal Subarachnoid Hemorrhage: A Case Series and Literature Review. Journal of Pharmacy Practice, 2023, 36, 689-694.	0.5	1
1381	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine, 2021, 49, e1063-e1143.	0.4	927
1382	Considerations for Inotrope and Vasopressor Use in Critically Ill Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2022, 79, e11-e17.	0.8	3
1383	Comparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients. European Journal of Hospital Pharmacy, 2023, 30, 214-220.	0.5	3

#	ARTICLE	IF	CITATIONS
1384	Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, 2021, 47, 1181-1247.	3.9	1,503
1385	Critical Care Medicine. Tuberculosis and Respiratory Diseases, 2008, 65, 169.	0.7	0
1387	Low dose arginine vasopressin is useful to keep the blood pressure during hemodialysis in patients with not only septic shock but also intradialytic hypotension. Nihon Toseki Igakkai Zasshi, 2008, 41, 779-784.	0.2	0
1388	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 429-434.	0.4	0
1389	Corticosteroid Treatment of Patients in Septic Shock. , 2009, , 753-760.		0
1390	Corticosteroid Treatment of Patients in Septic Shock. , 2009, , 753-760.		0
1391	VASOPRESSIN IN INTENSIVE CARE UNIT. Acta Endocrinologica, 2009, 5, 93-98.	0.1	0
1393	Acute-on-Chronic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction. , 2009, , 658-671.		2
1395	Choc septique. , 2009, , 589-604.		0
1396	New Concepts and Emerging Issues in Sepsis. , 2009, , 127-163.		0
1397	Vasoactive Drugs and Acute Renal Failure. , 2009, , 416-419.		0
1398	Pharmacologic Hemodynamic Therapy of Shock. , 2010, , 950-977.		0
1399	Pharmacological Interventions in Acute Kidney Injury. , 2010, , 677-686.		0
1401	Sepsis Syndromes. , 2010, , 1848-1858.		1
1402	Effets des agonistes V1a sur la circulation splanchnique. , 2010, , 231-238.		0
1404	Diagnose und Therapie der Sepsis. , 2011, , 789-799.		0
1405	Kardiovaskulär wirksame Medikamente und mechanische Kreislaufunterstützung. , 2011, , 59-75.		0
1410	Vasopressors and Inotropes. , 2011, , 69-96.		0

#	ARTICLE	IF	CITATIONS
1411	Kreislauftherapie. , 2011, , 341-355.		0
1412	Update in intensive care medicine: Studies that challenged our practice in the last 5 years. Cleveland Clinic Journal of Medicine, 2011, 78, 665-674.	0.6	2
1413	Future Application of Integrative Therapies for Sepsis: Bench and Experimental Animal Models. , 2012, , 189-206.		0
1415	Herz-Kreislauf-wirksame Medikamente. , 2012, , 331-351.		4
1416	Shock Syndromes Related to Sepsis. , 2012, , 658-666.		0
1417	Sepsis und Multiorganversagen. , 2012, , 231-244.		0
1418	The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients. , 2012, , 277-291.		0
1419	Kreislaufunterstützende Therapie. , 2012, , 1484-1503.		0
1420	Vasopressin Therapy in Septic Shock. , 2012, , 76-84.		0
1421	Hormonal Therapies in Severe Sepsis. , 0, , .		0
1426	Choc septique. , 2013, , 51-75.		0
1428	Inotropes and Vasopressors Review of Physiology and Clinical Use. Journal of Pulmonary & Respiratory Medicine, 2013, 02, .	0.1	1
1429	Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock. Current Vascular Pharmacology, 2013, 11, 196-207.	0.8	16
1430	SIRS, Sepsis und Multiorganversagen. , 2014, , 453-482.		0
1431	Kardiovaskulär wirksame Medikamente und mechanische Kreislaufunterstützung. , 2014, , 65-88.		0
1433	Vasoactive Drugs in Acute Care. , 2014, , 73-200.		1
1437	Sepsis: Diagnose und Therapie. , 2015, , 971-982.		0
1439	Pharmacologic Treatment of the Failing Right Heart. , 2015, , 89-107.		0

#	ARTICLE	IF	CITATIONS
1440	Sepsis, Treatment of. , 2015, , 1473-1478.		0
1441	Sepsis und Multiorganversagen. , 2015, , 253-266.		0
1442	Herz-Kreislauf-wirksame Medikamente in der Anästhesiologie. , 2015, , 1-26.		0
1443	Vasoactive Agents in the ICU. , 2015, , 1753-1761.		0
1444	Adrenergic Agents. , 2015, , 931-951.		0
1446	Hypotension and Shock in the Poisoned Patient. , 2015, , 1-30.		0
1447	Vasoactive Drugs for Septic Shock: Where are we now?. Cardiovascular Pharmacology: Open Access, 2015, 04, .	0.1	0
1449	Sepsis breakthroughs in 2014. F1000Research, 0, 4, 131.	0.8	0
1450	Volumentherapie, Vasopressoren und Inotropika. , 2016, , 117-127.		0
1451	Vasopressors and Inotropes. , 2016, , 55-60.		0
1452	Severe Sepsis. , 2016, , 207-217.		0
1453	Hypotension and Shock in the Poisoned Patient. , 2016, , 1-30.		0
1454	Vasopressin versus noradrenaline as initial therapy in septic shock. Is vasopressin-related renal protection doomed to "vanish" in the haze?. Annals of Translational Medicine, 2016, 4, S47-S47.	0.7	1
1455	Attempting to define and refine vasopressin use in septic shock: the VANISH trial. Annals of Translational Medicine, 2016, 4, 501-501.	0.7	1
1456	The Assessment and Management of Hypotension and Shock in the Poisoned Patient. , 2017, , 295-323.		0
1458	Septische Kreislaufinsuffizienz. , 2017, , 1-7.		0
1459	Management of Sepsis and Septic Shock. , 2017, , 457-469.		0
1460	Hypovolämie und traumatische Kreislaufinsuffizienz. , 2017, , 1-5.		0

#	ARTICLE	IF	CITATIONS
1462	Systemic Inflammatory Response-Syndrome (SIRS), Sepsis und Multiorganversagen. , 2018, , 1-19.		0
1463	Sepsis Diagnosis and Management. Journal of Medical Sciences and Health, 2017, 03, 1-12.	0.1	2
1465	Medications in Cardiogenic Shock. , 2018, , 237-252.		0
1467	Herz-Kreislauf-wirksame Medikamente in der AnÄsthesiologie. Springer Reference Medizin, 2019, , 417-442.	0.0	0
1468	Nonpharmacologic Management of Acute Renal Injury. , 2019, , 302-307.e2.		0
1471	Vaptans and the Treatment of Hyponatremia. , 2019, , 364-368.e1.		0
1472	Advances in vasodilatory shock: a concise review. Journal of Analytical & Pharmaceutical Research, 2019, 8, 25-27.	0.3	0
1473	La Haute AutoritÄ© de santÄ© prive les patients en choc septique de vasopressine : une perte de chance !. Medecine Intensive Reanimation, 2019, 28, 300-302.	0.1	0
1474	One approach to circulation and blood flow in the critical care unit. World Journal of Critical Care Medicine, 2019, 8, 36-58.	0.8	0
1475	Use of methylene blue in vasoplegic syndrome that developed during non-cardiac surgery - A case report -. Anesthesia and Pain Medicine, 2019, 14, 460-464.	0.5	0
1476	Higher versus lower blood pressure targets in adults with shock. The Cochrane Library, 0, , .	1.5	0
1477	A case of hyponatremia due to continuous intravenous infusion of vasopressin. Journal of the Japanese Society of Intensive Care Medicine, 2019, 26, 451-452.	0.0	0
1479	Sepsis and Septic Shock. , 2020, , 331-347.		0
1480	Blood Pressure and Blood Pressure Deficits as Predictors of Acute Kidney Injury in Vasopressor Dependent Patients Post Cardiovascular Surgery. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 542-547.	0.1	1
1481	Vasopressin for Septic Shock in a Medical-Surgical Intensive Care Unit. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	1
1482	Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. Shock, 2021, 55, 210-214.	1.0	8
1484	Monitoring, management, and outcome of hypotension in Intensive Care Unit patients, an international survey of the European Society of Intensive Care Medicine. Journal of Critical Care, 2022, 67, 118-125.	1.0	10
1485	Importance of haemodynamic stability and adjuvant therapy in the treatment of patients with sepsis and septic shock. Timocki Medicinski Glasnik, 2020, 45, 153-158.	0.0	0

#	ARTICLE	IF	CITATIONS
1486	Circulation and circulatory support in the critically ill. , 2020, , 3881-3891.		0
1487	Precision Medicine in Critical Illness: Sepsis and Acute Respiratory Distress Syndrome. Respiratory Medicine, 2020, , 267-288.	0.1	2
1488	Sepsis and Septic Shock. , 2020, , 395-414.		0
1489	Comparison of Single-Dose and Extended-Duration Empiric Aminoglycoside Combination Therapy in Patients With Septic Shock. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	0
1490	Fluids and Vasoactive Agents. , 2020, , 595-607.		0
1491	HÄ°POTANSÄ°YON TEDAVÄ°SÄ° : DOÄžRU BÄ°LÄ°NEN YANLIÄžLAR ve VAZOPRESSÄ–R AJANLARIN GÄœNCELLEMESÄ°. Kahramanmaraş SÄ¼tÄšÄ¼ Ä°mam Ä°niversitesi TÄ±p FakÄ¼ltesi Dergisi, 0, , .	0.1	0
1492	Modern Vasopressor Therapy of Septic Shock (Review). Obshchaya Reanimatologiya, 2020, 16, 77-93.	0.2	6
1493	The Utility of Early Warning Score in Adults Presenting With Sepsis in the Emergency Department of a Low Resource Setting. Cureus, 2020, 12, e9030.	0.2	1
1494	Antiarrhythmics, Inotropes, and Vasopressors. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 237-252.	0.3	0
1496	Controversies in Sepsis Managementâ€”What is the Way Forward?. Annals of the Academy of Medicine, Singapore, 2020, , 661-668.	0.2	2
1497	Crystalloids and colloids. Southern African Journal of Anaesthesia and Analgesia, 0, , S80-S85.	0.1	0
1498	Selecting a Vasopressor and Inotrope Drug in Perioperative Patients. The Journal of Japan Society for Clinical Anesthesia, 2020, 40, 516-519.	0.0	0
1499	Very High Dose Epinephrine for the Treatment of Vasoplegic Syndrome during Liver Transplantation. International Journal of Organ Transplantation Medicine, 2013, 4, 32-4.	0.5	1
1500	Initial resuscitation and management of pediatric septic shock. Minerva Pediatrica, 2015, 67, 141-58.	2.6	9
1501	Vasopressor and Inotropic Management Of Patients With Septic Shock. P and T, 2015, 40, 438-50.	1.0	17
1502	Impact of Norepinephrine Shortage on Outcomes in Patients with Septic Shock. , 2016, 2, 87-91.		0
1503	Vasopressor use in 41 critically ill cats (2007-2016). Canadian Veterinary Journal, 2018, 59, 1175-1180.	0.0	1
1504	Pulmonary Hypertension in Intensive Care Units: An Updated Review. Tanaffos, 2019, 18, 180-207.	0.5	7

#	ARTICLE	IF	CITATIONS
1505	Vasopressin for Septic Shock in a Medical-Surgical Intensive Care Unit. Canadian Journal of Hospital Pharmacy, 2020, 73, 209-215.	0.1	1
1506	Beyond the bundle: Clinical controversies in the management of sepsis in emergency medicine patients. American Journal of Emergency Medicine, 2022, 51, 296-303.	0.7	4
1507	MicroRNAs and their role in immunogenetic-dysregulation. , 2022, , 193-225.		0
1508	Advantages of score-based delirium detection compared to a clinical delirium assessmentâ€”a retrospective, monocentric cohort study. PLoS ONE, 2021, 16, e0259841.	1.1	2
1509	Manejo clÃnico del shock poscardiotomÃa en pacientes adultos. Medicina Intensiva, 2022, 46, 312-325.	0.4	1
1510	General Organisation of the Body. , 2019, , 1-5.		0
1511	The Upper Airways. , 2019, , 21-23.		0
1512	Sepsis-associated Acute Kidney Injury, Diagnosis, and Management, Review Article. International Journal of Pharmaceutical Research and Allied Sciences, 2021, 10, 129-136.	0.1	0
1513	Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU. , 2022, 4, e0623.		6
1514	Predicting the Response of Hydroxocobalamin in Postoperative Vasoplegia in Recipients of Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2908-2916.	0.6	5
1515	A Clinical Update on Vasoactive Medication in the Management of Cardiogenic Shock. Clinical Medicine Insights: Cardiology, 2022, 16, 117954682210750.	0.6	11
1516	Association of Arterial pH With Hemodynamic Response to Vasopressin in Patients With Septic Shock: An Observational Cohort Study. , 2022, 4, e0634.		9
1518	Sepsis-associated acute kidney injury and the need for renal replacement therapy: A physician's perspective. APIK Journal of Internal Medicine, 2022, 10, 60.	0.1	0
1519	Vasopressors in Resuscitation. , 2022, , 121-140.		0
1521	Sepsis and Septic Shock: Evolving Evidence, Evolving Paradigms. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 039-045.	0.8	3
1522	Influence of Timing and Catecholamine Requirements on Vasopressin Responsiveness in Critically ill Patients with Septic Shock. Journal of Intensive Care Medicine, 2022, 37, 1512-1519.	1.3	7
1523	Incidence of Hypotension Associated With Two Different Vasopressin Discontinuation Strategies in the Recovery Phase of Septic Shock. Journal of Pharmacy Practice, 2023, 36, 830-838.	0.5	1
1524	Terlipressin for refractory septic shock: a study protocol of a single center, placebo-controlled double-blind phase III RCT (The TERESEP study).. Clinical Critical Care, 2022, , .	0.0	0

#	ARTICLE	IF	CITATIONS
1525	Intraoperative Hypotension and Acute Kidney Injury, Stroke, and Mortality during and outside Cardiopulmonary Bypass: A Retrospective Observational Cohort Study. <i>Anesthesiology</i> , 2022, 136, 927-939.	1.3	24
1526	Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1047-1055.	0.5	2
1527	Non-occlusive mesenteric ischaemia: just avoid norepinephrine, what else?. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, , .	0.6	1
1528	Vasopressor Choice and Timing in Vasodilatory Shock. <i>Critical Care</i> , 2022, 26, 76.	2.5	42
1529	Vasopressin: The Impact of Predatory Patents on a Captive ICU Marketplace*. <i>Critical Care Medicine</i> , 2022, 50, 711-714.	0.4	0
1531	Association of Methylene Blue Dosing with Hemodynamic Response for the Treatment of Vasoplegia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	0.6	3
1532	Current practice and evolving concepts in septic shock resuscitation. <i>Intensive Care Medicine</i> , 2022, 48, 148-163.	3.9	55
1533	Early Diagnosis and Antibiotic Treatment Combined with Multicomponent Hemodynamic Support for Addressing a Severe Case of Lemierre's Syndrome. <i>Antibiotics</i> , 2021, 10, 1526.	1.5	1
1534	Clinical Update on Vasopressors and Titration Strategies. <i>AACN Advanced Critical Care</i> , 2021, 32, 369-374.	0.6	1
1535	Mecopropil (MCP) (A case of pesticide poisoning by Mecoprop (MCP) and Igakukai Zasshi, 2021, 32, 364-370.	0.0	0
1536	Machine learning to predict vasopressin responsiveness in patients with septic shock. <i>Pharmacotherapy</i> , 2022, 42, 460-471.	1.2	6
1539	Multiorgan failure and its prevention. , 0, , 955-959.		0
1554	Role of perioperative hypotension in postoperative acute kidney injury: a narrative review. <i>British Journal of Anaesthesia</i> , 2022, 128, 931-948.	1.5	25
1556	Comparison of Heart Rate After Phenylephrine vs Norepinephrine Initiation in Patients With Septic Shock and Atrial Fibrillation. <i>Chest</i> , 2022, 162, 796-803.	0.4	8
1557	Clinical management of postcardiotomy shock in adults. <i>Medicina Intensiva (English Edition)</i> , 2022, , .	0.1	0
1558	Evaluation and management of emergencies in the patient with cirrhosis. <i>Revista De Gastroenterología De México (English Edition)</i> , 2022, , .	0.1	0
1559	Endovascular Perfusion Augmentation for Critical Care Decreases Vasopressor Requirements while Maintaining Renal Perfusion. <i>Shock</i> , 2022, 57, 740-748.	1.0	3
1560	Relationship Between Mean Arterial Pressure and Furosemide Stress Test Success Rates: A Retrospective Cohort Study. <i>Annals of Pharmacotherapy</i> , 2023, 57, 44-50.	0.9	0

#	ARTICLE	IF	CITATIONS
1561	Vasopressin versus norepinephrine as the first-line vasopressor in septic shock: A systematic review and meta-analysis. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	2
1562	Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
1563	Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*. <i>Critical Care Medicine</i> , 2022, 50, 1306-1317.	0.4	10
1564	Timing of vasoactive agents and corticosteroid initiation in septic shock. <i>Annals of Intensive Care</i> , 2022, 12, .	2.2	23
1565	Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: A Randomized Control Study. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 669-675.	0.3	10
1566	Protocol for an individual patient data meta-analysis on blood pressure targets after cardiac arrest. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 890-897.	0.7	4
1567	DJ-1 binds to Rubicon to Impair LC-3 Associated Phagocytosis. <i>Cell Death and Differentiation</i> , 2022, 29, 2024-2033.	5.0	3
1568	Alternatives to norepinephrine in septic shock: Which agents and when?. <i>Journal of Intensive Medicine</i> , 2022, 2, 223-232.	0.8	1
1569	Therapeutic Strategies Targeting Mitochondrial Dysfunction in Sepsis-induced Cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 163-180.	1.3	3
1570	Vasopressin-Induced Hyponatremia in Infants Following Cardiovascular Surgery. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211035.	0.9	0
1571	Why So Salty? Transient Diabetes Insipidus After Discontinuation of Vasopressin. , 2022, 1, .		0
1572	Effect of fixed-dose hydrocortisone on vasopressor dose and mean arterial pressure in obese and nonobese patients with septic shock. <i>American Journal of Health-System Pharmacy</i> , 0, , .	0.5	1
1573	Vasopressin associated hyponatremia in critically ill children: A cross-sectional study. <i>Saudi Pharmaceutical Journal</i> , 2022, , .	1.2	0
1574	A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department. <i>American Journal of Emergency Medicine</i> , 2022, 58, 210-214.	0.7	0
1576	Selepressin in Septic Shock. <i>Shock</i> , 2022, 57, 172-179.	1.0	3
1577	Diabetes Insipidus after Vasopressin Withdrawal: A Scoping Review. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 846-852.	0.3	0
1578	Effects of 7.2% hypertonic saline solution on cardiovascular parameters and endogenous arginine vasopressin secretion in euvoletic isoflurane-anesthetized horses. <i>American Journal of Veterinary Research</i> , 2022, 83, .	0.3	0
1580	The effect of continuous intravenous norepinephrine infusion on systemic hemodynamics in a telemetrically-monitored mouse model of sepsis. <i>PLoS ONE</i> , 2022, 17, e0271667.	1.1	1

#	ARTICLE	IF	CITATIONS
1581	Subphenotypes of acute kidney injury in adults. <i>Current Opinion in Critical Care</i> , 2022, 28, 599-604.	1.6	7
1582	VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK. <i>Shock</i> , 2022, 58, 260-268.	1.0	1
1583	EARLY INITIATION OF VASOPRESSIN REDUCES ORGAN FAILURE AND MORTALITY IN SEPTIC SHOCK. <i>Shock</i> , 2022, 58, 269-274.	1.0	6
1584	The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 959-976.	1.3	1
1585	Subphenotypes in acute kidney injury: a narrative review. <i>Critical Care</i> , 2022, 26, .	2.5	27
1586	Endovascular Perfusion Augmentation After Resuscitative Endovascular Balloon Occlusion of the Aorta Improves Renal Perfusion and Decreases Vasopressors. <i>Journal of Surgical Research</i> , 2022, 279, 712-721.	0.8	4
1587	Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study. <i>Journal of Critical Care</i> , 2022, 72, 154121.	1.0	3
1588	Vasoactive Drugs. <i>Lessons From the ICU</i> , 2022, , 299-306.	0.1	0
1589	Timing of Vasopressin Addition to Norepinephrine and Efficacy Outcomes in Patients With Septic Shock. <i>Annals of Pharmacotherapy</i> , 2023, 57, 521-526.	0.9	3
1590	Perioperative Management of the Patient at High-Risk for Cardiac Surgery-Associated Acute Kidney Injury. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 4460-4482.	0.6	7
1591	Applicability of Vasopressor Trials in Adult Critical Care: A Prospective Multicentre Meta-Epidemiologic Cohort Study. <i>Clinical Epidemiology</i> , 0, Volume 14, 1087-1098.	1.5	1
1592	The Association of Elevated Lactate With Multiple Vasopressor Administration in Patients With Septic Shock: A Retrospective Cohort Study. <i>Journal of Pharmacy Practice</i> , 2024, 37, 110-117.	0.5	0
1593	Efficacy and Safety of Vasopressin Alone or in Combination With Catecholamines in the Treatment of Septic Shock: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	0
1594	Advances in Sepsis Care. <i>Clinics in Chest Medicine</i> , 2022, 43, 489-498.	0.8	1
1595	Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study. <i>Anaesthesia and Intensive Care</i> , 2023, 51, 20-28.	0.2	4
1596	Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0
1597	Biomarkers for the Prediction and Judgement of Sepsis and Sepsis Complications: A Step towards precision medicine?. <i>Journal of Clinical Medicine</i> , 2022, 11, 5782.	1.0	7
1600	Inotropes and Vasopressors Use in Critical Care and Perioperative Medicine: Evidence-Based Approach (Review). <i>Obshchaya Reanimatologiya</i> , 2022, 18, 60-77.	0.2	3

#	ARTICLE	IF	CITATIONS
1601	Therapeutic Dilemmas in Mixed Septic-Cardiogenic Shock. American Journal of Medicine, 2023, 136, 27-32.	0.6	2
1602	Kidney Dysfunction After Traumatic Brain Injury: Pathophysiology and General Management. Neurocritical Care, 2023, 38, 504-516.	1.2	6
1603	Updates in the Management of Perioperative Vasoplegic Syndrome. Advances in Anesthesia, 2022, 40, 71-92.	0.5	1
1604	Extended Stability of Vasopressin Injection in Polyvinyl Chloride Bags and Polypropylene Syringes and Its Impact on Critically Ill Patient Care and Medication Waste. Hospital Pharmacy, 0, , 001857872211302.	0.4	0
1605	Machine-learning-derived sepsis bundle of care. Intensive Care Medicine, 2023, 49, 26-36.	3.9	8
1606	Incidence, Severity and Clinical Factors Associated with Hypotension in Patients Admitted to an Intensive Care Unit: A Prospective Observational Study. Journal of Clinical Medicine, 2022, 11, 6832.	1.0	2
1607	Very Low Driving-Pressure Ventilation in Patients With COVID-19 Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation: A Physiologic Study. Journal of Cardiothoracic and Vascular Anesthesia, 2023, 37, 423-431.	0.6	2
1608	High-dose vasoactive agents in aeromedical retrievals for septic shock: A role for vasopressin?. EMA - Emergency Medicine Australasia, 0, , .	0.5	0
1609	A plea for personalization of the hemodynamic management of septic shock. Critical Care, 2022, 26, .	2.5	21
1610	Multimodal strategy to counteract vasodilation in septic shock. Anaesthesia, Critical Care & Pain Medicine, 2023, 42, 101193.	0.6	10
1611	Clinical Management of Endotoxemia: Vasoactive and Cardiot stimulant Drugs. , 2023, , 75-83.		0
1613	Circulatory shock in adults in emergency department. Turkish Journal of Emergency Medicine, 2023, .	0.3	0
1614	Transient diabetes insipidus in critically ill COVID19 patients. Journal of Critical Care, 2023, 74, 154211.	1.0	1
1615	Institution-free days after critical illness: A multicenter retrospective study. Journal of Critical Care, 2023, 74, 154253.	1.0	0
1616	An updated â€œnorepinephrine equivalentâ€•score in intensive care as a marker of shock severity. Critical Care, 2023, 27, .	2.5	21
1617	Safflower (Carthamus tinctorius L.). , 2023, , 683-731.		0
1618	After the Rebranding and Cost Increase, the Use of Vasopressin Continues to Increase Yearly Especially in Case of Acute Kidney Injury With Septic Shock: Is There Recent Data Justifying It?. Critical Care Medicine, 2023, 51, e68-e69.	0.4	1
1619	Norepinephrine dose, lactate or heart rate: what impacts prognosis in sepsis and septic shock? Results from a prospective, monocentric registry. Current Medical Research and Opinion, 2023, 39, 647-659.	0.9	1

#	ARTICLE	IF	CITATIONS
1620	Echocardiographic profiles and hemodynamic response after vasopressin initiation in septic shock: A cross-sectional study. <i>Journal of Critical Care</i> , 2023, 76, 154298.	1.0	4
1621	Shock: causes, assessment and investigation. <i>Anaesthesia and Intensive Care Medicine</i> , 2023, 24, 99-107.	0.1	0
1622	Resuscitation in the First 3 Hours of Sepsis-Induced Hypotension Varies by Patient and Hospital Factors. , 2023, 5, e0859.		0
1623	Evaluation of Dose Requirements Using Weight-Based versus Non-Weight-Based Dosing of Norepinephrine to Achieve a Goal Mean Arterial Pressure in Patients with Septic Shock. <i>Journal of Clinical Medicine</i> , 2023, 12, 1344.	1.0	2
1624	Norepinephrine May Exacerbate Septic Acute Kidney Injury: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1373.	1.0	3
1625	How Would You Resuscitate This Patient With Septic Shock?. <i>Annals of Internal Medicine</i> , 2023, 176, 253-259.	2.0	1
1626	Running from a Bear: How We Teach Vasopressors, Adrenoreceptors, and Shock. <i>ATS Scholar</i> , 0, , .	0.5	1
1627	Renal Microcirculation Injury as the Main Cause of Ischemic Acute Kidney Injury Development. <i>Biology</i> , 2023, 12, 327.	1.3	2
1628	Evaluation of Response to High-Dose Intravenous Vitamin K Administration. <i>Annals of Pharmacotherapy</i> , 0, , 106002802311542.	0.9	0
1629	Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. <i>Nature Reviews Nephrology</i> , 2023, 19, 401-417.	4.1	77
1630	Vasopressor Therapy in Septic Shock. , 2023, , 121-133.		0
1631	Fluid management in septic patients with pulmonary hypertension, review of the literature. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
1632	Tendency of dynamic vasoactive and inotropic medications data as a robust predictor of mortality in patients with septic shock: An analysis of the MIMIC-IV database. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	4
1634	Trends in Return of Spontaneous Circulation and Survival to Hospital Discharge for In-Intensive Care Unit Cardiac Arrests. <i>Annals of the American Thoracic Society</i> , 0, , .	1.5	0
1635	<i>Critical Care Medicine</i> . , 2017, , 1282-1300.e5.		0
1636	Precision Medicine in Septic Shock. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2023, , 49-68.	0.1	0
1637	Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	5
1638	Rare Case of Exogenous Vasopressin-Induced Hyponatremia. <i>American Journal of Therapeutics</i> , 0, Publish Ahead of Print, .	0.5	0

#	ARTICLE	IF	CITATIONS
1639	Effect of Early Administration of Vasopressin on New-Onset Arrhythmia Development in Patients With Septic Shock: A Retrospective, Observational Cohort Study. <i>Annals of Pharmacotherapy</i> , 2024, 58, 5-14.	0.9	1
1640	Emerging concepts in the care of patients with cirrhosis and septic shock. <i>World Journal of Hepatology</i> , 0, 15, 497-514.	0.8	1
1644	Norepinephrine dose and the grain of salt: a task force is needed. <i>Intensive Care Medicine</i> , 2023, 49, 716-717.	3.9	0
1665	Precision management of acute kidney injury in the intensive care unit: current state of the art. <i>Intensive Care Medicine</i> , 2023, 49, 1049-1061.	3.9	3
1673	Sepsis, septic shock, and its treatment. , 2024, , 770-783.e2.		0
1680	Inotropika und Vasopressoren. <i>Springer Reference Medizin</i> , 2023, , 1-12.	0.0	0